

Financial news for BIIB dated on 2020-06-10: Biogen Reports New Results From NURTURE Study Of SPINRAZA

Financial news for BIIB dated on 2020-06-09: Benzinga's Top Upgrades, Downgrades For June 9, 2020

Financial news for BIIB dated on 2020-06-09: Biogen shares are trading lower after Bernstein downgraded the stock from Outperform to Market Perform and lowered the price target from \$360 to \$297 per share.

Financial news for BIIB dated on 2020-06-09: Bernstein Downgrades Biogen to Market Perform, Lowers Price Target to \$297

Financial news for BIIB dated on 2020-06-08: 4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize

Financial news for BIIB dated on 2020-06-04: Biogen To Present Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020 Jun. 3-6

Financial news for BIIB dated on 2020-05-29: Vir Biotechnology And Biogen Execute Agreement To Manufacture SARS-CoV-2 Antibodies For Potential COVID-19 Coronavirus Treatment

Financial news for BIIB dated on 2020-05-18: Biogen shares are trading higher after the company published data showing that its SPINRAZA demonstrated sustained efficacy and longer-term safety.

Financial news for BIIB dated on 2020-05-18: Biogen Publishes Data Showing its SPINRAZA Demonstrated Sustained Efficacy and Longer Term Safety

Financial news for BIIB dated on 2020-05-15: 13F From Buffett's Berkshire Shows Cut Stake In Biogen By ~5.4K Shares

Financial news for BIIB dated on 2020-05-11: Biogen shares are trading higher. Not currently seeing company-specific news.

Financial news for BIIB dated on 2020-05-07: Shares of several healthcare companies are trading higher amid continued economic optimism as some US states ease lockdown restrictions. While jobless claims came in worse than estimates, figures were lower than in prior weeks.

Financial news for BIIB dated on 2020-05-01: Cantor Fitzgerald Reiterates Neutral on Biogen, Lowers Price Target to \$308

Financial news for BIIB dated on 2020-04-27: Biogen Prices \$3B In Senior Unsecured Notes

Financial news for BIIB dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for BIIB dated on 2020-04-24: Canaccord Genuity Maintains Buy on Biogen, Lowers Price Target to \$350

Financial news for BIIB dated on 2020-04-23: Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay

Financial news for BIIB dated on 2020-04-23: SunTrust Robinson Humphrey Maintains Buy on Biogen, Lowers Price Target to \$330

Financial news for BIIB dated on 2020-04-23: Morgan Stanley Maintains Underweight on Biogen, Lowers Price Target to \$301

Financial news for BIIB dated on 2020-04-23: 10 Biggest Price Target Changes For Thursday

Financial news for BIIB dated on 2020-04-23: Credit Suisse Maintains Neutral on Biogen, Lowers Price Target to \$310

Financial news for BIIB dated on 2020-04-23: Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to \$365

Financial news for BIIB dated on 2020-04-23: Barclays Maintains Overweight on Biogen, Lowers Price Target to \$370

Financial news for BIIB dated on 2020-04-23: A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings, Economic Reports

Financial news for BIIB dated on 2020-04-23: Citigroup Downgrades Biogen to Sell

Financial news for BIIB dated on 2020-04-23: Raymond James Downgrades Biogen to Underperform

Financial news for BIIB dated on 2020-04-23: 70 Biggest Movers From Yesterday

Financial news for BIIB dated on 2020-04-22: Hearing Raymond James Downgrades Biogen To Underperform

Financial news for BIIB dated on 2020-04-22: Jefferies Issues Mid-Day Note On Biogen, Notes 'Partner Biogen's 1Q Spinraza Sales Slightly Higher on Inventory & Ex-US Growth,' Says Remains Cautious On Ionis Pharma

Financial news for BIIB dated on 2020-04-22: 46 Stocks Moving In Wednesday's Mid-Day Session

Financial news for BIIB dated on 2020-04-22: Biogen Shares Unaffected; Traders Circulate Word Evercore Analyst Remains Positive On Stock After Speaking To Mgmt. Following Wed. Earnings Call

Financial news for BIIB dated on 2020-04-22: Morning Market Stats in 5 Minutes

Financial news for BIIB dated on 2020-04-22: Biogen Delays Regulatory Filing For Approval Of Alzheimer's Drug, Shares Slump

Financial news for BIIB dated on 2020-04-22: Recap: Biogen Q1 Earnings

Financial news for BIIB dated on 2020-04-22: Biogen shares are trading lower despite better-than-expected Q1 earnings results.

Financial news for BIIB dated on 2020-04-22: From Biogen Earnings Conference Call: CEO Says Had Initial Discussion With Regulators Outside US About Its Alzheimer's Drug Aducanumab

Financial news for BIIB dated on 2020-04-22: The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership

Financial news for BIIB dated on 2020-04-22: 17 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for BIIB dated on 2020-04-22: Biogen Q1 Adj. EPS \$9.140 Beats \$7.740 Estimate, Sales \$3.500B Beat \$3.410B Estimate

Financial news for BIIB dated on 2020-04-22: Earnings Scheduled For April 22, 2020

Financial news for BIIB dated on 2020-04-19: The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision

Financial news for BIIB dated on 2020-04-16: Shares of several healthcare companies are trading higher. Strength could potentially be related to the increased demand in medical products stemming from the coronavirus pandemic.

Financial news for BIIB dated on 2020-04-16: Biogen, Broad Institute Of MIT And Harvard, Partners HealthCare Launch Consortium To Build And Share A COVID-19 Biobank

Financial news for BIIB dated on 2020-04-15: Every Member Of Trump's 'Great American Economic Revival' Industry Groups

Financial news for BIIB dated on 2020-04-14: Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for BIIB dated on 2020-04-08: Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.

Financial news for BIIB dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for BIIB dated on 2020-04-01: Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.

Financial news for BIIB dated on 2020-03-30: Shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus. NOTE: The sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak.

Financial news for BIIB dated on 2020-03-27: Veeva Systems' CRM Product Is Seeing Ten Times More Usage During Coronavirus Pandemic

Financial news for BIIB dated on 2020-03-26: Shares of several healthcare companies are trading higher following Senate passage of a \$2 trillion economic stimulus package, which has lifted stocks across sectors.

Financial news for BIIB dated on 2020-03-25: Vir Biotechnology Says Proceeding With Two Clinical Development Candidates For Coronavirus

Financial news for BIIB dated on 2020-03-19: 12 Key Medical Meetings Canceled Or Postponed In The Face Of A Pandemic

Financial news for BIIB dated on 2020-03-19: 40 Stocks Moving in Thursday's Pre-Market Session

Financial news for BIIB dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for BIIB dated on 2020-03-15: The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review

Financial news for BIIB dated on 2020-03-13: Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.

Financial news for BIIB dated on 2020-03-12: Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.

Financial news for BIIB dated on 2020-03-12: Vir Biotechnology Announces It Signed A Letter Of Intent To Collaborate With Biogen To Manufacturing Antibodies To Potentially Treat COVID-19

Financial news for BIIB dated on 2020-03-06: Biogen Says, Following Co. Meeting With Employees In Boston Last Week, A Number Of Attendees Have Tested Positive For Coronavirus; Co. Has Directed Boston Meeting Attendees To Work From Home For 2 Weeks

Financial news for BIIB dated on 2020-03-04: Shares of several healthcare-related companies are trading higher after Joe Biden secured several key wins in Super Tuesday. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.

Financial news for BIIB dated on 2020-03-03: Shares of several healthcare companies are trading lower in sympathy with the overall market. The Fed cut rates to combat the coronavirus outbreak which caused an initial spike but then continued to trade lower.

Financial news for BIIB dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for BIIB dated on 2020-03-02: Shares of several healthcare companies are trading higher in sympathy with the overall market as it rebounds from a selloff caused by coronavirus fears.

Financial news for BIIB dated on 2020-02-28: Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.

Financial news for BIIB dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for BIIB dated on 2020-02-27: Biogen And Sangamo Announce Global Collaboration To Develop Gene Regulation Therapies for Alzheimer's, Parkinson's, Neuromuscular And Other Neurological Diseases; Biogen To Pay Sangamo \$350M Upfront, Sangamo Eligible For Up To \$2.37B In Milestones

Financial news for BIIB dated on 2020-02-27: Benzinga's Top Upgrades, Downgrades For February 27, 2020

Financial news for BIIB dated on 2020-02-27: Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.

Financial news for BIIB dated on 2020-02-27: Barclays Initiates Coverage On Biogen with Overweight Rating, Announces \$389 Price Target

Financial news for BIIB dated on 2020-02-25: Mizuho Maintains Neutral on Biogen, Raises Price Target to \$316

Financial news for BIIB dated on 2020-02-18: Q4 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios

Financial news for BIIB dated on 2020-02-18: Biogen shares are trading higher after Berkshire Hathaway's 13F filing showed that it paid \$192.5 million for roughly a 0.4% stake in the company.

Financial news for BIIB dated on 2020-02-18: 35 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for BIIB dated on 2020-02-18: Warren Buffett's Berkshire Hathaway Trims Apple Stake, Buys Into Kroger, Biogen

Financial news for BIIB dated on 2020-02-14: Berkshire Hathaway 13F Shows 648,447 Share Stake In Biogen

Financial news for BIIB dated on 2020-02-10: Eli Lilly Suffers Setback As Alzheimer's Study Fails To Meet Primary Endpoint

Financial news for BIIB dated on 2020-02-10: 30 Stocks Moving in Monday's Pre-Market Session

Financial news for BIIB dated on 2020-02-07: Nomura Maintains Buy on Biogen, Raises Price Target to \$392

Financial news for BIIB dated on 2020-02-06: Biogen shares are trading higher after the company won a patent decision against Mylan. Biogen will keep exclusive rights to its multiple sclerosis drug Tecfidera until 2028.

Financial news for BIIB dated on 2020-02-06: Morgan Stanley Maintains Underweight on Biogen, Raises Price Target to \$302

Financial news for BIIB dated on 2020-02-06: Twitter Up, Tesla Down: Strong User Numbers Help TWTR, But TSLA Selling Continues

Financial news for BIIB dated on 2020-02-06: SVB Leerink Maintains Outperform on Biogen, Raises Price Target to \$410

Financial news for BIIB dated on 2020-02-06: Baird Maintains Underperform on Biogen, Raises Price Target to \$290

Financial news for BIIB dated on 2020-02-06: Credit Suisse Maintains Neutral on Biogen, Raises Price Target to \$330

Financial news for BIIB dated on 2020-02-06: 10 Biggest Price Target Changes For Thursday

Financial news for BIIB dated on 2020-02-06: Wells Fargo Maintains Equal-Weight on Biogen, Raises Price Target to \$311

Financial news for BIIB dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for BIIB dated on 2020-02-06: Cantor Fitzgerald Reiterates Neutral on Biogen, Raises Price Target to \$361

Financial news for BIIB dated on 2020-02-06: 90 Biggest Movers From Yesterday

Financial news for BIIB dated on 2020-02-05: Hearing Mizuho Says Tecfidera Win Is Worth \$15-\$30/Share To DCF

Financial news for BIIB dated on 2020-02-05: Hearing Guggenheim Out On Biogen Saying With IPR Overhang Removed, 'Aducanumab Becomes The Key Focus Key Message'

Financial news for BIIB dated on 2020-02-05: Biogen Rallies On Tecfidera Patent Decision

Financial news for BIIB dated on 2020-02-05: Mylan Says Strongly Disagrees With Decision By US PTAB Upholding Biogen's Patent Covering Tecfidera, Plans To Pursue All Available Options For Appeal

Financial news for BIIB dated on 2020-02-05: Hearing Goldman Sachs On Biogen Decision

Says ' In our view today's decision removes a downside scenario for Tecfidera IP and we expect shares to react favorably' But Notes Ongoing Cases With Expected 2020 Decisions

Financial news for BIIB dated on 2020-02-05: UPDATE: USPTO's Final Written Decision Doc For Mylan v Biogen

Financial news for BIIB dated on 2020-02-05: Biogen shares trading higher following a report of a patent trial challenge by Mylan on '514 Tecfidera. The report suggests the company's patent claims remain valid.

Financial news for BIIB dated on 2020-02-05: Biogen Shares Resume Trade, Up 12% For Session

Financial news for BIIB dated on 2020-02-05: Biogen Shares Expected To Resume Trade At 1:28:36 EST

Financial news for BIIB dated on 2020-02-05: Biogen Shares Halted On A Circuit Breaker, Stock Up 11%

Financial news for BIIB dated on 2020-02-05: 'Biogen wins IPR patent trial on '514 Tecfidera patent as patent claims challenged by Mylan remain valid.'

Financial news for BIIB dated on 2020-02-04: Shares of healthcare companies are trading higher amid a rebound in global equities following last week's selloff on coronavirus fears.

Financial news for BIIB dated on 2020-02-03: 10 Biggest Price Target Changes For Monday

Financial news for BIIB dated on 2020-02-03: SunTrust Robinson Humphrey Maintains Buy on Biogen, Raises Price Target to \$360

Financial news for BIIB dated on 2020-01-31: Biogen shares are trading lower after Morgan Stanley analysts maintained an underweight rating on the stock and lowered the price target from \$270 to \$261.

Financial news for BIIB dated on 2020-01-31: Morgan Stanley Maintains Underweight on Biogen, Lowers Price Target to \$261

Financial news for BIIB dated on 2020-01-30: The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance

Financial news for BIIB dated on 2020-01-30: Biogen shares are trading higher after the company reported better-than-expected Q4 EPS and sales results. UPDATE: Shares are trading slightly lower as of 9:52 a.m.

Financial news for BIIB dated on 2020-01-30: Biogen Reports Q4 Earnings Beat

Financial news for BIIB dated on 2020-01-30: Biogen Q4 Adj. EPS \$8.34 Beats \$7.92 Estimate, Sales \$3.67B Beat \$3.52B Estimate; Sees FY20 Adj. EPS \$31.50-\$33.50, Sales \$14B-\$14.3B

Financial news for BIIB dated on 2020-01-30: Earnings Scheduled For January 30, 2020

Financial news for BIIB dated on 2020-01-27: Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says

Financial news for BIIB dated on 2020-01-27: Canaccord Genuity Upgrades Biogen to Buy, Announces \$360 Price Target

Financial news for BIIB dated on 2020-01-26: The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes

Financial news for BIIB dated on 2020-01-17: 9 Takeaways From The JPMorgan Healthcare Conference

Financial news for BIIB dated on 2020-01-17: Morgan Stanley Maintains Underweight on Biogen, Raises Price Target to \$270

Financial news for BIIB dated on 2020-01-13: Benzinga Pro's Top 5 Stocks To Watch For Mon., Jan. 13, 2020: WCC, LULU, XLF, TEAM, BIIB

Financial news for BIIB dated on 2020-01-13: Biogen To Acquire PF-05251749, A Novel Clinical Stage Asset With Application in Alzheimer's And Parkinson's From Pfizer; Pfizer To Receive \$75M Upfront And Up To \$635M In Milestones

Financial news for BIIB dated on 2020-01-10: 'California Gov. Gavin Newsom wants the state to become the first to create its own generic drug label, an attempt to create

more competition and bring down prices.' -Axios, From Earlier

Financial news for BIIB dated on 2020-01-10: A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations

Financial news for BIIB dated on 2020-01-10: CAMP4 Therapeutics Reports Collaboration With Biogen For Addressing Neurodegenerative, Neurological Disease; Co. To Receive \$15M Upfront Payment, Development, Milestone Payments Of Up To \$96M Plus Future Royalties For Up To \$173M

Financial news for BIIB dated on 2020-01-09: Banner Life Sciences Receives Favorable Ruling Against Biogen in Patent Infringement Challenge

Financial news for BIIB dated on 2020-01-02: Drugmakers Kick Off 2020 With Margin-Expanding Price Hikes

Financial news for BIIB dated on 2020-01-01: Bristol-Myers Squibb, Gilead Sciences, Biogen Raised U.S. List Prices on 50+ Drugs on Wednesday an Average of 5%

Financial news for BIIB dated on 2019-12-21: Barron's Picks And Pans: Alibaba, Biogen, China Mobile, Peter Lynch Picks And More

Financial news for BIIB dated on 2019-12-19: Biogen 8-K Shows \$5B Buyback

Financial news for BIIB dated on 2019-12-19: Benzinga Pro's Top 5 Stocks To Watch For Thurs., Dec. 19, 2019: NKE, TIVO, CBIO, APOG, RAD

Financial news for BIIB dated on 2019-12-19: UPDATE: Catalyst To Receive \$15M Upfront Payment, Is Eligible For Up To \$340M In Milestone Payments Plus Tiered Royalties Based On Net Sales

Financial news for BIIB dated on 2019-12-19: Catalyst Biosciences Reports Global License, Collab Deal With Biogen To Develop Pegylated CB 2782 For Treatment Of Dry Age-Related Macular Degeneration

Financial news for BIIB dated on 2019-12-19: Ionis Pharma Reports License Of IONIS-MAPT Therapy; Earned \$45M License Fee From Biogen, Is Eligible To Earn Up To \$155M In Added Milestone Payments

Financial news for BIIB dated on 2019-12-13: Biogen Reports Topline Results From Phase 2 Study Of Progressive Supranuclear Palsy: Primary Endpoint Was Not Met

Financial news for BIIB dated on 2019-12-13: Credit Suisse Upgrades Biogen to Neutral, Raises Price Target to \$300

Financial news for BIIB dated on 2019-12-08: Bulls And Bears Of The Week: Facebook, Intel, Netflix, Tesla And More

Financial news for BIIB dated on 2019-12-06: Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation

Financial news for BIIB dated on 2019-12-05: Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response

Financial news for BIIB dated on 2019-12-05: Biogen shares are trading higher after the company presented data for its Aducanumab.

Financial news for BIIB dated on 2019-12-05: Morgan Stanley Concludes By Saying 'From a stock prospective, we see the final point as incrementally negative but ultimately do not expect much movement in BIIB today'

Financial news for BIIB dated on 2019-12-05: Morgan Stanley Says 'The effect size of the drug is small. In EMERGE, the change in CDR-SB was 0.40 well below what has been noted as a clinically meaningful effect of 1'

Financial news for BIIB dated on 2019-12-05: Morgan Stanley On Biogen Alzheimer's Presentation Says 'The cumulative data presented today is not significantly different from the data previously presented.' And Notes 'there were no significant baseline imbalances which could have influenced results'

Financial news for BIIB dated on 2019-12-05: Boston Business Journal Biotech Reporter Allison DeAngelis, On Results From Biogen Alzheimer's Trials, Tweets, 'the drug appears to make a difference in amyloid plaque levels, but shows marginal effect in cognition, memory, etc'

Financial news for BIIB dated on 2019-12-05: Panel From Alzheimer's Conference, Stephen Salloway, Says Sees Data From Biogen's EMERGE Trial On Alzheimer's Treatment Was 'Positive'

Financial news for BIIB dated on 2019-12-05: Biogen Shares Now Positive For Session, Have Rebounded 7% From Low

Financial news for BIIB dated on 2019-12-05: UPDATE: Biogen Shares Now Down ~4% For Session

Financial news for BIIB dated on 2019-12-05: Biogen Shares Resume Trade, Move Lower, Now Down ~1.6%

Financial news for BIIB dated on 2019-12-05: From Biogen Call On Aducanumab: EMERGE Trial Showed Low-Dose Treatment With 50.5% Completion, High-Dose Treatment With 52.1% Completion, Placebo Showed 50.2%

Financial news for BIIB dated on 2019-12-05: Mike Khouw Highlights Unusual Options Activity In Biogen

Financial news for BIIB dated on 2019-12-05: Biogen Shares To Resume Trade At 11:35 a.m. EST

Financial news for BIIB dated on 2019-12-05: From Biogen Call On Aducanumab: Futility Data Set Showed EMERGE Trial By Mar. 20, 2019 Of 49% Opportunity To Complete, ENGAGE Trial 66%; ENGAGE Futility Data Did Not Reduce Clinical Decline

Financial news for BIIB dated on 2019-12-05: From Biogen Call On Aducanumab: High-Dose Regimen Showed 29% Of Patients In EMERGE, 22% Of Patients In ENGAGE Received Full Possible 14 Doses Of 10mg/kg Doses

Financial news for BIIB dated on 2019-12-05: Biogen Shares Halted Ahead Of Scheduled 11 a.m. EST Release/Conference Call For Phase 3 Topline Results Of Aducanumab

Financial news for BIIB dated on 2019-12-05: Biogen Shares Halted, News Pending

Financial news for BIIB dated on 2019-12-05: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

Financial news for BIIB dated on 2019-12-03: Cramer Weighs In On Biogen, Caterpillar And More

Financial news for BIIB dated on 2019-12-03: Biogen Announces Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE); Study Met Primary Endpoint

Financial news for BIIB dated on 2019-12-02: Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade

Financial news for BIIB dated on 2019-12-02: Benzinga's Top Upgrades, Downgrades For December 2, 2019

Financial news for BIIB dated on 2019-12-02: 10 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for BIIB dated on 2019-12-02: Biogen shares are trading lower after the company's stock was downgraded from Neutral to Underperform by analysts at Baird.

Financial news for BIIB dated on 2019-12-02: Baird Downgrades Biogen to Underperform, Announces \$250 Price Target

Financial news for BIIB dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for BIIB dated on 2019-11-27: Morgan Stanley On Biogen Notes 'We see BIIB up 5-10% on clean sub-group analysis, flat to down 5-10% on incrementally mixed data, and down 10%+ on marginal supportive evidence'

Financial news for BIIB dated on 2019-11-27: Morgan Stanley Maintains Underweight, \$262 Target On Biogen Notes 'We expect additional EMERGE/ENGAGE PHIII data at CTAD on December 5 with an 85% probability BIIB is pressured on the data'

Financial news for BIIB dated on 2019-11-26: RBC Out Positive On Biogen Hearing Developments, Noting One Of The Judges Is Being Replaced Due To Unavailability; Says Views This As Positive, As This Judge 'eemed most vocal around the potential obviousness of the 480mg dose in BIIB's '514 patent'

Financial news for BIIB dated on 2019-11-26: Biogen Reaches Generic Tecfidera Settlement/Dismissal With Aurobindo Pharma

Financial news for BIIB dated on 2019-11-25: Biogen shares are trading higher on continued momentum after the company presented data showing improved gastrointestinal tolerability with VUMERITY compared to TECFIDERA.

Financial news for BIIB dated on 2019-11-22: Biogen shares are trading higher after the company presented data showing improved gastrointestinal tolerability with VUMERITY compared to TECFIDERA.

Financial news for BIIB dated on 2019-11-22: Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are "MUCH CHEAPER"

Financial news for BIIB dated on 2019-11-22: Biogen Highlights Data Showing Improved Gastrointestinal Tolerability With VUMERITY Compared To TECFIDERA

Financial news for BIIB dated on 2019-11-21: Biogen Reports Completion Of Enrollment Of Global Phase 3 Therapy Study For Inherited Retinal Disorder

Financial news for BIIB dated on 2019-11-19: Biogen shares are trading higher. Not seeing any news to justify the price action.

Financial news for BIIB dated on 2019-11-14: Biogen shares are trading lower as a potential sell-off after the stock increased roughly 38% on October 22nd following the company reporting better-than-expected Q3 EPS and sales results.

Financial news for BIIB dated on 2019-11-13: Biogen shares are trading lower on seemingly no company-specific news.

Financial news for BIIB dated on 2019-11-12: Benzinga's Top Upgrades, Downgrades For November 12, 2019

Financial news for BIIB dated on 2019-11-12: Alkermes Receives \$150M Milestone Payment From Biogen Related To FDA Approval Of VUMERITY

Financial news for BIIB dated on 2019-11-12: SunTrust Robinson Humphrey Initiates Coverage On Biogen with Buy Rating, Announces \$337 Price Target

Financial news for BIIB dated on 2019-11-07: Biotech Stock On The Radar: Alkermes At A Crossroads

Financial news for BIIB dated on 2019-11-06: AstraZeneca Named The Most Innovative Global Pharma Company

Financial news for BIIB dated on 2019-11-06: Biogen Announces Proposed Transaction With Samsung Bioepis To Secure Exclusive Rights To Two Ophthalmology Biosimilars

Financial news for BIIB dated on 2019-11-04: Chinese Regulators Tentatively Approve Novel Alzheimer's Drug -- The First Since 2003

Financial news for BIIB dated on 2019-11-01: Standpoint Research Downgrades Biogen to Hold

Financial news for BIIB dated on 2019-10-31: Cramer Makes The Case Why Biogen's Stock Could Double In Value

Financial news for BIIB dated on 2019-10-30: Benzinga's Top Upgrades, Downgrades For October 30, 2019

Financial news for BIIB dated on 2019-10-30: Biogen shares are trading higher after the company announced it has recieved FDA approval for VUMERITY, a treatment of relapsing forms of multiple sclerosis. Bernstein earlier upgraded the stock from Market Perform to Outperform.

Financial news for BIIB dated on 2019-10-30: Biogen And Alkermes Announce FDA Approval Of VUMERITY (diroximel fumarate) For Multiple Sclerosis

Financial news for BIIB dated on 2019-10-30: Bernstein Upgrades Biogen to Outperform

Financial news for BIIB dated on 2019-10-29: Hearing Bernstein Upgrades Biogen To Outperform, \$370 Price Target

Financial news for BIIB dated on 2019-10-27: The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Financial news for BIIB dated on 2019-10-25: WeTrader Competition: Round Three Wrap-up

Financial news for BIIB dated on 2019-10-23: Biogen Analysts Debate About-Face On Aducanumab: 'Path To Market An Uphill Battle'

Financial news for BIIB dated on 2019-10-23: '7 burning questions now that Biogen \$BIIB has resurrected its 'failed' Alzheimer's drug' -Tweet From Stat News Snr Writer

Financial news for BIIB dated on 2019-10-23: UPDATE: Morgan Stanley Maintains Underweight On Biogen, Raises Target To \$262 As Firm Notes 'We add 35% risk-adjusted aducanumab sales into our model but remain UW given our concerns around the updated filing strategy and base business'

Financial news for BIIB dated on 2019-10-23: UPDATE:H.C. Wainwright Reiterates Buy On Biogen, Raises Tgt To \$335 Notes 'In light of the new analysis from the aducanumab Phase 3 trials and plans for BLA submission based on discussions with the FDA, we raised our probability of success to 15%' From 0%

Financial news for BIIB dated on 2019-10-23: UPDATE: Canaccord On Biogen Also Notes 'we would like to wait until BIIB presents a fuller data set at the Clinical Trials in Alzheimer's Disease (CTAD) conference in San Diego, CA (12/4-12/7)'

Financial news for BIIB dated on 2019-10-23: UPDATE: Canaccord Maintains Hold On Biogen, Raises Target To \$305 Notes 'There is still a lot of uncertainty and investor skepticism as it is unclear whether the FDA could approve adu based on one successful EMERGE trial supported by ENGAGE that failed'

Financial news for BIIB dated on 2019-10-23: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday, October 23, 2019

Financial news for BIIB dated on 2019-10-23: 10 Biggest Price Target Changes For Wednesday

Financial news for BIIB dated on 2019-10-23: BMO Capital Maintains Market Perform on Biogen, Raises Price Target to \$297

Financial news for BIIB dated on 2019-10-23: Canaccord Genuity Maintains Hold on Biogen, Raises Price Target to \$305

Financial news for BIIB dated on 2019-10-23: Credit Suisse Maintains Underperform on Biogen, Raises Price Target to \$260

Financial news for BIIB dated on 2019-10-23: SVB Leerink Upgrades Biogen to Outperform, Raises Price Target to \$350

Financial news for BIIB dated on 2019-10-23: 33 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for BIIB dated on 2019-10-23: JP Morgan Maintains Neutral on Biogen, Raises Price Target to \$260

Financial news for BIIB dated on 2019-10-23: Cowen & Co. Maintains Outperform on Biogen, Raises Price Target to \$325

Financial news for BIIB dated on 2019-10-23: Morgan Stanley Maintains Underweight on Biogen, Raises Price Target to \$262

Financial news for BIIB dated on 2019-10-23: H.C. Wainwright Reiterates Buy on Biogen, Raises Price Target to \$335

Financial news for BIIB dated on 2019-10-23: Guggenheim Upgrades Biogen to Buy

Financial news for BIIB dated on 2019-10-23: 41 Biggest Movers From Yesterday

Financial news for BIIB dated on 2019-10-22: PreMarket Prep: A Biotech Surprise, Stamps Shorts Take A Licking, Debating McDonald's Earnings Move

Financial news for BIIB dated on 2019-10-22: Jon Najarian Highlights Unusual Options Activity In Biogen

Financial news for BIIB dated on 2019-10-22: Biogen Alzheimer Drug Has 0% Chance Of Winning Approval -Raymond James

Financial news for BIIB dated on 2019-10-22: Mid-Afternoon Market Update: Health Care Shares Climb 1.04%, Biogen Shares Spike

Financial news for BIIB dated on 2019-10-22: 25 Stocks Moving In Tuesday's Mid-Day Session

Financial news for BIIB dated on 2019-10-22: Mid-Day Market Update: Energy Up 1.10%; Biogen Shares Spike Higher

Financial news for BIIB dated on 2019-10-22: Mid-Morning Market Update: Healthcare Shares Trend Higher, Biogen Shares Spike

Financial news for BIIB dated on 2019-10-22: Alzheimer's Association Issues Statement

Saying Is Encouraged To Learn Biogen Will Pursue Regulatory Approval From FDA For Aducanumab

Financial news for BIIB dated on 2019-10-22: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, October 22, 2019

Financial news for BIIB dated on 2019-10-22: Mixed Bag: Better Outlooks From Lockheed, United Technologies, But McDonald's Misses

Financial news for BIIB dated on 2019-10-22: Biogen Plans Filing For Failed Alzheimer's Drug After New Analysis

Financial news for BIIB dated on 2019-10-22: Biogen Inc Executive Says FDA Thought It Was 'Reasonable' To File For Regulatory Approval Of Aducanumab After Meeting With Co.

Financial news for BIIB dated on 2019-10-22: Biogen Inc Executive Says Results From New Analysis Of Aducanumab Are Positive For Other Alzheimer's Drug Ban2401

Financial news for BIIB dated on 2019-10-22: The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug

Financial news for BIIB dated on 2019-10-22: 8 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for BIIB dated on 2019-10-22: 16 Stocks Moving in Tuesday's Pre-Market Session

Financial news for BIIB dated on 2019-10-22: Biogen Earnings Call To Begin At 8:00 a.m. (Stream Link)

Financial news for BIIB dated on 2019-10-22: UPDATE: Seeing Reports Of Biogen Q3 Adj. EPS \$9.17

Financial news for BIIB dated on 2019-10-22: A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings

Financial news for BIIB dated on 2019-10-22: Biogen Q3 GAAP EPS \$8.39, Adj. EPS \$9.17 Beats \$8.27 Estimate, Sales \$3.6B Beat \$3.54B Estimate

Financial news for BIIB dated on 2019-10-22: Biogen shares are trading higher after the company announced it plans a regulatory filing for Aducanumab in Alzheimer's disease following new analysis. The terminated Phase 3 EMERGE study met its primary endpoint and the company now believes a subset of patients in the Phase 3 ENGAGE study also support the findings of EMERGE.

Financial news for BIIB dated on 2019-10-22: Biogen Plans Regulatory Filing For Aducanumab In Alzheimer's Disease Based On New Analysis Of Larger Dataset From Phase 3 Studies

Financial news for BIIB dated on 2019-10-22: 12 Stocks To Watch For October 22, 2019

Financial news for BIIB dated on 2019-10-22: Earnings Scheduled For October 22, 2019

Financial news for BIIB dated on 2019-10-21: Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition

Financial news for BIIB dated on 2019-10-21: Earnings Roll On With Light Schedule Today But McDonald's, Biogen On Tuesday Calendar

Financial news for BIIB dated on 2019-10-17: Bank of America Reinstates Underperform on Biogen, Announces \$200 Price Target

Financial news for BIIB dated on 2019-10-11: Morgan Stanley Maintains Underweight on Biogen, Raises Price Target to \$212

Financial news for BIIB dated on 2019-10-03: Biogen Reports Biogen Canada's Results From NURTURE Study

Financial news for BIIB dated on 2019-10-01: Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.

Financial news for BIIB dated on 2019-10-01: Apple, Biogen And More 'Fast Money' Picks For October 1

Financial news for BIIB dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator

Elizabeth Warren in the lead.

Financial news for BIIB dated on 2019-09-25: Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company

Financial news for BIIB dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for BIIB dated on 2019-09-20: Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.

Financial news for BIIB dated on 2019-09-18: Biogen Reports To Initiate DEVOTE Trial To Evaluate A Higher Dose Of SPINRAZA For Treatment Of Spinal Muscular Atrophy

Financial news for BIIB dated on 2019-09-16: Biogen Shares Tick Lower On Volume As Traders Circulate Word Of Negative Comments From RBC Capital Suggesting Firm's Checks Have Detected Co.'s Study Of BG00011 Has Been Discontinued Due To Toxicity

Financial news for BIIB dated on 2019-09-13: Eisai, Biogen Will Discontinue Phase 3 Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

Financial news for BIIB dated on 2019-09-12: Biogen shares are trading lower following reports that an intellectual property trial has been instituted against the company by Sawai Pharmaceutical.

Financial news for BIIB dated on 2019-09-12: Biogen Shares Fall ~1.3% Amid Report Intellectual Property Right Patent Trial Against Co.'s '514 Tecfidera By Sawai Has Been Instituted By Patent Trial, Appeal Board As Claims Have Been Determined To Be Likely Invalid

Financial news for BIIB dated on 2019-09-12: New Data Demonstrate Potential Benefits of Treatment With Tysabri, Plegridy and Avonex in Specific MS Patient Populations

Financial news for BIIB dated on 2019-09-11: The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With \$260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway

Financial news for BIIB dated on 2019-09-11: Biogen Announces New Data Presented atECTRIMS Reinforce Long-term Benefits of TECFIDERA Over 10 Years

Financial news for BIIB dated on 2019-08-20: Biogen And Invitae Announce Availability Of SMA STAT Rapid-Turnaround Genetic Test For Spinal Muscular Atrophy

Financial news for BIIB dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for BIIB dated on 2019-08-07: Shares of several healthcare companies are trading lower in sympathy with the overall market.

Financial news for BIIB dated on 2019-07-30: Alkermes, Biogen Report Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events

Financial news for BIIB dated on 2019-07-28: The Week In Cannabis: Tobacco And Retail Stray In The Weeds, Congress Holds SAFE Banking Hearings, New ETFs, And More

Financial news for BIIB dated on 2019-07-24: Morgan Stanley Maintains Underweight, \$211 Target On Biogen As Firm Notes '2Q Beats But Doesn't Change Our LT View'; Firm Notes 'With our tail concerns around Tecfidera IP, MS pricing, Rituxan biosimilars and Spinraza competition unchanged, we remain UW'

Financial news for BIIB dated on 2019-07-24: Canaccord Genuity Maintains Hold on Biogen, Raises Price Target to \$285

Financial news for BIIB dated on 2019-07-24: 60 Biggest Movers From Yesterday

Financial news for BIIB dated on 2019-07-23: 45 Stocks Moving In Tuesday's Mid-Day Session

Financial news for BIIB dated on 2019-07-23: ICC International Cannabis, Biotii Technologie Sign Advisory Agreement With Dr. Alexandros Makriyannis

Financial news for BIIB dated on 2019-07-23: Budget Deal, Earnings Strength From Lockheed, CocaCola, United Technologies Lift Spirits

Financial news for BIIB dated on 2019-07-23: Biogen shares are trading higher after

the company reported better-than-expected Q2 EPS and sales and raised FY19 guidance.

Financial news for BIIB dated on 2019-07-23: Biogen Reports Q2 Earnings Beat, Raises Guidance

Financial news for BIIB dated on 2019-07-23: Biogen Raises FY19 Adj. EPS Guidance From \$28-\$29 To \$31.50-\$32.30 vs \$29.70 Est.

Financial news for BIIB dated on 2019-07-23: Biogen Earlier Reported Q2 EPS \$9.15 Beats \$7.53 Estimate, Sales \$3.617B Beat \$3.48B Estimate

Financial news for BIIB dated on 2019-07-23: The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

Financial news for BIIB dated on 2019-07-23: Earnings Scheduled For July 23, 2019

Financial news for BIIB dated on 2019-07-20: The Week Ahead In Biotech: Pharma Earnings Pick Up Pace

Financial news for BIIB dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for BIIB dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for BIIB dated on 2019-07-08: Biogen to Collaborate with Skyhawk Therapeutics to Develop Novel Small Molecule RNA Splicing Modifiers, Biogen to Make Upfront and Milestone Payments

Financial news for BIIB dated on 2019-07-01: Biogen Announces New Data Further Establishing SPINRAZA as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients

Financial news for BIIB dated on 2019-06-28: 10 Biggest Price Target Changes For Friday

Financial news for BIIB dated on 2019-06-28: Benzinga's Top Upgrades, Downgrades For June 28, 2019

Financial news for BIIB dated on 2019-06-28: A Peek Into The Markets: US Stock Futures Gain Ahead Of Economic Reports

Financial news for BIIB dated on 2019-06-28: Piper Jaffray Downgrades Biogen to Neutral, Lowers Price Target to \$250

Financial news for BIIB dated on 2019-06-25: Shares of multiple drugmakers and biotech companies are trading higher after AbbVie announced it will acquire Allergan.

Financial news for BIIB dated on 2019-06-13: Biogen's Canada Unit Wins Broader Access To Spinraza By Province Of Ontario, Canada

Financial news for BIIB dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for BIIB dated on 2019-05-30: Biogen Reports New Phase 3 Interim Results Support Safety And Efficacy Of Diroximel Fumarate In Multiple Sclerosis

Financial news for BIIB dated on 2019-05-29: Nightstar Therapeutics Offers Expected Timetable For Purchase By Biogen

Financial news for BIIB dated on 2019-05-23: Benzinga's Top Upgrades, Downgrades For May 23, 2019

Financial news for BIIB dated on 2019-05-23: Wedbush Initiates Coverage On Biogen Inc. - Common Stock with Neutral Rating, Announces \$231 Price Target

Financial news for BIIB dated on 2019-05-21: Benzinga's Top Upgrades, Downgrades For May 21, 2019

Financial news for BIIB dated on 2019-05-21: Credit Suisse Initiates Coverage On Biogen Inc. - Common Stock with Underperform Rating, Announces \$198 Price Target

Financial news for BIIB dated on 2019-05-20: Biogen Shares Quiet After Hours Despite

Report Credit Suisse Initiated Coverage With An Underperform Rating And \$198 Price Target

Financial news for BIIB dated on 2019-05-20: Biogen Reports Received Notice Of Unsolicited Mini-Tender Offer By TRC Capital To Buy 500K Shares At \$216.25/Share In Cash

Financial news for BIIB dated on 2019-05-16: Shares of many Healthcare companies are trading higher as markets rebound from the recent volatility caused by uncertainty regarding US-China trade talks. Also, lawmakers were not able to pass a bill that would end 'surprise medical bills'.

Financial news for BIIB dated on 2019-05-15: The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGaA's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi

Financial news for BIIB dated on 2019-05-15: Biogen Reported Late Tues. SPINRAZA Received Positive Recommendation From NICE For Funding In US For Treatment of Infants, Children and Adults with Spinal Muscular Atrophy

Financial news for BIIB dated on 2019-05-14: Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.

Financial news for BIIB dated on 2019-05-09: Barclays Maintains Equal-Weight on Biogen Inc. - Common Stock, Lowers Price Target to \$245

Financial news for BIIB dated on 2019-05-08: Nightstar Therapeutics Reports Shareholders Approved Purchase By Biogen

Financial news for BIIB dated on 2019-05-07: The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

Financial news for BIIB dated on 2019-05-06: Notable Insider Buys This Past Week: ADM, Biogen, Grubhub and More

Financial news for BIIB dated on 2019-05-06: Biogen Highlights Data For Long-Term Safety, Durability Study With SPINRAZA At 2019 AAN Annual Meeting

Financial news for BIIB dated on 2019-05-02: What's The Buzz Around Novartis' Gene Therapy Zolgensma?

Financial news for BIIB dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for BIIB dated on 2019-05-01: Biogen Highlights Will Present New Data For Its Neuroscience Portfolio, Advancing Clinical Development Programs At American Academy of Neurology

Financial news for BIIB dated on 2019-04-30: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for BIIB dated on 2019-04-30: Biogen Highlights Publication Of SPINRAZA Data In Neurology Journal

Financial news for BIIB dated on 2019-04-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for BIIB dated on 2019-04-25: From Abbvie Conference Call; Co. Says Humira Biosimilars From Biogen And Amgen In Europe Have Been The Most Aggressive In The Market So Far

Financial news for BIIB dated on 2019-04-24: The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova

Financial news for BIIB dated on 2019-04-24: Biogen Q1 Sales \$3.49B vs \$3.39B Estimate, Adj. EPS \$6.98 vs \$6.84

Financial news for BIIB dated on 2019-04-24: Earnings Scheduled For April 24, 2019

Financial news for BIIB dated on 2019-04-23: Earnings Beats Keep Coming, With Verizon, CocaCola, Twitter, Procter & Gamble All Solid

Financial news for BIIB dated on 2019-04-21: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for BIIB dated on 2019-04-16: Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.

Financial news for BIIB dated on 2019-04-16: '\$BIIB *ALEX DENNER TALKS BIOGEN AT 13D CONFERENCE *DENNER: BIOGEN CASH FLOWS ARE THERE, 'LOTS AND LOTS OF CASH''-Tweets Christian Fromhertz

Financial news for BIIB dated on 2019-04-12: Biogen Reports Will Present New Data Showing Progressive Nature Of Spinal Muscular Atrophy In Adults, Adolescents, Older Children At The Muscular Dystrophy Association Clinical and Scientific Conference

Financial news for BIIB dated on 2019-04-10: UBS Upgrades Gilead, Sees EPS Upside In 2019

Financial news for BIIB dated on 2019-04-10: Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds

Financial news for BIIB dated on 2019-03-29: The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead

Financial news for BIIB dated on 2019-03-27: 6 Gene Therapy M&A Targets On The Radar

Financial news for BIIB dated on 2019-03-25: Biogen Announces a \$5B Buyback

Financial news for BIIB dated on 2019-03-24: Bulls & Bears Of The Week: Boeing, Facebook, Fox, Netflix, Starbucks And More

Financial news for BIIB dated on 2019-03-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for BIIB dated on 2019-03-22: 'Biogen-Eisai partnership may be hitting a rough patch following Alzheimer's drug blowup' -STAT News

Financial news for BIIB dated on 2019-03-22: Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'

Financial news for BIIB dated on 2019-03-22: Eisai Launches Confirmatory Late-Stage Trial Of Second Alzheimer's Asset After Setback

Financial news for BIIB dated on 2019-03-22: 10 Biggest Price Target Changes For Friday

Financial news for BIIB dated on 2019-03-22: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Mar. 22, 2019

Financial news for BIIB dated on 2019-03-22: Nomura Maintains Buy on Biogen, Lowers Price Target to \$320

Financial news for BIIB dated on 2019-03-22: Benzinga's Top Upgrades, Downgrades For March 22, 2019

Financial news for BIIB dated on 2019-03-22: Mizuho Downgrades Biogen to Neutral, Lowers Price Target to \$235

Financial news for BIIB dated on 2019-03-22: The Daily Biotech Pulse: Immute Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback

Financial news for BIIB dated on 2019-03-22: Canaccord Genuity Downgrades Biogen to Hold, Lowers Price Target to \$275

Financial news for BIIB dated on 2019-03-22: A Peek Into The Markets: US Stock Futures Tumble Ahead Of Economic Data

Financial news for BIIB dated on 2019-03-22: Citigroup Downgrades Biogen to Neutral, Lowers Price Target to \$230

Financial news for BIIB dated on 2019-03-22: UBS Downgrades Biogen to Neutral

Financial news for BIIB dated on 2019-03-22: Morgan Stanley Downgrades Biogen to Underweight

Financial news for BIIB dated on 2019-03-22: 60 Biggest Movers From Yesterday

Financial news for BIIB dated on 2019-03-21: Mid-Afternoon Market Update: Dow Surges 250 Points; Micron Shares Gain On Upbeat Earnings

Financial news for BIIB dated on 2019-03-21: 48 Stocks Moving In Thursday's Mid-Day Session

Financial news for BIIB dated on 2019-03-21: '@petenajarian biib goes way lower they are losing a patient too stk to 200 maybe 175 THIS drug was their future future dead 150 before 280' -sam tweets

Financial news for BIIB dated on 2019-03-21: Mid-Day Market Update: Superconductor Technologies Rises After Q4 Results; Staffing 360 Solutions Shares Slide

Financial news for BIIB dated on 2019-03-21: Cantor Fitzgerald Downgrades Biogen to Neutral

Financial news for BIIB dated on 2019-03-21: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Thurs., Mar. 21, 2019

Financial news for BIIB dated on 2019-03-21: Hearing Goldman Sachs Downgrades Biogen From Buy To Neutral

Financial news for BIIB dated on 2019-03-21: Biogen Shares Relatively Quiet As Hearing Wells Fargo Downgrades From Outperform To Market Perform

Financial news for BIIB dated on 2019-03-21: JP Morgan Removes Biogen From Analyst Focus List

Financial news for BIIB dated on 2019-03-21: JP Morgan Says Believes Without Alzheimer's Lottery Ticket In Hand, The Company Faces An Uncertain And Difficult Path Forward

Financial news for BIIB dated on 2019-03-21: Mid-Morning Market Update: Markets Open Higher; Conagra Earnings Top Expectations

Financial news for BIIB dated on 2019-03-21: Hearing Biogen Downgraded To Neutral By BTIG

Financial news for BIIB dated on 2019-03-21: '\$BIIB Scorecard for its "high RISK high reward" R&D strategy. Pretty much everything except Spinraza on this pipeline chart from 2015 failed' -Tweet From Notable Biotech Source

Financial news for BIIB dated on 2019-03-21: Atlantic Equities Downgrades Biogen to Neutral

Financial news for BIIB dated on 2019-03-21: William Blair Downgrades Biogen to Market Perform

Financial news for BIIB dated on 2019-03-21: Hearing Baird Cuts Price Target On Biogen From \$348 To \$250

Financial news for BIIB dated on 2019-03-21: Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study

Financial news for BIIB dated on 2019-03-21: Biogen shares are trading lower after the company said it will discontinue phase 3 trials of the company's Alzheimer's drug candidate.

Financial news for BIIB dated on 2019-03-21: iShares Nasdaq Biotech ETF Down 3% Premarket

Financial news for BIIB dated on 2019-03-21: The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering

Financial news for BIIB dated on 2019-03-21: 31 Stocks Moving In Thursday's Pre-Market Session

Financial news for BIIB dated on 2019-03-21: Watching Stocks With Alzheimer's Treatment Candidates: Merck, Roche, AbbVie, Neurotrope, AC Immune, Denali, INmune Bio, BioXcel Therapeutics, Intra-Cellular, Anavex, Pain Therapeutics, Grifols

Financial news for BIIB dated on 2019-03-21: Biogen Down ~\$16B In Market Cap Following News Alzheimer's Candidate Trial Will Be Discontinued

Financial news for BIIB dated on 2019-03-21: Biogen Shares Resume Trade, Down 25%

Financial news for BIIB dated on 2019-03-21: Biogen Shares To Resume Trade At 7:30 a.m. EDT

Financial news for BIIB dated on 2019-03-21: UPDATE: Biogen Says 'Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials'

Financial news for BIIB dated on 2019-03-21: Biogen, Eisai To Discontinue Phase 3 ENGAGE, EMERGE Trials Of Aducanumab In Alzheimer's

Financial news for BIIB dated on 2019-03-21: Biogen Shares Halted News Pending

Financial news for BIIB dated on 2019-03-12: Fujifilm To Acquire Large-Scale Biologics Manufacturing Site From Biogen for ~\$890M in Cash

Financial news for BIIB dated on 2019-03-10: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Financial news for BIIB dated on 2019-03-06: Shares of several biotech companies are trading lower after FDA commissioner Scott Gottlieb announced he will resign; he pushed to spur the development of new drugs and with his absence, there is concern on future FDA approvals.

Financial news for BIIB dated on 2019-03-05: Analysts Laud Biogen's M&A Strategy Following Deal to Buy Gene Therapy Company Nightstar

Financial news for BIIB dated on 2019-03-05: 62 Biggest Movers From Yesterday

Financial news for BIIB dated on 2019-03-04: Mid-Afternoon Market Update: Nightstar Therapeutics Surges On Acquisition News; Evoke Pharma Shares Plunge

Financial news for BIIB dated on 2019-03-04: 50 Stocks Moving In Monday's Mid-Day Session

Financial news for BIIB dated on 2019-03-04: Mid-Day Market Update: U.S. Stocks Turn Negative; Dow Down Over 350 Points

Financial news for BIIB dated on 2019-03-04: Mid-Morning Market Update: Markets Open Higher; Childrens Place Misses Q4 Expectations

Financial news for BIIB dated on 2019-03-04: Biogen Bets On Gene Therapy, Agrees To Acquire Nightstar For \$800M

Financial news for BIIB dated on 2019-03-04: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for BIIB dated on 2019-03-04: A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street

Financial news for BIIB dated on 2019-03-04: Nightstar Therapeutics Announces Agreement to be Acquired by Biogen for \$25.50/Share in Cash

Financial news for BIIB dated on 2019-02-28: Biogen Reports SPINRAZA Has Received Approval From China National Medical Products Association

Financial news for BIIB dated on 2019-02-25: Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis

Financial news for BIIB dated on 2019-02-22: 8 Biggest Price Target Changes For Friday

Financial news for BIIB dated on 2019-02-22: Benzinga's Top Upgrades, Downgrades For February 22, 2019

Financial news for BIIB dated on 2019-02-22: Guggenheim Downgrades Biogen to Neutral, Lowers Price Target to \$325

Financial news for BIIB dated on 2019-02-22: BMO Capital Initiates Coverage On Biogen with Market Perform Rating, Announces \$322 Price Target

Financial news for BIIB dated on 2019-02-21: Biogen shares are trading lower after Stifel Nicolaus downgraded the company's stock from Buy to Hold and lowered its price target from \$397 to \$346 per share.

Financial news for BIIB dated on 2019-02-21: 10 Biggest Price Target Changes For Thursday

Financial news for BIIB dated on 2019-02-21: Benzinga's Top Upgrades, Downgrades For February 21, 2019

Financial news for BIIB dated on 2019-02-21: Stifel Nicolaus Downgrades Biogen to Hold, Lowers Price Target to \$346

Financial news for BIIB dated on 2019-02-07: UPDATE: USPTO Says Mylan Has 'demonstrated a reasonable likelihood of success in proving that at least claim 1 of the '514 patent is unpatentable'

Financial news for BIIB dated on 2019-02-07: Biogen shares are trading lower after the U.S. Patent and Trademark Office reportedly stated that Mylan could likely succeed in a patent challenge against a Biogen multiple sclerosis drug.

Financial news for BIIB dated on 2019-02-07: Documents From Wednesday Show Mylan Pharmaceuticals Has Filed Petition Requesting Review Of Patent Claims Against Biogen

Financial news for BIIB dated on 2019-02-02: Insider Buys Of The Week: Biogen, Discover Financial, Kinder Morgan

Financial news for BIIB dated on 2019-01-30: Ionis Wins Price Target Hike On Partner Biogen's Guidance

Financial news for BIIB dated on 2019-01-30: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for BIIB dated on 2019-01-29: Biogen Earlier Guided FY19 Adj. EPS \$28-\$29 vs \$28.02 Estimate, Sales \$13.6B-\$13.8B vs \$13.65B Est.

Financial news for BIIB dated on 2019-01-29: The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive

Financial news for BIIB dated on 2019-01-29: Biogen Idec Q4 Adj. EPS \$6.99 Beats \$6.71 Estimate, Sales \$3.53B Beat \$3.39B Estimate

Financial news for BIIB dated on 2019-01-29: 12 Stocks To Watch For January 29, 2019

Financial news for BIIB dated on 2019-01-29: Earnings Scheduled For January 29, 2019

Financial news for BIIB dated on 2019-01-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for BIIB dated on 2019-01-04: Biogen shares are trading higher after the company announced it entered a strategic collaboration with C4 Therapeutics to discover and develop new treatments for neurological conditions.

Financial news for BIIB dated on 2019-01-04: Activision Blizzard, Biogen, Expedia, Newmont Mining: 'Fast Money' Picks For January 4

Financial news for BIIB dated on 2019-01-04: Biogen, Skyhawk Therapeutics Reports Deal To Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

Financial news for BIIB dated on 2019-01-04: Biogen, C4 Therapeutics Reports Strategic Collaboration To Discover, Develop Potential New Treatments For Neurological Conditions

Financial news for BIIB dated on 2019-01-03: Biogen Reports First Patient Enrolled In Phase 3b Study To Evaluate Extended Interval Dosing With Natalizumab In Multiple Sclerosis

Financial news for BIIB dated on 2018-12-26: 6 Valuable Pipeline Drugs With Upcoming Catalysts

Financial news for BIIB dated on 2018-12-21: When Larger Firms Walk Away From Partnerships With Smaller Ones: How Bad Is The Damage?

Financial news for BIIB dated on 2018-12-21: BTIG Research Initiates Coverage On Biogen with Buy Rating, Announces \$362 Price Target

Financial news for BIIB dated on 2018-12-19: Nearly 30 Drug Companies, Including Novartis, Bayer, Amgen, Biogen Notified Payers In California Of Plans To Raise Prices In January

Financial news for BIIB dated on 2018-12-19: Morgan Stanley Maintains Overweight on Biogen, Raises Price Target to \$401

Financial news for BIIB dated on 2018-12-17: Alkermes And Biogen Announce Submission Of New Drug Application To U.S. Food And Drug Administration For Diroximel Fumarate In Multiple Sclerosis

Financial news for BIIB dated on 2018-12-13: Sell-Side Roundup: What's Next For Applied Genetic After 50% Plunge?

Financial news for BIIB dated on 2018-12-13: The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

Financial news for BIIB dated on 2018-12-12: UPDATE: Applied Genetic Technologies Reports Will 'regain rights to 5 clinical and preclinical development programs; Biogen terminates collaboration agreement'

Financial news for BIIB dated on 2018-12-06: UPDATE: Biogen Made 1-Time \$35M Payment

To Ionis; Future Payments May Include Potential Post-Licensing Milestone Payments Of Up To \$55M And Royalties In Low To Mid Teen Percent Range

Financial news for BIIB dated on 2018-12-06: Biogen Reports Exercise Of Option With Ionis Pharma For Development, Commercialization Of BIIB067 For Subtype Of Familial Amyotrophic Lateral Sclerosis

Financial news for BIIB dated on 2018-11-21: HitGen Reports DNA-Encoded Library-Based Drug Discovery Research Collaboration With Biogen

Financial news for BIIB dated on 2018-11-14: From 13-F Filing: Temasek Dissolves Share Stakes in Disney, Amgen, Celgene, Biogen, Medtronic

Financial news for BIIB dated on 2018-11-02: Jim Cramer Weighs In On Biogen, Colgate-Palmolive And More

Financial news for BIIB dated on 2018-10-29: These Are The Biggest Stocks Reporting Earnings This Week, And Their Recent Track Records

Financial news for BIIB dated on 2018-10-29: Biogen, Eisai Announce Presentation of Detailed Analyses from Phase 1b Long-Term Extension Study of Aducanumab at CTAD

Financial news for BIIB dated on 2018-10-26: Biogen And Eisai Presented Analyses From Previous Phase 1b Long-Term Extension Study Of Aducanumab At Clinical Trials On Alzheimer's Disease (CTAD)

Financial news for BIIB dated on 2018-10-26: The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

Financial news for BIIB dated on 2018-10-26: Eisai, Biogen Announce Presentation of Additional Data from Phase II Clinical Trial of BAN2401 in Early Alzheimer's Disease at CTAD Conference

Financial news for BIIB dated on 2018-10-25: Eisai And Biogen To Present Additional Data From Phase II Clinical Trial Of BAN2401 In Early Alzheimer's Disease At The 2018 Clinical Trials On Alzheimer's Disease (CTAD) Conference Today

Financial news for BIIB dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for BIIB dated on 2018-10-24: US Appeals Court Has Affirmed Its Ruling For Biogen In Tecfidera Patent Dispute Against Forward Pharma

Financial news for BIIB dated on 2018-10-24: JP Morgan Maintains Overweight on Biogen, Lowers Price Target to \$436

Financial news for BIIB dated on 2018-10-24: Hearing Biogen Has Highlighted Adverse Events In Phase 1b Trial For Aducanumab

Financial news for BIIB dated on 2018-10-23: The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Financial news for BIIB dated on 2018-10-23: A Peek Into The Markets: US Stock Futures Tumble Ahead Of Earnings

Financial news for BIIB dated on 2018-10-23: Biogen Earlier Highlighted Topline Results From Phase 2b Study Of Dapirolizumab Pegol In Systemic Lupus Erythematosus: Primary Endpoint Not Met, But Study Did Show Consistent, Potentially Meaningful Improvements For Majority Of Endpoints vs Placebo

Financial news for BIIB dated on 2018-10-23: Biogen Earlier Reported Q3 EPS \$7.40 Beats \$6.80 Estimate, Sales \$3.439B Beat \$3.33B Estimate

Financial news for BIIB dated on 2018-10-23: Earnings Scheduled For October 23, 2018

Financial news for BIIB dated on 2018-10-22: Biogen Q3 Earnings Outlook

Financial news for BIIB dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for BIIB dated on 2018-10-19: Benzinga's Top Upgrades, Downgrades For October 19, 2018

Financial news for BIIB dated on 2018-10-19: Bernstein Downgrades Biogen to Market Perform

Financial news for BIIB dated on 2018-10-17: Biogen, Samsung Bioepis Announce European Launch of IMRALDI

Financial news for BIIB dated on 2018-10-12: Equillium's IPO: What You Need To Know

Financial news for BIIB dated on 2018-10-11: Biogen Advances Research To Improve Outcomes f=For Patients With Multiple Sclerosis

Financial news for BIIB dated on 2018-10-08: Biogen On Saturday Reported SPINRAZA Data At Annual Congress Of The World Muscle Society; Study Achieved Motor Milestones

Financial news for BIIB dated on 2018-10-01: Cantor Fitzgerald Reinstates Overweight on Biogen, Announces \$400 Price Target

Financial news for BIIB dated on 2018-09-24: Wells Fargo Bullish On Applied Genetic Technologies Ahead Of Program Update

Financial news for BIIB dated on 2018-09-20: The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut

Financial news for BIIB dated on 2018-09-04: Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093

Financial news for BIIB dated on 2018-08-29: The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent

Financial news for BIIB dated on 2018-08-29: Biogen, Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab

Financial news for BIIB dated on 2018-08-28: Biogen And Eisai Report Data From Long-Term Extension Phase 1b Study Of Investigational Alzheimer's Disease Treatment Aducanumab

Financial news for BIIB dated on 2018-08-07: Stifel Buys Back Into Biogen, Sees Upside In Alzheimer's Candidate

Financial news for BIIB dated on 2018-08-07: Stifel Nicolaus Reinstates Buy on Biogen, Announces \$394

Financial news for BIIB dated on 2018-08-03: Biogen 8-K Shows News Of \$3.5B Buyback Plan

Financial news for BIIB dated on 2018-07-27: 60 Biggest Movers From Yesterday

Financial news for BIIB dated on 2018-07-26: Benzinga Pro's Top 10 Most-Searchd Tickers For Afternoon Of Jul. 26, 2018

Financial news for BIIB dated on 2018-07-26: 40 Stocks Moving In Thursday's Mid-Day Session

Financial news for BIIB dated on 2018-07-26: Stocks Which Set New 52-Week High Yesterday, July 25th

Financial news for BIIB dated on 2018-07-26: Biogen Shares Down 12% After Announcing Results Of Phase 2 Clinical Study Of BAN2401, Developed With Drugmaker Eisai, In Early Alzheimer's Disease Patients, "No Reasonable Conclusions" To Dar From Data According To Baird's Brian Skorney

Financial news for BIIB dated on 2018-07-26: UBS Maintains Buy on Biogen, Raises Price Target to \$395

Financial news for BIIB dated on 2018-07-26: Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Financial news for BIIB dated on 2018-07-26: 32 Stocks Moving In Thursday's Pre-Market Session

Financial news for BIIB dated on 2018-07-26: Eisai, Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018

Financial news for BIIB dated on 2018-07-25: Biogen and Eisai Announce BAN2401 Data Presented at AAIC, Showed Statistically Significant Amyloid Plaque Reduction In All Doses

Financial news for BIIB dated on 2018-07-25: Biogen Shares Gain On Midstage Results For Alzheimer's Candidate

Financial news for BIIB dated on 2018-07-25: Stocks That Made New 52-Week Highs Earlier Include: Adobe, S&P Global, Baxter, Salesforce, Microsoft, Biogen, Becton, Norfolk Southern, Target, IHS Markit, Tiffany, Eli Lilly, Thermo Fisher, Facebook,

FLIR Systems, Medtronic, and Mastercard

Financial news for BIIB dated on 2018-07-25: Barclays Maintains Equal-Weight on Biogen, Raises Price Target to \$320

Financial news for BIIB dated on 2018-07-25: Stocks Which Set New 52-Week High Yesterday, July 24th:

Financial news for BIIB dated on 2018-07-25: 'I find the \$BIIB stock reaction this morning astonishing.'-STAT's Adam Feuerstein Tweets

Financial news for BIIB dated on 2018-07-25: UPDATE: Eisai, Biogen Say 'Although a small sample size, using the florbetapir PET tracer demonstrated a statistically significant decrease in brain amyloid load compared to placebo for the 50 mg total group arm at 18 months'

Financial news for BIIB dated on 2018-07-25: UPDATE: Eisai, Biogen Report 'a statistically significant reduction of brain amyloid load as compared to placebo was observed in the 50 mg total group arm with a reduction in SUVR of 0.104'

Financial news for BIIB dated on 2018-07-25: UPDATE: Eisai, Biogen On Elenbecestat Study Data: 'no dose-dependent response was observed for adverse events,' 'No adverse reactions suggestive of hepatic toxicity were observed in this study'

Financial news for BIIB dated on 2018-07-25: Eisai, Biogen Offer Detailed Results From Phase II Study Of Elenbecestat In MCI, Mild To Moderate Alzheimer's Disease At AAIC Conference

Financial news for BIIB dated on 2018-07-25: Concerns About Trade Picture Overshadowing Earnings As GM, Boeing Report

Financial news for BIIB dated on 2018-07-25: 10 Biggest Price Target Changes For Wednesday

Financial news for BIIB dated on 2018-07-25: Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

Financial news for BIIB dated on 2018-07-25: Baird Maintains Neutral on Biogen, Raises Price Target to \$348

Financial news for BIIB dated on 2018-07-25: Morgan Stanley Maintains Overweight on Biogen, Raises Price Target to \$392

Financial news for BIIB dated on 2018-07-25: Biogen Holding Investor Webcast 6pm ET Today To Discuss Its Alzheimer's Disease Portfolio

Financial news for BIIB dated on 2018-07-25: 46 Biggest Movers From Yesterday

Financial news for BIIB dated on 2018-07-24: 34 Stocks Moving In Tuesday's Mid-Day Session

Financial news for BIIB dated on 2018-07-24: Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering

Financial news for BIIB dated on 2018-07-24: From Biogen Q2 Earnings Conference Call: Co. Recently Informed FDA Placed Clinical Hold On Investigational New Drug For SMA Gene Therapy Program

Financial news for BIIB dated on 2018-07-24: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for BIIB dated on 2018-07-24: A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings

Financial news for BIIB dated on 2018-07-24: Biogen Acquires Muscle Enhancement Program From Alivegen For \$27.5M

Financial news for BIIB dated on 2018-07-24: Biogen Reports Q2 EPS \$5.80 vs \$5.21 Est., Sales \$3.4B vs \$3.25B Est.

Financial news for BIIB dated on 2018-07-24: '\$BIIB Q2 Spinraza sales \$423M, topping \$390M consensus.'-STAT's Adam Feuerstein Tweets

Financial news for BIIB dated on 2018-07-24: Earnings Scheduled For July 24, 2018

Financial news for BIIB dated on 2018-07-23: Biogen Q2 Earnings Preview

Financial news for BIIB dated on 2018-07-23: The Week Ahead: FANG Earnings Continue,

Fox Vote On Disney Deal, More IPOs

Financial news for BIIB dated on 2018-07-23: 10 Biggest Price Target Changes For Monday

Financial news for BIIB dated on 2018-07-23: Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to \$396

Financial news for BIIB dated on 2018-07-23: AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns \$10M Enrollment Milestone

Financial news for BIIB dated on 2018-07-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for BIIB dated on 2018-07-21: Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus

Financial news for BIIB dated on 2018-07-20: Biogen To Host Investor Webcast Alzheimer's Disease Portfolio on July 25th, 6pm ET

Financial news for BIIB dated on 2018-07-20: Jim Cramer Advises His Viewers On BlackRock, Target And More

Financial news for BIIB dated on 2018-07-19: Delivering Alpha 2018: Everything You Need To Know

Financial news for BIIB dated on 2018-07-19: American Express, Biogen, Huntsman, Take-Two: 'Fast Money' Picks For July 19

Financial news for BIIB dated on 2018-07-18: Biogen Shares Tick ~\$2 Higher Over Last Few Mins. As Alex Denner Of Sarissa Capital, At Delivering Alpha Conference, Reiterating He Is On Co. Board; Says He Will Mention 2 Other Stocks During His Presentation

Financial news for BIIB dated on 2018-07-13: Morgan Stanley Maintains Overweight on Biogen, Lowers Price Target to \$366

Financial news for BIIB dated on 2018-07-10: Benzinga's Top Upgrades, Downgrades For July 10, 2018

Financial news for BIIB dated on 2018-07-10: Baird Downgrades Biogen to Neutral

Financial news for BIIB dated on 2018-07-09: Hearing RBC Capital Raised Biogen Price Target From \$320 To \$349

Financial news for BIIB dated on 2018-07-09: What Trade War? Positive Sentiment Seems To Continue From Friday

Financial news for BIIB dated on 2018-07-09: 5 Stocks To Watch For July 9, 2018

Financial news for BIIB dated on 2018-07-09: 34 Biggest Movers From Friday

Financial news for BIIB dated on 2018-07-06: Mid-Afternoon Market Update: Dow Rises 150 Points; Biogen Shares Climb On Positive Alzheimer's Drug Trial

Financial news for BIIB dated on 2018-07-06: Benzinga Pro's Top 10 Most-Searchd Tickers For Fri., Jul. 6, 2018

Financial news for BIIB dated on 2018-07-06: After Biogen's Alzheimer's Update, Wall Street Reacts

Financial news for BIIB dated on 2018-07-06: 32 Stocks Moving In Friday's Mid-Day Session

Financial news for BIIB dated on 2018-07-06: Mid-Day Market Update: Crude Oil Up Over 1%; Black Box Shares Spike Higher

Financial news for BIIB dated on 2018-07-06: PreMarket Prep Recap For July 6: Digesting Biogen's News With Adam Feuerstein; A Sector Breakdown With Dan Russo

Financial news for BIIB dated on 2018-07-06: Mid-Morning Market Update: Markets Mostly Higher; U.S. Adds 213,000 Jobs For June

Financial news for BIIB dated on 2018-07-06: Adam Feuerstein Cautious On Biogen Following Alzheimer's Study

Financial news for BIIB dated on 2018-07-06: Benzinga's Top Upgrades, Downgrades For July 6, 2018

Financial news for BIIB dated on 2018-07-06: The Market In 5 Minutes: Biogen, Pruitt, Unemployment, Tariffs And More

Financial news for BIIB dated on 2018-07-06: Benzinga Pro's 5 Stocks To Watch Today

Financial news for BIIB dated on 2018-07-06: Citigroup Upgrades Biogen to Buy, Announces \$371 Price Target

Financial news for BIIB dated on 2018-07-06: Biogen Rallies On Positive Alzheimer's Drug Trial

Financial news for BIIB dated on 2018-07-06: STAT News' Adam Feuerstein On Benzinga's PreMarket Prep Says 'Something like [Biogen Alzheimer's news] could get people more interested in the larger cap [biotech stocks], like a Biogen,' But Again Warns Of Cautiousness In General Moving Forward

Financial news for BIIB dated on 2018-07-06: STAT News' Adam Feuerstein Is Currently Discussing Biogen's Alzheimer's News On Benzinga's PreMarket Prep; Is Urging Caution, Sees This 'as a sliver of good news'

Financial news for BIIB dated on 2018-07-06: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for BIIB dated on 2018-07-06: STAT News' Adam Feuerstein Will Be On Benzinga's PreMarket Prep Morning Trade Show At 8:10 a.m. EDT; He'll Be Discussing The Big Biogen News; Tune In At premarket.benzinga.com

Financial news for BIIB dated on 2018-07-06: Benzinga's Daily Biotech Pulse: Biogen And Eisai's Alzheimer's Drug Meets End Points In Mid-Stage Trial, Obseva To List Shares On Swiss Exchange

Financial news for BIIB dated on 2018-07-06: A Peek Into The Markets: US Stock Futures Drop As US-China Trade War Begins

Financial news for BIIB dated on 2018-07-06: Mizuho Earlier Noted Biogen, Eisai's BAN2401 Unexpectedly Hit In Phase 2 Trial, Said Expectations On Trial Were 'really low,' Sees Biogen Shares Being Up 10%+

Financial news for BIIB dated on 2018-07-06: Biogen Shares Up 13.8% Premarket After Data From Co.'s Phase II Study Of BAN2401 Showed Statistically Significant Slowing Of Clinical Decline In Early Alzheimer's Patients; Hearing Citi Upgraded To Buy

Financial news for BIIB dated on 2018-07-06: Eisai, Biogen Announce Positive Topline Results Of The Final Analysis For BAN2401 At 18 Months in Early Alzheimer's Disease

Financial news for BIIB dated on 2018-06-30: Barron's Picks And Pans: Apple, Mastercard, Sirius XM, Verizon And More

Financial news for BIIB dated on 2018-06-28: Biogen Exercises Option to Increase Ownership in Samsung Bioepis, Biogen Will Pay Samsung BioLogics ~\$700M To Increase Its Ownership In Samsung Bioepis To ~49.9%; Transaction To Close 2H Of 2018

Financial news for BIIB dated on 2018-06-25: Biogen To Report Q2 Earnings On Tues., Jul. 24, 2018 Before Market Opens

Financial news for BIIB dated on 2018-06-25: The Week Ahead: Senate Weighs Sprint-T-Mobile Merger, Nike Earnings And A Slew Of IPOs

Financial news for BIIB dated on 2018-06-13: Samsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF Biosimilars BENEPAI, FLIXABI and IMRALDI

Financial news for BIIB dated on 2018-06-07: Biogen Enters Exclusive Option Agreement To Acquire TMS' Phase 2 Asset For Acute Stroke; Co. To Pay \$4M Upfront And \$18M Upon Exercise Of Option And Potential Milestones Of Up To \$335M

Financial news for BIIB dated on 2018-06-06: UPDATE: Alkermes Says May Also Receive \$150M Milestone Payment From Biogen Upon FDA Approval Of NDA For BIIB098

Financial news for BIIB dated on 2018-06-06: Alkermes Reports Received \$50M Payment From Biogen Related To Review Of Prelim. Gastrointestinal Tolerability Data From Ongoing BIIB098 Development Program

Financial news for BIIB dated on 2018-06-05: Ionis Closes Strategic Collaboration With Biogen To Develop Drugs For Broad Range of Neurological Diseases; Biogen Paid Ionis \$1B In Cash Including \$625M For Purchase Of ~11.5M Shares Of Common Stock @ \$54.34/Share And An Upfront Payment Of \$375M

Financial news for BIIB dated on 2018-06-05: Biogen, Eisai Report Phase II Study Of Elenbecestat Showed Safety, Tolerability In MCI, Mild To Moderate Alzheimer's Disease

At 18 Months

Financial news for BIIB dated on 2018-06-05: Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index

Financial news for BIIB dated on 2018-06-05: Eisai, Merck Announce Data from Investigational Studies of Lenvima and Keytruda Combination Therapy in Four Different Tumor Types at #ASCO2018

Financial news for BIIB dated on 2018-06-05: Eisai, Biogen Report PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months

Financial news for BIIB dated on 2018-05-31: Canaccord Upgrades Biogen On Deal Opportunities, Alzheimer's Pipeline

Financial news for BIIB dated on 2018-05-31: Hearing RBC Says Allergan And Biogen Are Two Companies That Could Be Interested In Either Partnering Or Acquiring Alder Biopharmaceuticals

Financial news for BIIB dated on 2018-05-31: Benzinga's Top Upgrades, Downgrades For May 31, 2018

Financial news for BIIB dated on 2018-05-31: The Market In 5 Minutes: Right To Try, Uber, Buffett, Jobless Claims And More

Financial news for BIIB dated on 2018-05-31: A Peek Into The Markets: US Stock Futures Flat Ahead Of Economic Data

Financial news for BIIB dated on 2018-05-31: Canaccord Genuity Upgrades Biogen to Buy

Financial news for BIIB dated on 2018-05-17: UPDATE: FDA Offers Guidelines, Background For Reference Listed Drug Access Inquiries, Related To Claim Of Blocking Generic Rivals

Financial news for BIIB dated on 2018-05-17: FDA Commissioner Scot Gottlieb Highlights List Of Cos. Which Have Potentially Blocked Access To Samples Of Their Branded Products: Pfizer, Biogen, INSYS, VIVUS, Valeant, Corcept Therapeutics

Financial news for BIIB dated on 2018-05-02: 8 Biggest Price Target Changes For Wednesday

Financial news for BIIB dated on 2018-05-02: Citigroup Maintains Neutral on Biogen, Lowers Price Target to \$290.00

Financial news for BIIB dated on 2018-05-01: UPDATE: Biogen To Make 1-Time \$50M Payment To Neurimmune In Exchange For 5% Reduction In Original Royalty Rates On Potential Commercial Sales Of Aducanumab

Financial news for BIIB dated on 2018-05-01: Biogen Reports Exercise Of Option To Further Reduce Royalty Rates On Potential Future Sales Of Aducanumab With Neurimmune

Financial news for BIIB dated on 2018-04-29: Insider Buys Of The Week: Apollo Global, Biogen And More

Financial news for BIIB dated on 2018-04-25: Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises

Financial news for BIIB dated on 2018-04-25: Benzinga's Top Upgrades, Downgrades For April 25, 2018

Financial news for BIIB dated on 2018-04-25: Morgan Stanley Maintains Overweight on Biogen, Raises Price Target to \$369.00

Financial news for BIIB dated on 2018-04-25: Baird Upgrades Biogen to Outperform

Financial news for BIIB dated on 2018-04-24: 'Cowen defending \$BIIB. "We haven't seen a quality name this inexpensive in awhile.'

Financial news for BIIB dated on 2018-04-24: Biogen Q1 Adj. EPS \$6.05 Beats \$5.94 Est., Sales \$3.131B Misses \$3.16B

Financial news for BIIB dated on 2018-04-24: Earnings Scheduled For April 24, 2018

Financial news for BIIB dated on 2018-04-23: What's In Store For Biogen This Earnings Season?

Financial news for BIIB dated on 2018-04-23: The Week Ahead: Sohn Conference, FANG

Earnings, DocuSign IPO

Financial news for BIIB dated on 2018-04-23: Biogen Announces New data for SPINRAZA to Present at the American Academy of Neurology Event

Financial news for BIIB dated on 2018-04-20: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for BIIB dated on 2018-04-20: Benzinga Pro's 5 Stocks To Watch Today

Financial news for BIIB dated on 2018-04-20: Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases, Will Pay Ionis \$1B In Cash Which Will Include \$625M TO Purchase 11.5M Shares Of Ionis Stock At \$54.34/Share

Financial news for BIIB dated on 2018-04-17: Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'

Financial news for BIIB dated on 2018-04-11: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis To Merge With Novartis And More

Financial news for BIIB dated on 2018-04-11: Mizuho: Samsung Bioepis Renegotiation 'A Positive' For Biogen

Financial news for BIIB dated on 2018-04-11: UPDATE: Mizuho Says Alleged Negotiation Between Biogen, Samsung 'hasn't hit many investors' inboxes...so we're putting everything here'

Financial news for BIIB dated on 2018-04-11: UPDATE: Mizuho Highlights Business Korea Article Describing Samsung Group Negotiation With Biogen To Buy Stake Or Part Of Samsung Bioepis

Financial news for BIIB dated on 2018-04-11: UPDATE: Mizuho On Biogen Says Sees Business Korea Article As Seemingly 'Potential Upside Catalyst For BIIB'

Financial news for BIIB dated on 2018-04-11: Biogen Shares Up 1.3%; Asian Publications Overnight Discussed 'Samsung Begins Talks with Biogen to secure control of biosimilar joint venture'; BZ NOTE: Biogen Announced Last Thurs. Commercialization Deal With Samsung Bioepis, AbbVie For IMRALDI

Financial news for BIIB dated on 2018-04-11: Biogen Shares Spike Over \$268 Level, Up 0.5% Over Last Few Mins. As Traders Circulate Word Mizuho Believes Stock Should Be Up \$11-\$20 On News Out Of Korea

Financial news for BIIB dated on 2018-04-05: Benzinga's Top Upgrades, Downgrades For April 5, 2018

Financial news for BIIB dated on 2018-04-05: UPDATE: Biogen Says Expects To Launch IMRALDI In Europe On Oct. 16, 2018

Financial news for BIIB dated on 2018-04-05: Biogen, Samsung Bioepis Reach Deal With AbbVie For Commercialization Of IMRALDI In Europe

Financial news for BIIB dated on 2018-04-05: Barclays Downgrades Biogen to Equal-Weight

Financial news for BIIB dated on 2018-04-03: Biogen Shares Spike ~\$1.20 Higher Over Last Min. As Traders Circulate Questionable Takeover Chatter In Name; Stock Showing Resistance At \$268 Level

Financial news for BIIB dated on 2018-03-28: Biogen To Report Q1 Earnings Tues., Apr. 24 Before Market Open

Financial news for BIIB dated on 2018-03-12: Biogen to Acquire a Phase 2b Ready Asset for Cognitive Impairment from Pfizer for \$75M Upfront and Up to \$515M in Milestones and Royalties

Financial news for BIIB dated on 2018-03-09: Don't Bail On Biotech ETFs: 'There Are Several Reasons Why The Sector Took A Breather'

Financial news for BIIB dated on 2018-03-07: Height Casts 65% Odds That Congress Rolls Back Pharma Discounts

Financial news for BIIB dated on 2018-03-05: 5 Biggest Price Target Changes For Monday

Financial news for BIIB dated on 2018-03-05: BMO Capital Maintains Outperform on Biogen, Lowers Price Target to \$393.00

Financial news for BIIB dated on 2018-03-02: Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA for Relapsing Multiple Sclerosis

Financial news for BIIB dated on 2018-02-28: Biogen Shares Up 0.1% Wed.; Credit Suisse Earlier Commented On Celgene's Ozanimod News, Said, 'we would also view this as an incremental positive for Biogen, since it's a delay for a competitor'

Financial news for BIIB dated on 2018-02-18: Benzinga's Bulls & Bears Of The Week: Bristol-Myers, GE, Target, Under Armour And More

Financial news for BIIB dated on 2018-02-16: Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs

Financial news for BIIB dated on 2018-02-16: Benzinga's Top Upgrades, Downgrades For February 16, 2018

Financial news for BIIB dated on 2018-02-16: Argus Downgrades Biogen to Hold

Financial news for BIIB dated on 2018-02-14: RBC Issues Negative Comments On Biogen In Mid-Day Note Following Variability Comment On Alzheimer's Treatment: 'highlights the inherent challenges in Alzheimer's studies and risks to this outcome'

Financial news for BIIB dated on 2018-02-14: STAT News' Adam Feuerstein Tweets '...\$BIIB told investors at the Leerink conference 510 Alzheimer's patients are being added to the aducanumab clinical trial due to "increased variability." Stock reacting negatively to this selective disclosure'

Financial news for BIIB dated on 2018-02-14: Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma

Financial news for BIIB dated on 2018-02-08: The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease

Financial news for BIIB dated on 2018-02-07: Biogen Misses Primary and Secondary Efficacy Endpoints in its ACTION 2 Study for Natalizumab

Financial news for BIIB dated on 2018-02-05: Mizuho Maintains Buy on Biogen, Raises Price Target to \$433.00

Financial news for BIIB dated on 2018-01-31: UBS: Buy Biogen For Pipeline, M&A Potential

Financial news for BIIB dated on 2018-01-31: Benzinga's Top Upgrades, Downgrades For January 31, 2018

Financial news for BIIB dated on 2018-01-31: UBS Upgrades Biogen to Buy

Financial news for BIIB dated on 2018-01-29: Here's Why Forward Pharma Lost 30% Today

Financial news for BIIB dated on 2018-01-26: 5 Biggest Price Target Changes For Friday

Financial news for BIIB dated on 2018-01-26: 44 Biggest Movers From Yesterday

Financial news for BIIB dated on 2018-01-25: Benzinga Pro's 4 Stocks To Watch Today

Financial news for BIIB dated on 2018-01-25: Biogen to Acquire Karyopharm's KPT-350 for \$10M Upfront an Up to An Additional \$207M in Milestones and Royalties

Financial news for BIIB dated on 2018-01-25: Biogen Sees FY18 Adj. EPS \$24.20 to \$25.20 vs \$24.16 Est., Sales \$12.7B to \$13.0B vs \$12.7B Est.

Financial news for BIIB dated on 2018-01-25: Biogen Reports Q4 EPS \$5.26 vs \$5.45 Est., Sales \$3.31B vs \$3.08B Est.

Financial news for BIIB dated on 2018-01-25: Earnings Scheduled For January 25, 2018

Financial news for BIIB dated on 2018-01-24: Argus: Bioverativ Shares Fully Valued After Sanofi Buyout Offer

Financial news for BIIB dated on 2018-01-23: Biotech M&A Off To A Strong Start In 2018: More Deals To Follow?

Financial news for BIIB dated on 2018-01-22: The Week Ahead: IPOs, Earnings, And FDA Actions Provide Catalysts

Financial news for BIIB dated on 2018-01-22: 34 Biggest Movers From Friday

Financial news for BIIB dated on 2018-01-19: 28 Stocks Moving In Friday's Mid-Day Session

Financial news for BIIB dated on 2018-01-19: 14 Stocks Moving In Friday's Pre-Market Session

Financial news for BIIB dated on 2018-01-19: Benzinga Pro's 6 Stocks To Watch Today

Financial news for BIIB dated on 2018-01-19: Acorda Therapeutics Shares Indicated Up 8.8% Premarket Fri. Following Renewed Takeover Chatter; Thurs. Stock Rallied As Much As ~7%, Only to Sell Off During Afternoon Session; Report Fri. Morning Suggests Biogen, UCB Are Interested

Financial news for BIIB dated on 2018-01-16: The 10 Most Undervalued Stocks Kicking Off Earnings Season

Financial news for BIIB dated on 2018-01-08: JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma

Financial news for BIIB dated on 2018-01-05: BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A

Financial news for BIIB dated on 2018-01-04: Biogen To Report Q4 Earnings Thurs., Jan 25 Before Market Open

Financial news for BIIB dated on 2017-12-22: Biogen Issues Response To Coverage Recommendation By CDEC For SPINRAZA

Financial news for BIIB dated on 2017-12-21: On Today's PreMarket Prep: An Interview With The CME's Tim McCourt On Bitcoin Futures

Financial news for BIIB dated on 2017-12-21: UPDATE: Biogen, Eisai Say, 'Study to Remain Blinded Per Protocol until Final Readout of Comprehensive 18-Month Data'

Financial news for BIIB dated on 2017-12-21: UPDATE: Biogen, Eisai Say, 'Criteria for Success at 12-Month Analysis of ADCOMS Not Met'

Financial news for BIIB dated on 2017-12-21: Biogen, Eisai Report Adaptive Phase II Study Of BAN2401 In Early Alzheimier's Disease Continues Toward 18-Month Endpoint

Financial news for BIIB dated on 2017-12-20: 5 Stocks Moving In Wednesday's After-Hours Session

Financial news for BIIB dated on 2017-12-20: Biogen To Report Q4 Earnings Thurs., Jan. 25 Before Market Open

Financial news for BIIB dated on 2017-12-20: 3 Biotech Pipeline Areas To Keep An Eye On In 2018

Financial news for BIIB dated on 2017-12-19: UPDATE: Ionis To Receive \$25M Upfront Payment, Development, Regulatory Milestone Payments From Biogen

Financial news for BIIB dated on 2017-12-19: Biogen Reports New Collaboration With Ionis Pharma For Identification Of Novel Therapies For Treatment Of Spinal Muscular Atrophy

Financial news for BIIB dated on 2017-12-15: Biogen Issues Response To INESSS Recommendation For SPINRAZA

Financial news for BIIB dated on 2017-11-30: CMS Head Verma Says Agency Considering Ways To Curb Costs For Expensive New Medications

Financial news for BIIB dated on 2017-11-27: Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis, Plans to Submit NDA in 2018

Financial news for BIIB dated on 2017-11-21: Biogen Names Jeff Capello CFO

Financial news for BIIB dated on 2017-11-15: Steven Cohen's 6 Best Performing Stocks That Still Have Big Upside

Financial news for BIIB dated on 2017-11-10: Buybacks And Dividends In One ETF

Financial news for BIIB dated on 2017-11-09: Benzinga's Top Upgrades, Downgrades For November 9, 2017

Financial news for BIIB dated on 2017-11-09: Oppenheimer Initiates Coverage On Biogen with Outperform Rating, Announces \$350.00 Price Target

Financial news for BIIB dated on 2017-11-08: A Big Biotech ETF Is About To Get Cheaper

Financial news for BIIB dated on 2017-11-02: Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab

Financial news for BIIB dated on 2017-10-27: Benzinga's Top Upgrades, Downgrades For October 27, 2017

Financial news for BIIB dated on 2017-10-27: Canaccord Genuity Initiates Coverage On Biogen with Hold Rating, Announces \$340.00 Price Target

Financial news for BIIB dated on 2017-10-26: It's A Bad Day For Biotechs

Financial news for BIIB dated on 2017-10-26: Lightning Round: Jim Cramer Shares His Thoughts On Kroger, Corning And More

Financial news for BIIB dated on 2017-10-25: BMO: Biogen's Risks Quickly Becoming Priced In, But This May Not Be The Bottom

Financial news for BIIB dated on 2017-10-25: Benzinga's Top Upgrades, Downgrades For October 25, 2017

Financial news for BIIB dated on 2017-10-25: BMO Capital Upgrades Biogen to Outperform

Financial news for BIIB dated on 2017-10-25: Biogen Announces Initiation of AFFINITY Phase 2 Trial for Opicinumab in MS

Financial news for BIIB dated on 2017-10-24: Mid-Day Market Update: Dow Rises 175 Points; Identiv Shares Plunge

Financial news for BIIB dated on 2017-10-24: Adam Feuerstein Tweets: \$BIIB blockbuster rare-disease therapy staggers after a strong start statnews.com/2017/10/24/bio... Spinraza \$IONS w/ @damiangarde co-byline!

Financial news for BIIB dated on 2017-10-24: 14 Technical Levels Discussed On Tuesday's PreMarket Prep

Financial news for BIIB dated on 2017-10-24: Guggenheim Initiates Coverage On Biogen with Buy Rating, Announces \$402.00 Price Target

Financial news for BIIB dated on 2017-10-24: Biogen Earnings Release Included Collaboration Deal Update Showing Co. 'will now receive 55% of potential aducanumab profits in the U.S., 68.5% of profits in Europe, and 20% of profits in Japan'

Financial news for BIIB dated on 2017-10-24: A Peek Into The Markets: U.S. Stock Futures Gain; McDonald's, General Motors Earnings In Focus

Financial news for BIIB dated on 2017-10-24: Biogen Q3 EPS \$6.31 vs \$5.70 Est., Sales \$3.08B vs \$3.03B Est.

Financial news for BIIB dated on 2017-10-24: Biogen to Pay Neurimmune Holding \$150M for a 15% Reduction in Royalty Rates for Aducanumab

Financial news for BIIB dated on 2017-10-24: Biogen, Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab

Financial news for BIIB dated on 2017-10-24: Earnings Scheduled For October 24, 2017

Financial news for BIIB dated on 2017-10-23: Biogen Bull Thesis Baked In, No Longer A Buy At Citi

Financial news for BIIB dated on 2017-10-23: Benzinga's Top Upgrades, Downgrades For October 23, 2017

Financial news for BIIB dated on 2017-10-23: The Week Ahead: Earnings Season Starts In Earnest

Financial news for BIIB dated on 2017-10-23: Citigroup Downgrades Biogen to Neutral

Financial news for BIIB dated on 2017-10-23: Biogen and Eisai Expand Existing Partnership Agreement to Develop and Commercialize Investigational Alzheimer's

Disease Treatments Including Phase 3 Aducanumab

Financial news for BIIB dated on 2017-10-23: PiperJaffray Assumes Biogen at Overweight, Announces price target \$390.00

Financial news for BIIB dated on 2017-10-18: Biogen Offers Highlights From Efforts 'To Tackle MS' AtECTRIMS-ECTRIMS

Financial news for BIIB dated on 2017-10-17: Biogen's Best-In-Class R&D Earn Makes It A Buy

Financial news for BIIB dated on 2017-10-17: 5 Biggest Price Target Changes For Tuesday

Financial news for BIIB dated on 2017-10-17: Benzinga's Top Upgrades, Downgrades For October 17, 2017

Financial news for BIIB dated on 2017-10-17: The Market In 5 Minutes: Netflix, Goldman Sachs, And Morgan Stanley Keep The Earnings Beats Going

Financial news for BIIB dated on 2017-10-17: A Peek Into The Markets: U.S. Stock Futures Flat; Goldman Sachs Earnings In Focus

Financial news for BIIB dated on 2017-10-17: Mizuho Upgrades Biogen to Buy

Financial news for BIIB dated on 2017-10-17: Stifel Nicolaus Upgrades Biogen to Buy

Financial news for BIIB dated on 2017-10-10: 5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings

Financial news for BIIB dated on 2017-10-06: Life (Science) Lessons: The Hows And Whos To Play Biotech

Financial news for BIIB dated on 2017-10-06: Heaps Of Healthy Health Care ETFs

Financial news for BIIB dated on 2017-10-05: Biogen's Core Business Impresses While Potential Alzheimer's Catalyst Looms

Financial news for BIIB dated on 2017-10-05: The Market In 5 Minutes: Shopify, Equifax And More

Financial news for BIIB dated on 2017-10-05: Benzinga's Top Upgrades, Downgrades For October 5, 2017

Financial news for BIIB dated on 2017-10-05: Biogen Reports SPINRAZA Data Showed Earlier Treatment Initiation Could Lead to Improved Motor Function Across Broad Population Of People Living With Spinal Muscular Atrophy

Financial news for BIIB dated on 2017-10-05: Morgan Stanley Upgrades Biogen to Overweight

Financial news for BIIB dated on 2017-10-04: Amgen Enters Into An Immuno-Oncology Partnership With CytomX

Financial news for BIIB dated on 2017-10-04: After Strong Q3, Vetr Issues Hold Downgrade On Biogen

Financial news for BIIB dated on 2017-09-26: Biogen To Report Q3 Earnings On Tues., Oct. 24, Before Market Open

Financial news for BIIB dated on 2017-09-21: Benzinga's Top Upgrades, Downgrades For September 21, 2017

Financial news for BIIB dated on 2017-09-21: Raymond James Downgrades Biogen to Market Perform

Financial news for BIIB dated on 2017-09-20: Biogen Spinoff Bioverativ Is A Buy

Financial news for BIIB dated on 2017-09-20: Benzinga's Top Upgrades, Downgrades For September 20, 2017

Financial news for BIIB dated on 2017-09-20: SunTrust Robinson Humphrey Initiates Coverage On Biogen with Buy Rating, Announces \$360.00 Price Target

Financial news for BIIB dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for BIIB dated on 2017-09-11: Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine

Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers

Financial news for BIIB dated on 2017-09-05: Why It's Useful To Know A Company's Competitors When Trading

Financial news for BIIB dated on 2017-08-28: Biogen Says Aducanumab Phase 1b Study Supports Ongoing Phase 3 Studies

Financial news for BIIB dated on 2017-08-17: Democrats On House Committee On Oversight & Govt. Reform Say Launching Into MS Drug Pricing, Committee Send Letters To Biogen, Teva, Sanofi, Roche, Novartis, And Bayer

Financial news for BIIB dated on 2017-08-16: Goldman Sachs Adds Biogen to Conviction Buy

Financial news for BIIB dated on 2017-08-02: Meg Tirrell Tweets: And what \$IONS says of the \$BIIB @CSHL relationships in its last 10K sec.gov/Archives/edgar...

Financial news for BIIB dated on 2017-08-02: CNBC's Meg Tirrell Tweets: I don't see the specifics laid out anywhere. 2012 \$BIIB \$IONS announcement just cited "double-digit royalties" newsroom.biogen.com/press-release/...

Financial news for BIIB dated on 2017-08-02: CNBC's Meg Tirrell Tweets: Cuban calls for pressure on \$BIIB & \$IONS CEOs for Spinraza price \$IBB

Financial news for BIIB dated on 2017-08-02: CNBC's Meg Tirrell Tweets: .@mcuban is tweeting about biotech and drug pricing

Financial news for BIIB dated on 2017-08-01: 3 ETFs To Watch Out For On Biotech Earnings

Financial news for BIIB dated on 2017-07-26: 19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug

Financial news for BIIB dated on 2017-07-26: 5 Biggest Price Target Changes For Wednesday

Financial news for BIIB dated on 2017-07-26: Benzinga's Top Upgrades, Downgrades For July 26, 2017

Financial news for BIIB dated on 2017-07-26: The Market In 5 Minutes

Financial news for BIIB dated on 2017-07-26: A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Earnings, Fed Decision

Financial news for BIIB dated on 2017-07-26: Goldman Sachs Upgrades Biogen to Buy

Financial news for BIIB dated on 2017-07-25: Biogen 10-Q Just Out; Prosecution Office of Milan Investigates Biogen For Interactions With Italian Health-Care Providers

Financial news for BIIB dated on 2017-07-25: Biogen Surrenders All Early Gains After Q2 Beat And Raise

Financial news for BIIB dated on 2017-07-25: Adam Feurestein Tweets: \$BIIB is shopping for neuroscience drug assets. Here's a target list --> statnews.com/2017/07/25/bio...

Financial news for BIIB dated on 2017-07-25: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for BIIB dated on 2017-07-25: Biogen On Conf. Call Says It's 'Making Progress' In Search For A New CFO To Replace Paul Clancy

Financial news for BIIB dated on 2017-07-25: Biogen Raises FY 2017 Guidance, Sees EPS \$20.80-\$21.40 from \$20.45-\$21.25 vs \$20.38 Est., Sees Sales \$11.5B-\$11.8B from \$11.1B-\$11.4B vs \$11.4B Est

Financial news for BIIB dated on 2017-07-25: Biogen Q2 EPS \$5.04 vs \$4.41 Est., Sales \$3.08B vs \$2.81B Est.

Financial news for BIIB dated on 2017-07-25: Earnings Scheduled For July 25, 2017

Financial news for BIIB dated on 2017-07-24: 2 Ways To Trade This Week's Healthcare Earnings

Financial news for BIIB dated on 2017-07-17: Exclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock

Financial news for BIIB dated on 2017-07-11: Benzinga's Top Upgrades, Downgrades For July 11, 2017

Financial news for BIIB dated on 2017-07-11: Jefferies Assumes Biogen at Hold, Announces price target \$310.00

Financial news for BIIB dated on 2017-07-10: The Royalty-Amassing Strategy Of Royalty Pharma

Financial news for BIIB dated on 2017-07-10: Cowen Upgrades Bioverativ Shares To Outperform As TNT009 Heats Up

Financial news for BIIB dated on 2017-06-29: Biogen Issues Release Highlighting New Data Reaffirmed Clinically Meaningful Benefit Of SPINRAZA For Spinal Muscular Atrophy Across Disease Severity

Financial news for BIIB dated on 2017-06-23: Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold

Financial news for BIIB dated on 2017-06-23: Biogen's IMRALDI Was Granted Positive Opinion by Committee for Medicinal Products for Human Use

Financial news for BIIB dated on 2017-06-23: Deutsche Bank Initiates Coverage On Biogen with Buy Rating, Announces \$315.00 Price Target

Financial news for BIIB dated on 2017-06-22: Watching Biogen Shares Following Roche Press Release To Highlight Approval For RITUXAN HYCELA; BZ NOTE: Biogen Holds A Trademark For Roche Product

Financial news for BIIB dated on 2017-06-22: Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma

Financial news for BIIB dated on 2017-06-21: ACADIA Pharma Shares Spike ~\$0.90 Over Last Min, Now Pulling Back From Session Highs; Traders Circulating Chatter Of Biogen Interest

Financial news for BIIB dated on 2017-06-19: The Near-Term Setup For Biogen Has Positive Risk/Reward Written All Over It

Financial news for BIIB dated on 2017-06-19: Benzinga's Top Upgrades, Downgrades For June 19, 2017

Financial news for BIIB dated on 2017-06-19: The Market In 5 Minutes

Financial news for BIIB dated on 2017-06-19: UBS Upgrades Biogen to Neutral

Financial news for BIIB dated on 2017-06-15: C-Suite Shake Up: How Paul Clancy Jumping Ship Affects Alexion, Biogen

Financial news for BIIB dated on 2017-06-13: Biogen CFO Paul Clancy To Leave Co. For 'Another Biopharmaceutical Company'

Financial news for BIIB dated on 2017-06-05: Biogen Shares Volatile Over Last Min, Briefly Pullback from Afternoon Highs as Traders Circulating FDA.gov Link Listing Tecfidera with Paragraph IV Patent Certification

Financial news for BIIB dated on 2017-06-01: Ionis Pharma Reports Earning of \$50M Milestone Payment from Biogen Following EC Marketing Authorization for SPINRAZA

Financial news for BIIB dated on 2017-06-01: Biogen Reports EC Has Granted Marketing Authorization for SPINRAZA for Treatment of 5q SMA

Financial news for BIIB dated on 2017-05-31: Bernstein Strategic Decisions Conference Begins Today, Presenters Include: Eli Lilly, Clorox, Celgene, Discovery Communications, Mastercard, Biogen, Nasdaq, Motorola, And Yum Brands

Financial news for BIIB dated on 2017-05-24: Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected

Financial news for BIIB dated on 2017-05-18: Biogen Reports Purchase of Remedy Pharma's CIRARA for Upfront Payment of \$120M Plus Added Milestone Payments, Royalties

Financial news for BIIB dated on 2017-05-15: Biogen Acquires Remedy Pharmaceuticals' CIRARA for Large Hemispheric Stroke For \$120M In Upfront Payment Plus Potential Milestone And Royalty Payments

Financial news for BIIB dated on 2017-05-05: A New Active Alternative For Equity Exposure

Financial news for BIIB dated on 2017-05-04: With House Vote, Trump And GOP Cheer As Obamacare Officially Begins Roll-Back Process

Financial news for BIIB dated on 2017-05-01: Feuerstein On Neurotrope: The Study Failed And There Was Never 'A Lot Of Hope Here'

Financial news for BIIB dated on 2017-05-01: Adam Feuerstein on Alzheimer's and the Market: 'Its an Exceedingly Difficult Disease to Treat,' Highlights Biogen as 'the Next Big Co. Which Will Have Results from a Phase 3 Trial,' But That Won't Be Til 2019

Financial news for BIIB dated on 2017-05-01: Forward Pharma A/S Offers Update on Strategic Focus, Related Initiatives to Reduce Operating, Personnel Costs Following Statement, License Deal with Biogen

Financial news for BIIB dated on 2017-04-25: 20 Biggest Mid-Day Gainers For Tuesday

Financial news for BIIB dated on 2017-04-25: Biogen Gains After Q1 Beat

Financial news for BIIB dated on 2017-04-25: Eying 6,000: Nasdaq Close To New Big Number As Relief Rally Seen Continuing

Financial news for BIIB dated on 2017-04-25: Adam Feuerstein Tweets: \$BIIB says < \$10M Spinraza sales were from inventory build.

Financial news for BIIB dated on 2017-04-25: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for BIIB dated on 2017-04-25: Biogen Reports Q1 Adj. EPS \$5.20 vs \$5 Est., Sales \$2.8B vs \$2.74B Est.

Financial news for BIIB dated on 2017-04-25: Earnings Scheduled For April 25, 2017

Financial news for BIIB dated on 2017-04-24: Adam Feurestein Tweets: \$BIIB Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boosts Sales thestreet.com/story/14099459... via @TheStreet

Financial news for BIIB dated on 2017-04-24: Biogen Reports Data Further Confirmed Strong Efficacy of TECFIDERA in Newly Diagnosed, Early Switch Patients

Financial news for BIIB dated on 2017-04-24: Biogen Reports Final Phase 3 Study Data Show SPINRAZA Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy

Financial news for BIIB dated on 2017-04-21: Hearing Biogen Head of R&D, Michael Ehlers, Has Said More Deals for Drugs Are Expected

Financial news for BIIB dated on 2017-04-21: EMA Recommends Approval Of Biogen's Spinraza For Spinal Muscular Atrophy Drug

Financial news for BIIB dated on 2017-04-18: Biogen Issues Release Highlighting Advances from Neurology Research Programs: TECFIDERA, TYSABRI Data Support Early Treatment to Improve MS Patient Outcomes, New SPINRAZA(r) Data Show Robust Efficacy and Safety Across a Broad Range of Individuals with SMA

Financial news for BIIB dated on 2017-04-13: A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Initial Jobless Claims Report

Financial news for BIIB dated on 2017-04-13: UPDATE: Bristol-Myers Says Will Receive Combined \$470M Upfront

Financial news for BIIB dated on 2017-04-13: Bristol-Myers Squibb Reports Separate Deals with Biogen, Roche to License Anti-eTau, Anti-Myostatin Compounds, Respectively

Financial news for BIIB dated on 2017-04-06: Your Cheat Sheet For Q1 Biotech Earnings

Financial news for BIIB dated on 2017-03-31: Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher

Financial news for BIIB dated on 2017-03-31: Acorda Issues Press Release Confirming US District Court Decision to Invalidate 4 AMPYRA Patents, Says Co. Will Appeal Ruling

Financial news for BIIB dated on 2017-03-31: Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient

Financial news for BIIB dated on 2017-03-31: BZ NOTE: Forward Pharma Has Been Arguing Its Patent On dimethyl fumarate (DMF), Which Is The Active Ingredient In Tecfidera, Was filed Before Biogen's; Forward Is Claiming Royalty Rights To Drug Via Patent

Dispute

Financial news for BIIB dated on 2017-03-31: Biogen Spikes to High of \$275 on Volume

Financial news for BIIB dated on 2017-03-31: Argus Initiates Bioverativ With Hold

Financial news for BIIB dated on 2017-03-29: Diplomat Pharmacy Reports Will Dispense OCREVUS to Treat MS

Financial news for BIIB dated on 2017-03-29: Earlier FDA.gov Release Confirmed FDA Approval of Biogen's Ocrevus

Financial news for BIIB dated on 2017-03-27: Adam Feuerstein Tweets: Tomorrow's FDA drug approval decision will be Roche Ocrevus in MS. (Also affecting \$BIIB) Wednesday -- \$REGN \$SNY Dupixent in eczema.

Financial news for BIIB dated on 2017-03-21: Hearing Biogen Prevails In Kyle Bass IPR Challenge of Tecfidera '514 Patent Claim, Upheld In Final Written Decision

Financial news for BIIB dated on 2017-03-21: Biogen Spikes to \$279.50 on Volume

Financial news for BIIB dated on 2017-03-17: Get Ready For A Slew of Data As Weekend Nears

Financial news for BIIB dated on 2017-03-17: AC Immune Says Entered R&D Collaboration in Neurodegenerative Diseases with Biogen

Financial news for BIIB dated on 2017-03-16: 18 Biggest Mid-Day Losers For Thursday

Financial news for BIIB dated on 2017-03-16: Mid-Day Market Update: U.S. Stocks Turn Negative; GoPro Shares Spike Higher

Financial news for BIIB dated on 2017-03-16: Biogen's Catalysts May Be Waning; Leerink Downgrades To Market Perform

Financial news for BIIB dated on 2017-03-16: 7 Biggest Price Target Changes For Thursday

Financial news for BIIB dated on 2017-03-16: Morgan Stanley Takes A Breather On Biogen, Downgrades Stock

Financial news for BIIB dated on 2017-03-16: Benzinga's Top Upgrades, Downgrades For March 16, 2017

Financial news for BIIB dated on 2017-03-16: The Market In 5 Minutes

Financial news for BIIB dated on 2017-03-16: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for BIIB dated on 2017-03-16: Leerink Swann Downgrades Biogen To Market Perform

Financial news for BIIB dated on 2017-03-16: Morgan Stanley Downgrades Biogen To Equal-Weight, Lowers Price Target To \$305

Financial news for BIIB dated on 2017-03-04: Icahn's (Potential) Move Into Biotech

Financial news for BIIB dated on 2017-03-02: Why Perrigo Is Divesting Rights To The Best Multiple Sclerosis Drug

Financial news for BIIB dated on 2017-02-28: Ionis Shares Pop As Aetna Adds Spinraza To Precertification List

Financial news for BIIB dated on 2017-02-28: Ionis Shares Up 5.42%; Ionis And Biogen's Spinraza Added To Aetna's Precertification List, Aetna Spokesperson Tells Benzinga 'Appearance on this list does not indicate one way or the other what the clinical policy will be.'

Financial news for BIIB dated on 2017-02-24: Carl Icahn's Track Record In Big Pharma

Financial news for BIIB dated on 2017-02-23: Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'

Financial news for BIIB dated on 2017-02-16: After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?

Financial news for BIIB dated on 2017-02-16: Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One

Financial news for BIIB dated on 2017-02-15: Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma

Financial news for BIIB dated on 2017-02-13: Key Presenters At Leerink's Healthcare Conference

Financial news for BIIB dated on 2017-02-09: Forward Pharma Reports Received \$1.25B Pursuant to Settlement, License Deal with Biogen

Financial news for BIIB dated on 2017-02-08: Humana To Only Cover Ionis Spinraza For Type 1 SMA and Will Be Medically Necessary When Certain Criteria Is Met

Financial news for BIIB dated on 2017-02-08: Benzinga's Top Upgrades, Downgrades For February 8, 2017

Financial news for BIIB dated on 2017-02-08: Citigroup Upgrades Biogen To Buy

Financial news for BIIB dated on 2017-02-07: Biogen's Slow Rebound Prompts A Vetr Downgrade

Financial news for BIIB dated on 2017-02-07: Benzinga's Top Upgrades, Downgrades For February 7, 2017

Financial news for BIIB dated on 2017-02-07: The Market In 5 Minutes: GM And Gap Earnings, Retail Sales Data

Financial news for BIIB dated on 2017-02-07: A Peek Into The Markets: U.S. Stock Futures Climb Ahead Of General Motors Earnings

Financial news for BIIB dated on 2017-02-07: Citigroup Upgrades Biogen To Buy

Financial news for BIIB dated on 2017-02-06: Chardan Analyst Suggests An AveXis-Ionis Pair Trade

Financial news for BIIB dated on 2017-02-02: Hemophilia Fighter Bioverativ Launches On NASDAQ

Financial news for BIIB dated on 2017-02-02: Ionis Earns \$5 Million Milestone Payment from Biogen For Advancing Program Under Neurology Strategic Partnership

Financial news for BIIB dated on 2017-01-30: Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail

Financial news for BIIB dated on 2017-01-26: Biogen Higher After Mixed Q4 Report, Lower Guidance

Financial news for BIIB dated on 2017-01-26: Q4 2016 Real-Time Call Brief

Financial news for BIIB dated on 2017-01-26: Adam Feuerstein Tweets: \$BIIB call: Striking to me, no questions about drug pricing, particularly co.'s habit of raising price of old MS drugs multiple times/yr.

Financial news for BIIB dated on 2017-01-26: Biogen Says Patients Enrolling Ahead Of Expectations For Phase 3 Aducanumab Alzheimer's Trial

Financial news for BIIB dated on 2017-01-26: Biogen Sees FY 2017 EPS \$20.45 to \$21.25 vs \$21.02 Est, Revenue \$11.1B to \$11.4B vs \$12.07B Est

Financial news for BIIB dated on 2017-01-26: Biogen Q4 EPS \$5.04 vs \$4.96 Est, Revenue \$2.87B vs \$2.94B Est

Financial news for BIIB dated on 2017-01-26: Earnings Scheduled For January 26, 2017

Financial news for BIIB dated on 2017-01-25: UPDATE: Bernstein on Biogen Says Would Not Be Surprised to See Near-Term Pressure on Shares as News on Tecfidera Label Change Over the Weekend Becomes Known

Financial news for BIIB dated on 2017-01-25: Biogen Shares Pullback from Highs as Bernstein Cautious Amid Tecfidera Label Change

Financial news for BIIB dated on 2017-01-24: STAT News Reports, Consumer Group Will Urge Feds To Take Patents For A Pricey New Biogen Drug

Financial news for BIIB dated on 2017-01-23: The Street's Adam Feuerstein Posts Story, Says 5 Reasons Celgene Should Buy Biogen

Financial news for BIIB dated on 2017-01-20: Don't Get Too Excited About Biogen's Q4

Earnings

Financial news for BIIB dated on 2017-01-18: Orphan Drugs Among 2015's Top 10 Best-Selling Medications

Financial news for BIIB dated on 2017-01-17: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for BIIB dated on 2017-01-17: Mid-Day Market Update: Clayton Williams Energy Surges On Acquisition News; Christopher & Banks Shares Slide

Financial news for BIIB dated on 2017-01-17: Forward Pharma Reports Deal to Settle, License with Biogen; Biogen Will Pay Forward Non-Refundable Cash Fee of \$1.25B

Financial news for BIIB dated on 2017-01-17: Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Tops Q4 Estimates

Financial news for BIIB dated on 2017-01-17: 18 Stocks Moving In Tuesday's Pre-Market Session

Financial news for BIIB dated on 2017-01-17: Biogen to Pay \$1.25B to FOrward Pharma Intellectual Property for License Agreement

Financial news for BIIB dated on 2017-01-12: Biogen Spin-off to Begin Trading on a When Issue Basis Under Ticker BIVVV

Financial news for BIIB dated on 2017-01-11: All The Markets Trump Moved During His Speech Today

Financial news for BIIB dated on 2017-01-11: Trump: Drug Industry Is 'Getting Away With Murder'

Financial news for BIIB dated on 2017-01-11: Watching Weakness In Amgen, Biogen, Gilead, Mylan, Pfizer And Other Biotechs After Pres. Elect Trump Negative Statement On Drug Pricing

Financial news for BIIB dated on 2017-01-06: Why Spinraza Is The Only Exciting Thing About Ionis Pharmaceuticals

Financial news for BIIB dated on 2017-01-05: Biogen exercises option to enter exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN

Financial news for BIIB dated on 2017-01-05: TheStreet's Adam Feuerstein Recently Tweets Article Highlighting Call from RBC Analyst on Ionis-Biogen Drug Which Failed Due to Projectile Vomiting

Financial news for BIIB dated on 2017-01-03: Spinraza Cost Estimates Could Reignite The Drug Pricing Debate

Financial news for BIIB dated on 2016-12-30: Hemispherx BioPharma CEO Explains Chronic Fatigue Syndrome And How The Company Is Treating It

Financial news for BIIB dated on 2016-12-29: Biogen's Spinraza Could Cost \$125,000 Per Dose

Financial news for BIIB dated on 2016-12-29: Ionis Pharma's Target Lifted To \$68 Following More Favorable Spinraza Ramp Estimates

Financial news for BIIB dated on 2016-12-27: Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week

Financial news for BIIB dated on 2016-12-27: Biogen Inc. Retreats From High After FDA Approval Of Spinraza

Financial news for BIIB dated on 2016-12-27: Why The Biogen-Ionis News Is A Boon For AveXis

Financial news for BIIB dated on 2016-12-27: Spinraza Wins 'Best Case Approval'; Leerink Raises Targets On Biogen, Ionis

Financial news for BIIB dated on 2016-12-27: Ionis Pharmaceuticals +8.6% Premarket @ \$58; FDA Said on Friday it had Approved Spinraza to Treat Spinal Muscular Atrophy

Financial news for BIIB dated on 2016-12-22: Biogen Says Effectiveness of Bioverativ as Independent Co. Expected to be Closed on Feb. 1, 2017

Financial news for BIIB dated on 2016-12-20: Biogen Approves Separation Of Bioverative Unit, Declares Special Dividend Related To Separation; Every 2 Shares Of Biogen Stock, Biogen Shareholders Will Receive One Bioverativ Stock

Financial news for BIIB dated on 2016-12-20: What Does Biogen's New CEO Mean For The Buyout Argument?

Financial news for BIIB dated on 2016-12-19: Biogen PR Confirms Michel Vounatsos as CEO

Financial news for BIIB dated on 2016-12-19: Biogen to Name Chief Commercial Officer Michel Vounatsos as CEO -Reuters

Financial news for BIIB dated on 2016-12-19: Hearing Biogen Will Name Chief Commercial Officer Michael Vounatsos as CEO

Financial news for BIIB dated on 2016-12-16: Benzinga's Top Upgrades, Downgrades For December 16, 2016

Financial news for BIIB dated on 2016-12-16: Cantor Fitzgerald Initiates Coverage On Biogen at Neutral, Announces \$293.00 Target

Financial news for BIIB dated on 2016-12-15: Citron Research On AveXis: This Will Be One Of 2017's Biotech Blowups

Financial news for BIIB dated on 2016-12-14: Adam Feuerstein Tweets: If \$AVXS gene therapy works, it has significant advantages over \$BIIB nusinersen. Data will tell us.

Financial news for BIIB dated on 2016-12-12: Barron's Picks And Pans: Goodyear, Johnson & Johnson And More

Financial news for BIIB dated on 2016-12-09: Despite Drug Trial Miss, Here's Why Biogen Should Trade Higher

Financial news for BIIB dated on 2016-12-09: Biogen CTAD Conf. Slides Say One Patient Taking aducanumab Had Treatment-Related Seizure With Loss of Pulse

Financial news for BIIB dated on 2016-12-09: Biogen Shares Sell Off To Below \$300 Level, Now Trading At \$295.58/Share

Financial news for BIIB dated on 2016-12-09: Technical Alert: Biogen Inc. Higher Off Trial Results For Aducanumab

Financial news for BIIB dated on 2016-12-09: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for BIIB dated on 2016-12-09: Biogen Presents Data from Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab at CTAD 2016

Financial news for BIIB dated on 2016-12-08: Biogen Spikes On Leaked Data

Financial news for BIIB dated on 2016-12-08: Bernstein Out Cautious On Biogen, Says Large Discontinuation Between Blind Stage And Open Label; Results Should Be Interpreted With Caution

Financial news for BIIB dated on 2016-12-08: UPDATE: Biogen PRIME Results Show Slowing Of Decline On CDR-SB Was Statistically Significant With Titrated aducanumab vs. Placebo, Titration of aducanumab Appears To Reduce Incidence Of ARIA-E vs. Fixed Dosing In This Cohort

Financial news for BIIB dated on 2016-12-08: Biogen Results For PRIME Include Significant Decreases In Brain Amyloid Plaque Burden Were Observed With titrated aducanumab Compared With Placebo In 196 Patients With 31 Patients In titration Cohort

Financial news for BIIB dated on 2016-12-08: Adam Feuerstein Tweets: Media are embargoed from disclosing \$BIIB aducanumab data but I'm getting really close to breaking that.,...

Financial news for BIIB dated on 2016-12-08: Adam Feuerstein Tweets: \$BIIB -- I believe updated and embargoed aducanumab titration data have leaked from CTAD conference. Stock ticking higher.

Financial news for BIIB dated on 2016-12-05: Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell

Financial news for BIIB dated on 2016-12-03: Biogen Announces Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE and ALPROLIX at ASH 2016

Financial news for BIIB dated on 2016-11-25: Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects

Financial news for BIIB dated on 2016-11-25: The Market In 5 Minutes: Black Friday Closes Shortened Trading Week

Financial news for BIIB dated on 2016-11-25: Experts React To Concerning Alzheimer's News From Eli Lilly

Financial news for BIIB dated on 2016-11-23: Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock

Financial news for BIIB dated on 2016-11-23: 18 Biggest Mid-Day Losers For Wednesday

Financial news for BIIB dated on 2016-11-23: Biotech Down In Early Trading: PDL BioPharma 15%, Eli Lilly 13%, Biogen, 6%, Collectis, Insys 5.5%, Dynavax, Kite 5%

Financial news for BIIB dated on 2016-11-23: Credit Suisse Says Hard To Get Strong Read-Through Conclusions On Biogen From Lilly's Study Without More Details, Today's News Represents Negative Headline In A Time Where Positive Headlines Are Needed; Biotech Space Could Be Weak On This Headline News

Financial news for BIIB dated on 2016-11-23: JP Morgan Highlighting Downside in Biogen Shares This Morning (Down ~8%) Related to Lilly's Alzheimer Drug News; Sees Transient 5-15% Move Lower in Biogen Shares, But Sees Possibility Stock Recovers

Financial news for BIIB dated on 2016-11-23: Eli Lilly's Solanezumab Failure Is Bad News For Biogen

Financial news for BIIB dated on 2016-11-23: Morgan Stanley Calling For Biogen To End The Day Flat To Slightly Up Following Eli Lilly Data Results; Says aducanumab More Potent Than solanezumab, Believes Indication Of Activity/Trends Could Keep Amyloid Debate Alive

Financial news for BIIB dated on 2016-11-23: Raymond James Out Saying They Would Be Buyers of Biogen On Weakness Following Eli Lilly's Failed EXPEDITION 3 Trail; May Actually Be Clearing Event With Respect To Any Takeout

Financial news for BIIB dated on 2016-11-23: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for BIIB dated on 2016-11-23: Can You Guess This Chart?

Financial news for BIIB dated on 2016-11-23: Biogen -10.41% Premarket @\$285 Following Lilly Trial Results

Financial news for BIIB dated on 2016-11-23: Adam Feuerstein Tweets: Worst thing: \$LLY gamed sola study to win but still failed badly, which tells you these amyloid mAbs are weak drugs. Watch out, \$BIIB

Financial news for BIIB dated on 2016-11-09: Can Trump Make Your Portfolio Great Again?

Financial news for BIIB dated on 2016-11-08: Benzinga's Top Initiations

Financial news for BIIB dated on 2016-11-08: Mizuho Initiates Coverage On Biogen Inc. - Common Stock at Neutral, Announces \$290.00

Financial news for BIIB dated on 2016-11-07: 18 Biggest Mid-Day Gainers For Monday

Financial news for BIIB dated on 2016-11-07: Mid-Day Market Update: Dow Gains Over 300 Points; Concordia International Shares Drop Following Disappointing Earnings

Financial news for BIIB dated on 2016-11-07: Technical Alert: Biogen Inc. Higher Off Piper-Jaffray Upgrade

Financial news for BIIB dated on 2016-11-07: Leerink Swann Upgrades Biogen Inc. - Common Stock to Outperform

Financial news for BIIB dated on 2016-11-07: Benzinga's Volume Movers

Financial news for BIIB dated on 2016-11-07: Mid-Morning Market Update: Markets Open Higher; LendingClub Posts Narrower-Than-Expected Loss

Financial news for BIIB dated on 2016-11-07: The Market In 5 Minutes: Stock Futures Boosted By FBI's Latest Clinton News

Financial news for BIIB dated on 2016-11-07: Biogen Is A Frustrating Case, And Piper Jaffray Hopes It Doesn't Regret Upgrade

Financial news for BIIB dated on 2016-11-07: Benzinga's Top Upgrades

Financial news for BIIB dated on 2016-11-07: 16 Stocks Moving In Monday's Pre-Market Session

Financial news for BIIB dated on 2016-11-07: Adam Feuerstein @adamfeuerstein Tweet: Piper's Josh Schimmer calls for \$BIIB to buy \$AVXS to defend the SMA franchise.

Financial news for BIIB dated on 2016-11-07: Biogen and Ionis Pharmaceuticals Announce SPINRAZA Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy

Financial news for BIIB dated on 2016-11-07: PiperJaffray Upgrades Biogen Inc. - Common Stock to Overweight

Financial news for BIIB dated on 2016-10-28: Biogen Reports Nusinersen Granted Priority Review by FDA, EMA Planning to Follow Accelerated Assessment Timeline

Financial news for BIIB dated on 2016-10-26: Biogen Reports Q3 EPS \$5.19 vs. Est. \$4.97, Rev. \$2.95B vs. Est. \$2.9B

Financial news for BIIB dated on 2016-10-26: Earnings Scheduled For October 26, 2016

Financial news for BIIB dated on 2016-10-24: 25 Stocks Which Rallied Four Days, Then Sold Off On Friday

Financial news for BIIB dated on 2016-10-18: AC Immune Is An Alzheimer's Pure Play With A Lot On The Line

Financial news for BIIB dated on 2016-10-13: John Stumpf And 15 Major CEO Departures In 2016

Financial news for BIIB dated on 2016-10-03: A Possible Trading Opportunity Presents Itself In Biogen's Approaching Phase 3 Results

Financial news for BIIB dated on 2016-09-28: Anavex Life Sciences Shares Experimenting With 2-Month Highs

Financial news for BIIB dated on 2016-09-28: Anavex Compound to be Tested in Biogen Neurological Protection Model

Financial news for BIIB dated on 2016-09-26: Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy

Financial news for BIIB dated on 2016-09-21: Allergan Going After Gilead? Gabelli Says CEO 'Playing Chess While The Market Is Playing Checkers'

Financial news for BIIB dated on 2016-09-15: Biogen, AbbVie Presented Data at ECTRIMS Reinforce Efficacy of ZINBRYTA, Support Long-Term Safety Profile

Financial news for BIIB dated on 2016-09-14: Biogen Reports TECFIDERA Treatment Significantly Reduced Time to First Relapse vs Glatiramer Acetate, Interferon ss, Teriflunomide, Showed Comparable Efficacy to Fingolimod

Financial news for BIIB dated on 2016-09-06: Benzinga's Top Downgrades

Financial news for BIIB dated on 2016-09-06: The Market In 5 Minutes: Stocks Return Higher From Three-Day Weekend

Financial news for BIIB dated on 2016-09-06: Biogen Downgraded To Hold At Jefferies, Citing Valuation

Financial news for BIIB dated on 2016-09-06: Biogen Expands Ophthalmology Partnership With BioMotive

Financial news for BIIB dated on 2016-09-06: Jefferies Downgrades Biogen to Hold

Financial news for BIIB dated on 2016-09-01: Biogen's Aducanumab For Alzheimers Gets Fast Track Designation

Financial news for BIIB dated on 2016-08-31: Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen's Investigational Alzheimer's Disease Treatment Aducanumab

Financial news for BIIB dated on 2016-08-17: ETFs, Stocks See Dwindling Buyback Support

Financial news for BIIB dated on 2016-08-17: 10 Biggest Price Target Changes For Wednesday

Financial news for BIIB dated on 2016-08-17: Morgan Stanley Adjusts Their View Of

Biogen After Spinoff

Financial news for BIIB dated on 2016-08-12: Jefferies Upgrades AveXis To Buy Following Positive AVXS-101 Data, Doc Feedback

Financial news for BIIB dated on 2016-08-11: Biogen Cancels Out Of Citigroup Conference Following Weeks Of Rumors

Financial news for BIIB dated on 2016-08-11: Biogen Spokesperson Confirms Co. Has Canceled Out Of Citi's Biotech Conf., Cites Executive Scheduling Conflict; Says Mgmt Will Be Attending Morgan Stanley Conf. Next Week

Financial news for BIIB dated on 2016-08-11: Biogen Shares Spike to Session Highs as Hearing Co. Has Cancelled Out of Citi's 11th Annual Biotech Conference, Scheduled Sept. 6-8

Financial news for BIIB dated on 2016-08-08: Biogen Shares Unaffected Amid Dealreporter Report Suggesting Pfizer, J&J Could Also Be Looking at Co.

Financial news for BIIB dated on 2016-08-04: Benzinga's M&A Chatter for Thursday August 4, 2016

Financial news for BIIB dated on 2016-08-03: Benzinga's M&A Chatter for Wednesday August 3, 2016

Financial news for BIIB dated on 2016-08-03: Biogen Shares Down \$3 Over Last Min Following Reuters Report Co. Not Soliciting Offers; Allergan, Merck Shares Relatively Quiet, Not Impacted

Financial news for BIIB dated on 2016-08-03: Hearing Biogen Has Said Co. Has Not Received Any Formal Expressions of Interest from Suitors and is Not Soliciting Offers

Financial news for BIIB dated on 2016-08-03: Technical Alert: Finding Support In Biogen As Takeover Rumors Subside

Financial news for BIIB dated on 2016-08-03: The Market In 5 Minutes: Downtrend Continues

Financial news for BIIB dated on 2016-08-03: Amyris Enters Partnership with Biogen to Develop Alternative Cell Lines Supporting Production of Therapeutics

Financial news for BIIB dated on 2016-08-03: Why Is Biogen Attractive? Credit Suisse Sees 12-24% Upside Takeout Potential

Financial news for BIIB dated on 2016-08-02: Benzinga's M&A Chatter for Tuesday August 2, 2016

Financial news for BIIB dated on 2016-08-02: Standpoint Research Earlier Issued Late-Intraday Downgrade on Biogen, from Buy to Hold

Financial news for BIIB dated on 2016-08-02: CNBC's Meg Tirrell Reports Allergan Unlikely to Pursue Biogen Deal

Financial news for BIIB dated on 2016-08-02: 6 Stocks Moving In Tuesday's After-Hours Session

Financial news for BIIB dated on 2016-08-02: TheStreet's Adam Feuerstein Tweets: '\$BIIB Takeover value baked in? A lot surely is.'

Financial news for BIIB dated on 2016-08-02: Hearing RBC Capital Analyst Has Said Biogen Could Be Worth \$375-\$475/Share in Takeover Scenario

Financial news for BIIB dated on 2016-08-02: Option Alert: BIIB Oct16 290 Calls: 504 @ Above Ask! \$48.00: 814 traded vs 726 OI: \$328.59 Ref

Financial news for BIIB dated on 2016-08-02: Biogen Shares Resume, Spiking Higher

Financial news for BIIB dated on 2016-08-02: Wall Street Journal Reports Biogen Drawing Interest From Merck, Allergan On Possibility Of Huge Deal

Financial news for BIIB dated on 2016-08-02: Adam Feuerstein Tweet: 'That having a lame-duck CEO thing has a way of motivating sellers and buyers. \$BIIB'

Financial news for BIIB dated on 2016-08-02: Biogen Shares Halted On Volatility

Financial news for BIIB dated on 2016-08-02: Biogen Sees Takeover Interest from Allergan, Merck-DJ

Financial news for BIIB dated on 2016-08-02: Biogen, JC Penney And More: Fast Money

Picks For August 2

Financial news for BIIB dated on 2016-08-01: Mid-Afternoon Market Update: Trina Solar Gains Following Go-Private Deal; Insperity Shares Drop

Financial news for BIIB dated on 2016-08-01: Can You Name This Chart?

Financial news for BIIB dated on 2016-08-01: 15 Biggest Mid-Day Gainers For Monday

Financial news for BIIB dated on 2016-08-01: Mid-Day Market Update: Crude Oil Down 3%; FleetMatics Group Shares Rise Following Acquisition News

Financial news for BIIB dated on 2016-08-01: Benzinga's Volume Movers

Financial news for BIIB dated on 2016-08-01: Mid-Morning Market Update: Markets Mostly Higher; Tesla To Acquire SolarCity

Financial news for BIIB dated on 2016-08-01: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for BIIB dated on 2016-08-01: Biogen, Ionis Reveal Nusinersen Meets Primary Endpoint At Interim Analysis Of Final Stage ENDEAR Trial

Financial news for BIIB dated on 2016-08-01: UPDATE: Biogen To Pay Ionis A \$75M License Fee, Will Initiate Regulatory Filings Globally In Months To Come

Financial news for BIIB dated on 2016-08-01: Biogen, Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy

Financial news for BIIB dated on 2016-07-22: Baird Still Isn't Buying Biogen

Financial news for BIIB dated on 2016-07-21: 15 Biggest Mid-Day Gainers For Thursday

Financial news for BIIB dated on 2016-07-21: Earnings Parade: Technology Shines While Other Sectors Also Out-Perform

Financial news for BIIB dated on 2016-07-21: The Market In 5 Minutes: Jam-Packed Day Of Earnings And Economic Data

Financial news for BIIB dated on 2016-07-21: Biogen's Q2 Numbers, Outlook Exceed Street Expectations

Financial news for BIIB dated on 2016-07-21: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for BIIB dated on 2016-07-21: Biogen +6.13% Premarket @\$278.50 Following Announcement of Earnings Beat, Raised Guidance, \$5B Share Buyback

Financial news for BIIB dated on 2016-07-21: Biogen Sees FY16 Rev. \$11.2-\$11.4B vs. Est. \$11.28B, EPS \$19.70-\$20.00 vs. Est. \$18.96

Financial news for BIIB dated on 2016-07-21: Biogen CEO George Scangos Will Be Leaving Company One Successor Identified

Financial news for BIIB dated on 2016-07-21: Biogen Raises Guidance

Financial news for BIIB dated on 2016-07-21: Biogen Authorizes \$5B Buyback

Financial news for BIIB dated on 2016-07-21: Biogen Reports Q2 EPS \$5.21 vs. Est. \$4.67, Rev. \$2.9B vs. Est. \$2.79B

Financial news for BIIB dated on 2016-07-21: Earnings Scheduled For July 21, 2016

Financial news for BIIB dated on 2016-07-18: A Peek Into The Markets: U.S. Stock Futures Up; Bank of America Profit Tops Views

Financial news for BIIB dated on 2016-07-18: Biogen, Sobi to Report Long-Term Efficacy, Safety Data from A-LONG, ASPIRE, B-Long, B-YOND Trials at World Federation of Hemophilia World Congress

Financial news for BIIB dated on 2016-07-18: Biogen's SB5 Adalimumab Biosimilar Referencing Humira, Accepted for Review by EMA

Financial news for BIIB dated on 2016-07-05: Biogen And AbbVie's Once-Monthly ZINBRYTA Gets European Union Approval For Multiple Sclerosis Treatment

Financial news for BIIB dated on 2016-07-05: Biogen, AbbVie Report Once-Monthly ZINBRYTA Approved in EU for Treatment of MS

Financial news for BIIB dated on 2016-06-29: Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform

Financial news for BIIB dated on 2016-06-29: Stiff Biosimilar Headwinds To Negatively Impact Amgen's Aging Drug Portfolio

Financial news for BIIB dated on 2016-06-29: The Market In 5 Minutes: Swoosh And A Miss

Financial news for BIIB dated on 2016-06-29: Bernstein Initiates Coverage on Biogen at Outperform

Financial news for BIIB dated on 2016-06-22: Is Biogen Becoming A Reasonable Target For Acquisition? Baird Says So

Financial news for BIIB dated on 2016-06-21: Stocks Hitting 52-Week Lows

Financial news for BIIB dated on 2016-06-12: Biogen And Gilead Sciences Buck Biotech Short Interest Trend

Financial news for BIIB dated on 2016-06-09: New Data Presented at the Annual European Congress of Rheumatology Demonstrate Safety and Efficacy of Biogen's Anti-TNF Biosimilars Portfolio

Financial news for BIIB dated on 2016-06-08: Biogen Shares Selling Off Further, Traders Passing Around Comments From Moody's Saying Anti-Lingo Study Failure Is Credit Negative

Financial news for BIIB dated on 2016-06-08: Lingo Failure Leads Citi To Downgrade Biogen

Financial news for BIIB dated on 2016-06-07: Mid-Afternoon Market Update: Navistar Climbs Following Earnings Beat; Biogen Shares Tumble

Financial news for BIIB dated on 2016-06-07: 8 Biggest Mid-Day Losers For Tuesday

Financial news for BIIB dated on 2016-06-07: Mid-Day Market Update: LDR Rises On Acquisition News; DryShips Shares Drop

Financial news for BIIB dated on 2016-06-07: Biogen Blitzed, Hits Lowest Level Since March

Financial news for BIIB dated on 2016-06-07: Mid-Morning Market Update: Markets Mostly Higher; Valeant Earnings Miss Views

Financial news for BIIB dated on 2016-06-07: Citigroup Downgrades Biogen to Neutral

Financial news for BIIB dated on 2016-06-07: 12 Stocks Moving In Tuesday's Pre-Market Session

Financial news for BIIB dated on 2016-06-07: Biogen -9% to \$263 as Phase 2 Study of Opicinumab Misses Primary, Secondary Endpoint

Financial news for BIIB dated on 2016-06-07: Biogen Phase 2 Study of Opicinumab Misses Primary and Secondary Endpoint

Financial news for BIIB dated on 2016-06-06: Acadia Pharmaceuticals May Be Subject Of A Bidding War

Financial news for BIIB dated on 2016-06-05: Benzinga's Weekend M&A Chatter

Financial news for BIIB dated on 2016-06-03: AstraZeneca, Teva, Biogen, Allergan Said to be Potential Bidders for Acadia -Daily Mail

Financial news for BIIB dated on 2016-06-01: Biogen Says EU Medicines Agency Accepted Its Investigational Alzheimer's Disease Treatment Aducanumab

Financial news for BIIB dated on 2016-06-01: Biogen Announces Aducanumab Was Accepted Into EMA's PRIME Program

Financial news for BIIB dated on 2016-05-31: Biogen Gets Favorable View For TYSABRI Use In Highly Active RRMS

Financial news for BIIB dated on 2016-05-31: Biogen Announces Positive CHMP Opinion for TYSABRI

Financial news for BIIB dated on 2016-05-27: Government Study: Cellphone Radiation Linked To Cancer

Financial news for BIIB dated on 2016-05-20: Option Alert: SWEEP (SELL) - BIIB May 27 \$270 Call - 772 @ 2.02 in 13 orders. 848 traded. OI: 68

Financial news for BIIB dated on 2016-05-17: Has A Biotech Recovery Started Yet?

Financial news for BIIB dated on 2016-05-16: Biogen and Regenxbio to Collaborate with University of Pennsylvania on Gene Therapy Programs

Financial news for BIIB dated on 2016-05-13: Biogen, Swedish Orphan Biovitrum Announce EC Approves Alprolix for Treatment of Haemophilia B

Financial news for BIIB dated on 2016-05-03: The Next Sector Rotation Will Be To Biotechs

Financial news for BIIB dated on 2016-05-03: Biogen Plans To Spin-Off Its Hemophilia Unit As Publicly Traded Firm

Financial news for BIIB dated on 2016-05-03: Biogen to Spin-off Hemophilia Business, Anchored by ELOCTATE and ALPROLIX into Separate Publicly-Traded Company

Financial news for BIIB dated on 2016-05-03: Biogen to Spin Off Its Hemophilia Business as Independent, Publicly Traded Company

Financial news for BIIB dated on 2016-05-01: Barron's 500: America's Top Companies

Financial news for BIIB dated on 2016-04-29: EMA Recommends Approval of Biogen's/Abbvie's Daclizumab to Treat MS

Financial news for BIIB dated on 2016-04-28: Biotech Boom May Continue Through Earnings Season

Financial news for BIIB dated on 2016-04-21: Biogen Says Received Subpoena from Federal Government for Documents Relating to Relationship with Non-profit Organizations

Financial news for BIIB dated on 2016-04-21: Goldman Sachs Maintains Neutral on Biogen, Raises PT to \$285.00

Financial news for BIIB dated on 2016-04-21: 12 Stocks Moving In Thursday's Pre-Market Session

Financial news for BIIB dated on 2016-04-21: Biogen Reports Q1 EPS \$4.79 vs. Est. \$4.47, Rev. \$2.7B vs. Est. \$2.75B

Financial news for BIIB dated on 2016-04-21: Earnings Scheduled For April 21, 2016

Financial news for BIIB dated on 2016-04-20: Biogen Presented Data Of ZINBRYTA Impact On Cognitive Outcomes And Reversibility Of Targeted Mechanism Of Action

Financial news for BIIB dated on 2016-04-18: Biogen Reports TECFIDERA Data Confirms Strong, Sustained Efficacy in Newly-Diagnosed MS Patients

Financial news for BIIB dated on 2016-04-15: Option Alert: BIIB Fri 4/22 280 Calls (Wkly) Sweep: 580 @ ASK \$4.67: 867 traded vs 191 OI: Earnings 4/21 Before Open \$267.30 Ref

Financial news for BIIB dated on 2016-04-11: Citi Surprised, Confused Amid Report Biogen May Divest Hemophilia Unit

Financial news for BIIB dated on 2016-04-11: Citigroup Confused Over Possible Biogen Sale Of Hemophilia Business, Questions If Co. May Be Setting Itself Up As An M&A Target

Financial news for BIIB dated on 2016-04-08: Biogen Explores Sale Of Hemophilia Assets -Reuters

Financial news for BIIB dated on 2016-04-07: How One Analyst Is Playing The Biotech Rebound This Week

Financial news for BIIB dated on 2016-04-05: BMO Capital Initiates Coverage on Biogen at Market Perform, Announces \$283.00 PT

Financial news for BIIB dated on 2016-04-01: Biogen Announces CHMP Has Issued Positive Opinion on FLIXABI

Financial news for BIIB dated on 2016-03-31: Ionis Pharmaceuticals Advances Nusinersen in the Ongoing SHINE Study in Patients with SMA, Earns \$7.5M Milestone Payment From Biogen

Financial news for BIIB dated on 2016-03-30: Biogen Names Michel Vounatsos Chief Commercial Officer

Financial news for BIIB dated on 2016-03-23: What's Going On With Kyle Bass And Biogen?

Financial news for BIIB dated on 2016-03-17: A Rare Opportunity With A Biotechnology ETF

Financial news for BIIB dated on 2016-03-11: Morgan Stanley Calls AMGN, BMY, BIIB, MCK, STJ It's Favorite Health Care Names

Financial news for BIIB dated on 2016-03-03: Option Alert: BIIB Apr16 280 Calls: 540 @ ASK \$8.60: 600 traded vs 597 OI: Earnings 4/22 \$268.66 Ref

Financial news for BIIB dated on 2016-03-01: Stocks To Watch During Cowen's 36th Annual Healthcare Conference

Financial news for BIIB dated on 2016-02-26: Sobi, Biogen Receive Positive Opinion from CHMP for Alprolix for the Treatment of Hemophilia B

Financial news for BIIB dated on 2016-02-26: EMA Recommends Approval of Biogen's Eftrenonacog Alfa to Treat Haemophilia B

Financial news for BIIB dated on 2016-02-25: Benzinga's Top Initiations

Financial news for BIIB dated on 2016-02-25: Citi: Buy Celgene, Gilead, Biogen And Regeneron As Biotechs Recover

Financial news for BIIB dated on 2016-02-25: Citigroup Initiates Coverage on Biogen at Buy

Financial news for BIIB dated on 2016-02-24: Biotech Investors Shouldn't Fear Legislation, Even If Hillary Is President And Dems Win Senate Majority

Financial news for BIIB dated on 2016-02-22: Slump Could Be Healthcare ETF Buying Opportunity

Financial news for BIIB dated on 2016-02-16: Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug

Financial news for BIIB dated on 2016-02-13: Schroer: Biotech Will Turn Around

Financial news for BIIB dated on 2016-02-08: Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts

Financial news for BIIB dated on 2016-02-05: Leerink Is Back On Board The Biotech Train

Financial news for BIIB dated on 2016-02-05: Leerink Swann Initiates Coverage on Biogen at Market Perform

Financial news for BIIB dated on 2016-02-03: The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors

Financial news for BIIB dated on 2016-02-03: Joe McCann: Here's How To Play Biotech Market In Earnings Season

Financial news for BIIB dated on 2016-01-29: Biogen Drug 'Increasingly Vulnerable,' Analyst Warns After Speaking With MS Expert

Financial news for BIIB dated on 2016-01-29: Piper Jaffray Considers Recent Meeting with High Volume MS Specialist: Biogen's Franchise is Increasingly Vulnerable, Roche's Ocrelizumab is Well Positioned

Financial news for BIIB dated on 2016-01-29: Maybe Some Good News For A Big Biotech ETF

Financial news for BIIB dated on 2016-01-28: 7 Biotech Traders Pick Their Favorite Stocks For 2016

Financial news for BIIB dated on 2016-01-28: Sobi to present new interim ASPIRE data at EAHAD congress suggesting that patients can reduce bleeding rates with long-term Elocta treatment

Financial news for BIIB dated on 2016-01-27: Earnings Recap For January 27

Financial news for BIIB dated on 2016-01-27: Apple and Boeing Earnings, Plus Oil

Drag, Combine To Dent Stocks

Financial news for BIIB dated on 2016-01-27: Biogen's Stock Pops Following Better-Than-Expected Q4 Results

Financial news for BIIB dated on 2016-01-27: 10 Stocks Moving In Wednesday's Pre-Market Session

Financial news for BIIB dated on 2016-01-27: CORRECTION: Biogen Sees FY16 Sales ~\$11.1B-\$11.3B vs \$11.3B Est., Adj. EPS \$18.30-\$18.60 vs \$18.45 Est.

Financial news for BIIB dated on 2016-01-27: Biogen Sees FY16 Sales ~\$11.1B-\$11.3B vs \$11.3B Est., Adj. EPS \$18.30-\$18.60 vs \$18.45 Est.

Financial news for BIIB dated on 2016-01-27: Biogen Reports Q4 EPS \$4.50 vs. Est. \$4.08, Rev. \$2.839B vs. Est. \$2.71B

Financial news for BIIB dated on 2016-01-27: Earnings Scheduled For January 27, 2016

Financial news for BIIB dated on 2016-01-24: Big Earnings Expectations For Big Biotech

Financial news for BIIB dated on 2016-01-22: Barclays Prefers Biogen Over Celgene Heading Into Q4 Results

Financial news for BIIB dated on 2016-01-20: Credit Suisse Bullish On Most Big Pharma Names

Financial news for BIIB dated on 2016-01-20: Why This Analyst Is Cautious On Biogen

Financial news for BIIB dated on 2016-01-20: Credit Suisse Initiates BIIB At Neutral, Fears Competition From New Regiments To Impact Base Business Growth, Believes Pipeline Offers 'big upside driver'

Financial news for BIIB dated on 2016-01-19: Credit Suisse Initiates Coverage on Biogen at Neutral, Announces \$322.00 PT

Financial news for BIIB dated on 2016-01-19: Biogen Ticks Up Following EU Marketing Authorization Of Benepali

Financial news for BIIB dated on 2016-01-17: Biogen, Samsung JV Announces Etanercept Biosimilar Referencing Enbrel, BENEPAI, Approved in EU

Financial news for BIIB dated on 2016-01-11: This Week Is Paramount For Biotech Stocks

Financial news for BIIB dated on 2016-01-07: Standpoint Research Initiates Coverage on Biogen at Buy

Financial news for BIIB dated on 2016-01-07: Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences

Financial news for BIIB dated on 2016-01-06: Jefferies' Best Biotech Ideas For 2016 (And Beyond)

Financial news for BIIB dated on 2016-01-06: Rodin Therapeutics Reports Financing Commitments of \$17.3M from Atlas Venture, Biogen, R&D Collaboration

Financial news for BIIB dated on 2016-01-05: Jacobs Reports Two Contracts: Option at NASA's Marshall Space Flight Center, with Biogen

Financial news for BIIB dated on 2016-01-04: Cowen Thinks Biogen Has 20% Upside After MS Therapies Price Hike

Financial news for BIIB dated on 2015-12-23: Not All Of Clinton's Policies Are Bad For Pharmaceuticals

Financial news for BIIB dated on 2015-12-22: Ionis Pharmaceuticals Receives Milestone Payment From Biogen Of \$5M For Advancing A Neurology Program

Financial news for BIIB dated on 2015-12-18: Biogen No Longer 'Too Risky,' Atlantic Analyst Sees Massive Upside

Financial news for BIIB dated on 2015-12-18: Atlantic Equities Initiates Coverage on Biogen at Overweight, Announces \$344.00 PT

Financial news for BIIB dated on 2015-12-16: Arisia Therapeutics, Biogen Report Signing of Research Collab for Development of Subcutaneous Biologics

Financial news for BIIB dated on 2015-12-08: Biogen Releases Elocata and Alprolix Data, Says May Help Joint Bleeds in People With Hemophilia A and B

Financial news for BIIB dated on 2015-12-04: Early Global News: Virtual Reality Market Getting Really Big, Facebook To Sell You Concert Tickets, And More

Financial news for BIIB dated on 2015-11-24: Sobi and Biogen's Elocata Approved by EC for Treatment of Haemophilia A

Financial news for BIIB dated on 2015-11-20: Biogen Reports Benepali is the First Biosimilar of Enbrel to Receive a Positive Opinion from CHMP

Financial news for BIIB dated on 2015-11-18: Samsung-Biogen Biosimilar for Amgen's Enbrel Could Receive EMA Recommendation This Week -Reuters

Financial news for BIIB dated on 2015-11-16: 5 Biotechs That Can Win From Ophthalmology Innovation

Financial news for BIIB dated on 2015-11-12: 3 Top Biotech Stocks See Their Short Interest Plunge

Financial news for BIIB dated on 2015-11-10: 10 S&P 500 Companies With Green Operations

Financial news for BIIB dated on 2015-11-05: ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

Financial news for BIIB dated on 2015-11-02: Biotechs Among Stocks That Insiders Have Been Buying Lately

Financial news for BIIB dated on 2015-10-28: Wild Short Interest Swings For Three Top Biotech Stocks

Financial news for BIIB dated on 2015-10-27: Biogen Shares Rise 5.5% Following Form 4 Filing Late Monday, Showing 310K Share Buy by Alexander Denner

Financial news for BIIB dated on 2015-10-21: Biogen Volatile After Q3 Beat, Raised Guidance And Disappointing Phase 3 Study

Financial news for BIIB dated on 2015-10-21: Why Biogen Stock Is Having A Huge Day

Financial news for BIIB dated on 2015-10-21: Morning Market Gainers

Financial news for BIIB dated on 2015-10-21: From Biogen Call: Exec Says Co. Expects to Complete \$5B Buyback Plan by End of '15

Financial news for BIIB dated on 2015-10-21: Biogen +5.5% Premarket Following Announcement of 11% Workforce Cut

Financial news for BIIB dated on 2015-10-21: Benzinga's Top #PreMarket Gainers

Financial news for BIIB dated on 2015-10-21: Shares of Biogen Resume; Now Up Nearly 6%

Financial news for BIIB dated on 2015-10-21: Shares of Biogen to Resume Trade at 8 a.m. EDT

Financial news for BIIB dated on 2015-10-21: UPDATE: Biogen Sees FY15 Adj. EPS \$16.20-\$16.50 vs \$15.84 Est., Sales Growth 8-9% YoY

Financial news for BIIB dated on 2015-10-21: UPDATE: Biogen Phase 3 Study Did Not Meet Primary, Secondary Endpoints

Financial news for BIIB dated on 2015-10-21: UPDATE: Biogen Reports Q3 Adj. EPS \$4.48 vs \$3.80 Est., Sales \$2.8B vs \$2.65B Est.

Financial news for BIIB dated on 2015-10-21: Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS

Financial news for BIIB dated on 2015-10-21: Biogen Reports Q3 Earnings; Raises FY Outlook

Financial news for BIIB dated on 2015-10-21: Biogen Shares Halted News Pending

Financial news for BIIB dated on 2015-10-21: Earnings Scheduled For October 21, 2015

Financial news for BIIB dated on 2015-10-20: Fast Money Picks For October 20

Financial news for BIIB dated on 2015-10-19: 5 Must-Watch Stocks For This Week

Financial news for BIIB dated on 2015-10-19: Stock Week Ahead: Housing Data, Broad-Based Earnings Line Up

Financial news for BIIB dated on 2015-10-19: Cowen: In Biotech Earnings We Trust

Financial news for BIIB dated on 2015-10-12: Watching Volatility In Other Big Pharma Names Amid Eli Lilly Halt

Financial news for BIIB dated on 2015-10-08: Biogen, Abbvie Offer Results from ZINBRYTA Phase 3 DECIDE Study Showing Effect on Disability, Cognitive Outcomes: 'Additional Analyses Reinforce Safety Profile'

Financial news for BIIB dated on 2015-10-07: Biogen Says Tecfidera Data is Positive

Financial news for BIIB dated on 2015-10-06: Historical Biotech IPO Data From The 'Godfather Of Biotechnology'

Financial news for BIIB dated on 2015-10-06: Trans Pacific Trade Pact Finally Agreed

Financial news for BIIB dated on 2015-10-01: Fast Money Traders Share The Stocks They Would Buy In Fourth Quarter

Financial news for BIIB dated on 2015-09-22: Watch Out Biotech Investors: Outrage Culture + Election Season = Ugly Rhetoric Ahead

Financial news for BIIB dated on 2015-09-22: Rich Ross Sees Upside Potential In Disney, United Continental And Biogen

Financial news for BIIB dated on 2015-09-21: Feuerstein Says While Biogen Has Had Drug Pricing Issues As Well, They Are Currently Researching Drugs That Are Better To Replace AVONEX; Could Justify Higher, Older Drug Price

Financial news for BIIB dated on 2015-09-21: Adam Feuerstein Agrees With Interviewee That Big Biotech Companies Could Be Shielded From Drug Pricing Issues, "Yea, To Some Extent They Are A Bit Shielded As Long As They Continue To Innovate"

Financial news for BIIB dated on 2015-09-21: Biogen Approaches Support Levels In \$290 Handle

Financial news for BIIB dated on 2015-09-21: Biotechs Are Getting Killed Because Of Hillary Clinton's Response To This Drug Price Hike

Financial news for BIIB dated on 2015-09-15: Why Leerink Is Cutting Biogen Targets (But Still Bullish On The Stock)

Financial news for BIIB dated on 2015-09-15: Kyle Bass On CNBC Talking Drug Patents

Financial news for BIIB dated on 2015-09-15: Despite Flat Tecfidera Prescription Trends, Leerink Analyst Sees Attractive Risk-Reward Scenario For Biogen Given Negative Investor Sentiment, Achievable Guidance, And Discount Valuation To Peer Group

Financial news for BIIB dated on 2015-09-14: Amgen And Biogen Lead Short Interest Surge In Biotechs

Financial news for BIIB dated on 2015-09-14: Biotechs Coming Off One Of The Busiest Weeks In Recent Memory

Financial news for BIIB dated on 2015-09-14: JMP Analyst Says He Believes Biotech Megacaps Appear To Be Generating A Shopping List After Raising Cash; Implying Possible M&A Activity In Biotech Space After Recent Investor Conference Activity

Financial news for BIIB dated on 2015-09-09: Biotech Investors Still Have Opportunity

Financial news for BIIB dated on 2015-09-09: Biogen Licenses Mitsubishi Tanabe Pharma's MT-1303 for Autoimmune Diseases

Financial news for BIIB dated on 2015-09-08: JD.com Reports \$1B Share Repurchase Program

Financial news for BIIB dated on 2015-09-08: Biogen Enrolls Initial Patient in Global Phase 3 Study of Investigational Treatment Aducanumab (BIIB037) for Early Alzheimer's Disease

Financial news for BIIB dated on 2015-09-01: Biogen: 'A Nice Little Trade' Or Heading To New Lows?

Financial news for BIIB dated on 2015-08-27: Biogen And Gilead Sciences Catch The Eye

Of Short Sellers

Financial news for BIIB dated on 2015-08-21: The Other Bearish Biotech ETF Is Looking Groovy, Too

Financial news for BIIB dated on 2015-08-20: 13G Filing from Biogen on Applied Genetic Technologies Shows New 8.1% Stake

Financial news for BIIB dated on 2015-08-20: Using ETFs To Run Your Own Hedge Fund

Financial news for BIIB dated on 2015-08-20: Morning Market Gainers

Financial news for BIIB dated on 2015-08-20: Benzinga's Top #PreMarket Gainers

Financial news for BIIB dated on 2015-08-19: AGTC Release Confirms Strategic Collaboration With Biogen Effective and Biogen Equity Investment Closed

Financial news for BIIB dated on 2015-08-18: Biogen Announces Collaboration with Columbia University, Funded With \$30M From CUMC and \$3.5M from ALS

Financial news for BIIB dated on 2015-08-17: Biogen Announces Positive Interim Data Regarding Bleeding Rates

Financial news for BIIB dated on 2015-08-13: Biogen Canada Says Health Canada Approves Plegridy for Adults With Relapsing Remitting Multiple Sclerosis -Reuters

Financial news for BIIB dated on 2015-08-11: Benzinga's Top Initiations

Financial news for BIIB dated on 2015-08-11: H.C. Wainwright: Biogen Is Now A Buy Worth \$380/Share

Financial news for BIIB dated on 2015-08-11: H.C. Wainwright Initiates Coverage on Biogen at Buy, Announces \$380.00 PT

Financial news for BIIB dated on 2015-08-10: Biogen Releases Positive Interem Phase 3 Results For Elocetate Study

Financial news for BIIB dated on 2015-08-07: The Historical Correlation Between Biotech Stocks And Interest Rates

Financial news for BIIB dated on 2015-07-28: Is More M&A On The Way For Large-Cap Biotechs?

Financial news for BIIB dated on 2015-07-27: With The Teva Money, Allergan Could Engage In 'Large M&A' Next: Evercore ISI

Financial news for BIIB dated on 2015-07-27: Evercore ISI says Allergan may now engage in "large M&A," buy-side survey indicates Biogen, AbbVie, BioMarin, or a combination with Pfizer as possible takeout targets.

Financial news for BIIB dated on 2015-07-27: Caution Continues In Options Market This Week

Financial news for BIIB dated on 2015-07-27: A Big Day For Biotech And It's Not Going So Well

Financial news for BIIB dated on 2015-07-27: Morgan Stanley Still Likes Biogen After Bleak Earnings

Financial news for BIIB dated on 2015-07-27: Benzinga's Volume Movers

Financial news for BIIB dated on 2015-07-27: A Look Ahead: Biotech And Energy ETFs To Watch This Week

Financial news for BIIB dated on 2015-07-27: Bernstein Upgrades Biogen On 'Compelling' Pipeline, Stock Now Undervalued

Financial news for BIIB dated on 2015-07-27: Bernstein's Geoffrey Porges on Biogen upgrade to Outperform: "The current value of the key pipeline programs was unaffected by Friday's disclosure"

Financial news for BIIB dated on 2015-07-27: Bernstein Upgrades Biogen to Outperform, Lowers PT to \$385.00

Financial news for BIIB dated on 2015-07-27: Baird Cuts Biogen Rating, Says Near-Term Growth 'Diminished'

Financial news for BIIB dated on 2015-07-27: Biogen Enters Collaboration with the Parkinson's Institute and Clinical Center

Financial news for BIIB dated on 2015-07-27: Baird Downgrades Biogen to Neutral, Lowers PT to \$316.00

Financial news for BIIB dated on 2015-07-26: Biotech Stocks Falling Broadly, Here's Why And How Much

Financial news for BIIB dated on 2015-07-24: Mid-Day Market Update: U.S. Stocks Slide; Marketo Shares Surge On Earnings Beat

Financial news for BIIB dated on 2015-07-24: Market Update: Friday's Mid-Day Market Movers: Amazon Shocks The Markets; Anthem, Cigna, StanCorp, Pandora

Financial news for BIIB dated on 2015-07-24: RBC's Michael Yee Still Sees Value in Biogen's Long-Term Pipeline

Financial news for BIIB dated on 2015-07-24: Evercore ISI's Schoenebaum Offers Downside/Worst Case Scenario Analysis on Biogen Amid ~18% Intraday Decline: Discounted Cash Flow Model Target ~\$305

Financial news for BIIB dated on 2015-07-24: Mid-Morning Market Update: Markets Slightly Higher; Amazon Earnings Top Views

Financial news for BIIB dated on 2015-07-24: Morning Market Losers

Financial news for BIIB dated on 2015-07-24: From Conf Call Biogen Says Don't Think it's a Panic Situation; As We See Good Opportunities We Will Be Aggressive About Bringing Them In

Financial news for BIIB dated on 2015-07-24: Biogen's Final Catalyst Of 2015 Is A 'Coin Flip,' Evercore ISI Analyst Says

Financial news for BIIB dated on 2015-07-24: From Conf Call: Biogen Says Assuming Extremely Limited Patient Growth for Tecfidera on Sequential Basis for Balance of Year in US

Financial news for BIIB dated on 2015-07-24: From Conf Call Biogen Says if Stock is Under Pressure as it Was in Pre-Market, I Suspect We Will Look for Opportunities to Lower Share Base

Financial news for BIIB dated on 2015-07-24: From Conf Call: Biogen Says Expects Primary Source of Value Creation to Be from Introducing New Therapies

Financial news for BIIB dated on 2015-07-24: From Conf Call: Biogen Says Overall Very Disappointed in Change of Outlook for Year

Financial news for BIIB dated on 2015-07-24: From Conf Call: Biogen Says Overall Very Disappointed in Change of Outlook for Year

Financial news for BIIB dated on 2015-07-24: From Conf Call: Biogen's Douglas Williams Executive VP of R&D Leaving to Become CEO of Startup

Financial news for BIIB dated on 2015-07-24: Benzinga's Top #PreMarket Losers

Financial news for BIIB dated on 2015-07-24: On Biogen's earnings, Evercore analyst Mark Schoenebaum wrote, "people expected a weak quarter, but this is probably even worse...need call."

Financial news for BIIB dated on 2015-07-24: US Stock Futures Edge Higher; Amazon Profit Beats Views

Financial news for BIIB dated on 2015-07-24: Biogen Posts Higher Q2 Earnings, But Sales Miss Views

Financial news for BIIB dated on 2015-07-24: Biogen Sees FY15 Sales Growth 6-8% YoY

Financial news for BIIB dated on 2015-07-24: Biogen Cuts FY15 Adj. EPS Guidance to \$15.50-\$15.95 vs \$16.63 Est.

Financial news for BIIB dated on 2015-07-24: Biogen Reports Q2 Adj. EPS \$4.22 vs \$4.10 Est., Sales \$2.6B vs \$2.71B Est.

Financial news for BIIB dated on 2015-07-24: Earnings Scheduled For July 24, 2015

Financial news for BIIB dated on 2015-07-24: 10 Must Watch Stocks for Today

Financial news for BIIB dated on 2015-07-23: Wall Street Mixed On Biogen Before Earnings

Financial news for BIIB dated on 2015-07-22: Deutsche Bank Bullish On Biogen: New Data Doesn't Change Probability Of Success For Alzheimer's

Financial news for BIIB dated on 2015-07-22: Deutsche Bank's Karnauskas Keeps Buy On Biogen With \$460 PT, Says Doesn't 'See Any Major Change To The Probability Of Alzheimer's Program'

Financial news for BIIB dated on 2015-07-22: Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidence...Even More Speculative Than Before'

Financial news for BIIB dated on 2015-07-22: Disappointing Drug News Sends Biogen And XOMA Shares Down

Financial news for BIIB dated on 2015-07-22: Piper Jaffray Downgrades Biogen to Neutral

Financial news for BIIB dated on 2015-07-22: Biogen Shares Fall 6% Premarket on Mixed Results in Phase 1 Alzheimer's Study; 6MG Dose Failed to Significantly Slow Mental Decline

Financial news for BIIB dated on 2015-07-22: Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab at Alzheimer's Association International Conference 2015

Financial news for BIIB dated on 2015-07-21: Piper Jaffray Still Overweight Biogen But Notes It's Least-Preferred Play; Hikes Celgene Target

Financial news for BIIB dated on 2015-07-20: Oppenheimer's 10 'Best Of The Best' Technical Buy Ideas

Financial news for BIIB dated on 2015-07-20: Biogen's Parkinson's Antibody Could Boost Prothena, RBC Says

Financial news for BIIB dated on 2015-07-20: Stifel, JMP Securities Discuss What To Expect From AAIC Conference

Financial news for BIIB dated on 2015-07-17: Why Big Biotech Could Have Another Leg Up

Financial news for BIIB dated on 2015-07-15: Biogen Alert From Deutsche Bank: Tecfidera Could Hit Consensus Forecast

Financial news for BIIB dated on 2015-07-15: Nomura: 'We Are Bullish On Celgene's Acquisition Of Receptos'

Financial news for BIIB dated on 2015-07-14: Biogen Boost: Bank Of America Upgrades Stock To Buy Ahead Of Alzheimer's Data

Financial news for BIIB dated on 2015-07-14: Benzinga's Top Upgrades

Financial news for BIIB dated on 2015-07-14: Bank of America Upgrades Biogen to Buy, Maintains \$466.00 PT

Financial news for BIIB dated on 2015-07-13: 11 Stocks With Near-Term Catalysts

Financial news for BIIB dated on 2015-07-10: RBC Says Biogen Can Move 10% After BIIB-037 Data Is Revealed

Financial news for BIIB dated on 2015-07-10: Douglas Williams to Leave Biogen for Biotechnology Start-Up

Financial news for BIIB dated on 2015-07-10: Here's Why Biogen Shares Are Crashing Today

Financial news for BIIB dated on 2015-07-10: Morning Market Losers

Financial news for BIIB dated on 2015-07-10: Cowen On Biogen: View June 22 Aducanumab Presentation As 'having the potential to substantially alter perceptions of the probability of ph III success and be worth +/- \$50 to BIIB'

Financial news for BIIB dated on 2015-07-10: Biogen Bounces Back To \$388.05/Share After Dropping To A Low Of \$383 On The Open

Financial news for BIIB dated on 2015-07-09: Large-Cap Biotechs Poised For Second-Half Rally, RBC Says

Financial news for BIIB dated on 2015-07-06: Benzinga's Volume Movers

Financial news for BIIB dated on 2015-07-06: Biogen Collaboration With Applied

Genetic Is 'Interesting,' But Morgan Stanley Will Wait For More Data

Financial news for BIIB dated on 2015-07-03: AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors

Financial news for BIIB dated on 2015-07-02: Mid-Afternoon Market Update: International Speedway Slips On Weak Results; Applied Genetic Technologies Shares Spike Higher

Financial news for BIIB dated on 2015-07-02: UPDATE: Wedbush's Nierengarten Views AGTC, Biogen Deal as 'validation of AGTC's patent-protected manufacturing technology and treatment focus on monogenic disorders'

Financial news for BIIB dated on 2015-07-02: Wedbush's David Nierengarten on Applied Genetics Following Biogen Deal: Calls Partnership an 'Operational Inflection Point' for AGTC; Outperform Rating, \$36 Price Target Reiterated

Financial news for BIIB dated on 2015-07-02: Mid-Day Market Update: US Stocks Down; Xoom Shares Jump On Acquisition News

Financial news for BIIB dated on 2015-07-02: Thursday's Mid-Day Movers: Real Good Solar, Xoom, ConformMIS, Health Net And More

Financial news for BIIB dated on 2015-07-02: Mid-Morning Market Update: Markets Edge Higher; Centene To Acquire Health Net For \$6.3B

Financial news for BIIB dated on 2015-07-02: Benzinga's Volume Movers

Financial news for BIIB dated on 2015-07-02: Morning Market Gainers

Financial news for BIIB dated on 2015-07-02: JP Morgan Defends Biogen, Calls Initial \$124M Applied Genetic Investment An 'incremental positive'

Financial news for BIIB dated on 2015-07-02: Benzinga's Top #PreMarket Gainers

Financial news for BIIB dated on 2015-07-02: Applied Genetic Technologies Shares to Resume Trading at 7:30AM ET

Financial news for BIIB dated on 2015-07-02: UPDATE: Biogen's Upfront Payment to AGTC Includes \$30M Equity Investing in AGTC

Financial news for BIIB dated on 2015-07-02: UPDATE: AGTC Will Receive ~\$124M Upfront Payment, Includes Potential for Future Milestone Payments

Financial news for BIIB dated on 2015-07-02: Biogen, AGTC Announce Entering of Collab Related to Development of Gene Therapies in Ophthalmology

Financial news for BIIB dated on 2015-07-01: Biogen Announces 1B Swiss Franc Investment in New Production Plant in Luterbach in the Canton of Solothurn

Financial news for BIIB dated on 2015-07-01: Biogen Announces 1B Swiss Franc Investment in New Production Plant in Luterbach in the Canton of Solothurn

Financial news for BIIB dated on 2015-06-26: Biogen, Sobi Announce EMA Validates ALPROLIX Marketing Authorization Application

Financial news for BIIB dated on 2015-06-23: Morgan Stanley On Biogen: Here's The 'Other' Coming Tysabri Catalyst

Financial news for BIIB dated on 2015-06-23: Morgan Stanley on Biogen: Sees Initial Data on Tysabri in SPMS 'Promising,' With 'Better Than 50/50 Odds of Clinical Success,' Maintains Overweight, \$520 Price Target

Financial news for BIIB dated on 2015-06-23: Biogen Phase 3 Study Of Aducanumab

Financial news for BIIB dated on 2015-06-18: New Biogen Hemophilia Data At ISTH Congress to Showcase Extension Study Outcomes, Pediatric Use

Financial news for BIIB dated on 2015-06-17: The Note Moving Pharma Giants Today

Financial news for BIIB dated on 2015-06-12: Big Biotech Stocks See Declining Short Interest

Financial news for BIIB dated on 2015-06-11: Highlights From ISIS Pharmaceuticals At Goldman Sachs Healthcare Conference

Financial news for BIIB dated on 2015-06-10: Hedge Funds Buying Biotech IPO Operated By Ex-Fund Manager

Financial news for BIIB dated on 2015-06-10: Biogen Reports Samsung Bioepis Drugs Well Tollerated

Financial news for BIIB dated on 2015-05-20: 5 NASDAQ Healthcare Stocks With The Highest EPS

Financial news for BIIB dated on 2015-05-13: 3 Biotech Stocks See Growing Short Interest

Financial news for BIIB dated on 2015-05-07: Biogen Announces \$5B Buyback Plan To Take Place Over A Five Year Period

Financial news for BIIB dated on 2015-04-30: Isis Pharma Reports Earned \$10M Milestone Payment from Biogen

Financial news for BIIB dated on 2015-04-30: Biogen Or Bluebird: Which Will Lead In SCD?

Financial news for BIIB dated on 2015-04-30: Expert: Biogen Is Closing In On The 'Holy Grail' For Biotech Stocks

Financial news for BIIB dated on 2015-04-29: AbbVie, Biogen Announce FDA Acceptance of BLA for ZINBRYTA for Treatment of MS

Financial news for BIIB dated on 2015-04-27: Hearing Biogen CEO Scangos Currently Speaking in Boston: Investing \$2.5B Before Alzheimer's Trial Outcome Known, Planning Two Phase 3 Trials with 2.7-2.8K Patients

Financial news for BIIB dated on 2015-04-27: Biogen Continues To Decline After Friday's Rout

Financial news for BIIB dated on 2015-04-27: Did The AAN Meeting Affect Biogen, PTC Therapeutics, GW Pharma Or Isis Pharma?

Financial news for BIIB dated on 2015-04-27: Oppenheimer Assumes Biogen at Perform

Financial news for BIIB dated on 2015-04-27: Swedish Orphan Biovitrum AB Confirms Receipt of Preliminary and Conditional Non-binding Proposal for Acquisition of All Shares Issued by Company

Financial news for BIIB dated on 2015-04-25: Pfizer, Biogen Potential Buyers for Swedish Orphan Biovitrum AB, According to Sources -Bloomberg

Financial news for BIIB dated on 2015-04-24: Biogen Shares Not Too Healthy After Q1 Miss

Financial news for BIIB dated on 2015-04-24: Morgan Stanley Reviews Biogen Earnings

Financial news for BIIB dated on 2015-04-24: Biogen Misses Q1 Estimates, Shares Slide

Financial news for BIIB dated on 2015-04-24: Biogen Q1 EPS \$3.82 vs \$3.91 est, Revenue \$2.55B vs \$2.6B Est.

Financial news for BIIB dated on 2015-04-24: Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni

Financial news for BIIB dated on 2015-04-24: Must Watch Stocks for April 24, 2015

Financial news for BIIB dated on 2015-04-24: Earning & Economic Calendar for Friday April 24, 2015

Financial news for BIIB dated on 2015-04-24: Earnings Scheduled For April 24, 2015

Financial news for BIIB dated on 2015-04-22: Kyle Bass Challenges Biogen Fumaderm Patent

Financial news for BIIB dated on 2015-04-22: Kyle Bass Files IPR vs Biogen

Financial news for BIIB dated on 2015-04-21: US Stock Futures Rise Ahead Of Earnings

Financial news for BIIB dated on 2015-04-21: PLEGRIDY 3-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients

Financial news for BIIB dated on 2015-04-20: CAR-T Therapy Stocks Hit Hard Following AACR Data

Financial news for BIIB dated on 2015-04-20: 5 Biotech Earnings Under The Microscope This Week

Financial news for BIIB dated on 2015-04-20: Biogen Announces TECFIDERA Data Reinforces Strong, Sustained Efficacy for Newly-Diagnosed MS Patients

Financial news for BIIB dated on 2015-04-19: Why This Trader Likes Gilead Better Than Biogen

Financial news for BIIB dated on 2015-04-17: It's A Big Weekend For Biotech

Financial news for BIIB dated on 2015-04-14: GoPro, Avon and Intel Highlight Tuesday's After-Hours Movers

Financial news for BIIB dated on 2015-04-14: Biogen Reports New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair

Financial news for BIIB dated on 2015-04-09: Biogen Investors: Active Ingredient In Patient Death Is Not Changing BofA's Forecast

Financial news for BIIB dated on 2015-04-08: Inovio Pharmaceuticals, Zynga Among Big Movers In Wednesday's After-Hours Session

Financial news for BIIB dated on 2015-04-08: Bloomberg Reports Patient Using Drug Similar to Biogen's Tecfidera Died While Taking the Drug

Financial news for BIIB dated on 2015-04-02: Biomed Realty Signs Biogen to 80,000 Square Feet Lease in Cambridge, MA

Financial news for BIIB dated on 2015-04-02: How RBC Capital Called A 50% Gain In This Biotech Stock

Financial news for BIIB dated on 2015-04-01: Barclays Raises Biogen Forecasts After Physician Survey

Financial news for BIIB dated on 2015-03-30: Bulls, Bears Squaring Off At Biogen

Financial news for BIIB dated on 2015-03-27: US Stock Futures Edge Lower Ahead Of GDP, Consumer Sentiment Data

Financial news for BIIB dated on 2015-03-27: Biogen, AbbVie Announce EMA Validates Marketing Authorisation Application for ZINBRYTA for Treatment of MS

Financial news for BIIB dated on 2015-03-26: Is It Closing Time At The Biotech Bar?

Financial news for BIIB dated on 2015-03-24: Biogen's Alzheimer's Drug Is Promising, Wall Street Says

Financial news for BIIB dated on 2015-03-24: Why Intercept Might Be A Better Bet Than Biogen Right Now

Financial news for BIIB dated on 2015-03-23: Weekly Options Outlook: Bulls Leave Money On The Table Despite A Week-End Win

Financial news for BIIB dated on 2015-03-23: Biogen: The Day After

Financial news for BIIB dated on 2015-03-23: ICYMI: Pharmaceutical Stocks Are Moving Big On Monday

Financial news for BIIB dated on 2015-03-23: Morning Market Losers

Financial news for BIIB dated on 2015-03-23: Stifel Downgrades Biogen Amid Concerns Of Lack Of Upcoming Data, Overvaluation

Financial news for BIIB dated on 2015-03-23: Benzinga's Top #PreMarket Losers

Financial news for BIIB dated on 2015-03-23: Stifel Nicolaus Downgrades Biogen Idec to Hold

Financial news for BIIB dated on 2015-03-23: UPDATE: Biogen Idec Becomes Biogen

Financial news for BIIB dated on 2015-03-23: Biogen Idec to be Become Biogen; CEO Says Co to Expand Drug Pipeline to Include Alzheimer's, ALS Treatments -Reuters

Financial news for BIIB dated on 2015-03-22: These 4 Stocks Finished The Week At All-Time Highs

Financial news for BIIB dated on 2015-03-20: Major Profit-Taking In Biogen As It Bolts To New All-Time Highs

Financial news for BIIB dated on 2015-03-20: Benzinga's Volume Movers

Financial news for BIIB dated on 2015-03-20: Morning Market Gainers

Financial news for BIIB dated on 2015-03-20: Biotech Stocks Soar Amid Positive News

Financial news for BIIB dated on 2015-03-20: Benzinga's Top #PreMarket Gainers

Financial news for BIIB dated on 2015-03-20: US Stock Futures Signal Higher Start On Wall Street

Financial news for BIIB dated on 2015-03-20: UPDATE: Biogen Shares +5% Premarket on Positive Alzheimer's Study Results

Financial news for BIIB dated on 2015-03-20: Biogen Shares Rise ~2% Premarket on Light Trading Following Alzheimer's Study Results

Financial news for BIIB dated on 2015-03-20: UPDATE: Biogen Says Alzheimer's Drug Shows Significant Reduction in Amyloid Brain Plaque, Slows Cognitive Decline vs Placebo in Phase I Study; Enrollment in Phase III Trial to Begin Later This Year

Financial news for BIIB dated on 2015-03-20: Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD Conference

Financial news for BIIB dated on 2015-03-17: Analysts See Biogen Catalyst Coming On Friday

Financial news for BIIB dated on 2015-03-13: Analyst Sees Upside To Outlook At 4 Biotechs

Financial news for BIIB dated on 2015-03-11: The 4 Biggest Biotech Stocks In The Market

Financial news for BIIB dated on 2015-03-11: 18 Biotech Stocks These Wall Street Analysts Are Tracking

Financial news for BIIB dated on 2015-02-27: Biogen, Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 ALPROLIX Pediatric Study

Financial news for BIIB dated on 2015-02-24: The Catalysts Biogen Idec Investors Should Watch

Financial news for BIIB dated on 2015-02-23: Evercore ISI Technical Analysis: The 'Single Best Idea'

Financial news for BIIB dated on 2015-02-16: 4 Stocks Wall Street Loves This Year...And 4 It Doesn't

Financial news for BIIB dated on 2015-02-10: UPDATE: Isis Pharmaceuticals Earns \$5M Milestone Payment from Biogen Idec

Financial news for BIIB dated on 2015-02-06: After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?

Financial news for BIIB dated on 2015-02-04: Should You Stick With Biogen Stock?

Financial news for BIIB dated on 2015-02-02: iShares NASDAQ Biotech ETF Pulls Back Off All-Time Highs

Financial news for BIIB dated on 2015-02-01: Biotech Breakdown: Market Breaks...Gilead, Kite Pharma & Biogen Idec Worth Watching

Financial news for BIIB dated on 2015-01-30: Stocks Hitting 52-Week Highs

Financial news for BIIB dated on 2015-01-30: Morning Market Gainers

Financial news for BIIB dated on 2015-01-30: Friday Morning Movers: Amazon Pops, Deckers Outdoor Plummets Following Earnings Results

Financial news for BIIB dated on 2015-01-29: Biogen Idec Q4 Net Nearly Doubles; Beats Views

Financial news for BIIB dated on 2015-01-29: Biogen Reports Q4 Adj. EPS \$4.09 vs \$3.78 Est., Sales \$2.64B vs \$2.64B Est.; Sees FY Adj. EPS \$16.60-\$17

Financial news for BIIB dated on 2015-01-29: Notable Earnings After The Close: AMZN, GOOG, V, BIIB

Financial news for BIIB dated on 2015-01-29: Credit Suisse Previews Biogen, Says 'Consensus Tecfidera Downgrades = Pipeline Buying Opportunity'

Financial news for BIIB dated on 2015-01-29: Earnings Scheduled For January 29, 2015

Financial news for BIIB dated on 2015-01-29: Biogen Idec, Fondazione Telethon, Ospedale San Raffaele to Collaboration to Develop Gene Therapies for Hemophilia

Financial news for BIIB dated on 2015-01-28: Earnings Scheduled For January 28, 2015

Financial news for BIIB dated on 2015-01-28: Must Watch Stocks for January 28, 2015

Financial news for BIIB dated on 2015-01-26: Biogen Idec to Report Q4 And Year End 2014 Financial Results on January 29, 2015 Instead Of Wednesday January 28, 2015

Financial news for BIIB dated on 2015-01-26: 5 Big Biotech Earnings Releases To Watch This Week

Financial news for BIIB dated on 2015-01-20: The 5 Biggest Biotech Stocks

Financial news for BIIB dated on 2015-01-20: Jefferies 'Encouraged' By Biogen Idec's New Data

Financial news for BIIB dated on 2015-01-16: Nomura's Takeways From Biogen Idec's Analyst Meeting

Financial news for BIIB dated on 2015-01-14: Biogen Idec To Acquire Convergence Pharmaceuticals In Deal Worth \$675 Million

Financial news for BIIB dated on 2015-01-14: UPDATE: Biogen Idec Acquisition of Convergence Pharmaceuticals was Announced on January 11, International Biotechnology Trust Mentioned the Acquisition on Wednesday

Financial news for BIIB dated on 2015-01-12: A Look At 3 Biotech Stocks With Upside Potential

Financial news for BIIB dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for BIIB dated on 2015-01-11: UPDATE: Biogen to Pay Convergence Shareholders Upfront Payment of \$200M, Plus Up to Additional \$475M Contingent on Future Milestones

Financial news for BIIB dated on 2015-01-11: Biogen Idec to Acquire Convergence Pharmaceuticals

Financial news for BIIB dated on 2015-01-08: These Stocks Are Trending On Social Media This Thursday

Financial news for BIIB dated on 2015-01-08: Biogen Reports anti-LINGO Treatment Shows Evidence of Primary Endpoint Improvement, No Effect on Secondary Endpoint

Financial news for BIIB dated on 2015-01-06: J.P Morgan Just Chimed In With Ratings On Biotech Stocks

Financial news for BIIB dated on 2015-01-06: What Investors Are Looking For In NPS Pharmaceuticals Ahead Of A Potential Sale

Financial news for BIIB dated on 2015-01-06: UPDATE: Barclays Capital Initiates Coverage On Biogen On Tecfidera Upside

Financial news for BIIB dated on 2015-01-06: Benzinga's Top Initiations

Financial news for BIIB dated on 2015-01-06: Barclays Initiates Biogen Idec At Overweight

Financial news for BIIB dated on 2015-01-06: Barclays Initiates Coverage on Biogen Idec at Overweight, Announces \$425.00 PT

Financial news for BIIB dated on 2015-01-05: CORRECTION: Nomura Downgrades Biogen Idec to Neutral, Lowers PT to \$378.00

Financial news for BIIB dated on 2015-01-05: Nomura Downgrades Biogen Idec to Neutral, Lowers PT to \$378.00

Financial news for BIIB dated on 2014-12-24: Are There Any Winners Left In The Biotech Space?

Financial news for BIIB dated on 2014-12-24: How Gilead And Johnson & Johnson's Tumble Could've Burned These Hedge Funds

Financial news for BIIB dated on 2014-12-22: Morning Market Losers

Financial news for BIIB dated on 2014-12-22: Benzinga's Top #PreMarket Losers

Financial news for BIIB dated on 2014-12-17: Is Illumina Worth Adding To Your Portfolio?

Financial news for BIIB dated on 2014-12-11: The Biotech Stock With The Most Upside In 2015, According To Morgan Stanley

Financial news for BIIB dated on 2014-12-08: 3 Biotech ETFs Rally On Merger News

Financial news for BIIB dated on 2014-12-03: Great News For Biogen, But What's Next For The Stock?

Financial news for BIIB dated on 2014-12-03: A Technical Look At Biogen's Huge Rally

Financial news for BIIB dated on 2014-12-03: Biogen Announces Expanded Data from Phase 3 Studies Further Define the Safety, Efficacy of ELOCTATE, ALPROLIX

Financial news for BIIB dated on 2014-12-02: Markets Close Higher Following Strong November Auto Sales

Financial news for BIIB dated on 2014-12-02: Deutsche Bank Sees More Upside For Biogen

Financial news for BIIB dated on 2014-12-02: Why Biogen Shares Soared Today

Financial news for BIIB dated on 2014-12-02: Biogen Up Sharply On Promising Alzheimer's Results

Financial news for BIIB dated on 2014-12-02: CNBC's Meg Tirrell Tweets: '\$BIIB up 5% pre-market as Alzheimer's drug BIIB037 shows promise in ph 1b study, co outlines plans to move to ph 3'

Financial news for BIIB dated on 2014-12-02: Biogen Shares Spiking Higher, Now Up More Than 15 Points

Financial news for BIIB dated on 2014-11-25: FDA Orders New Label For Biogen Idec's MS Drug

Financial news for BIIB dated on 2014-11-25: Biogen Shares Now Down 0.6% Following FDA Warning

Financial news for BIIB dated on 2014-11-25: UPDDATE: FDA Says Information Describing Case of PML Being Added to Tecfidera Label

Financial news for BIIB dated on 2014-11-25: UPDATE: FDA Says MS Patient Treated With Biogen's Tecfidera Developed Serious Brain Infection, Later Died

Financial news for BIIB dated on 2014-11-25: FDA Warns About Case Of Rare Brain Infection With Biogen's MS Drug

Financial news for BIIB dated on 2014-11-19: UPDATE: Credit Suisse Reiterates On Biogen Idec On Gilenya PPMS Risk

Financial news for BIIB dated on 2014-11-19: Credit Suisse Maintains Outperform on Biogen Idec Inc., Lowers PT to \$400.00

Financial news for BIIB dated on 2014-11-13: The Bull/Bear Breakdown On Biogen Idec

Financial news for BIIB dated on 2014-10-23: Citi, Jefferies Weigh In On Biogen Idec Amid Q3 Earnings

Financial news for BIIB dated on 2014-10-23: US Stock Futures Rise Ahead Of Earnings, Economic Data

Financial news for BIIB dated on 2014-10-23: Leading Researchers Join Biogen Idec To Advance Drug Discovery For Neurodegenerative Diseases

Financial news for BIIB dated on 2014-10-22: Markets Reverse Early Morning Gains Following Canadian Shooting

Financial news for BIIB dated on 2014-10-22: CORRECTION: Baird Upgrades Biogen Idec Inc. to Outperform

Financial news for BIIB dated on 2014-10-22: Baird Upgrades Biogen Idec Inc. to Outperform

Financial news for BIIB dated on 2014-10-22: Hearing Biogen Idec Upgrade at Baird

Financial news for BIIB dated on 2014-10-22: Morning Market Losers

Financial news for BIIB dated on 2014-10-22: Biogen Idec Shares Fall 5% Premarket on Report of Patient Death; Patient was Taking MS Drug Tecfidera and Died of Pneumonia

Financial news for BIIB dated on 2014-10-22: Benzinga's Top #PreMarket Losers

Financial news for BIIB dated on 2014-10-22: UPDATE: Biogen Idec Posts Upbeat Q3 Results, Raises Earnings Forecast

Financial news for BIIB dated on 2014-10-22: Biogen Idec Inc. Reports Q3 EPS of \$3.80 vs \$3.46 Est; Revenue of \$2.50B vs \$2.48B Est

Financial news for BIIB dated on 2014-10-22: Earnings Scheduled For October 22, 2014

Financial news for BIIB dated on 2014-10-13: Which Fund Has The Most To Gain From Biogen Idec?

Financial news for BIIB dated on 2014-10-09: Biogen Idec Inc's Stock Is Set To Drop

Financial news for BIIB dated on 2014-10-03: #Premarket Prep Technical Update - Biogen Trading Higher

Financial news for BIIB dated on 2014-09-30: Biogen Idec Inc Still Showing Relative Weakness Compared To Biotech Peers

Financial news for BIIB dated on 2014-09-18: 2 Columbia Growth Funds Notch Impressive Three-Month Performance

Financial news for BIIB dated on 2014-09-12: Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA

Financial news for BIIB dated on 2014-09-11: Biogen Idec, Inc. Suddenly Struggling To Keep Up With The Biotech Joneses

Financial news for BIIB dated on 2014-09-11: Biogen Reports PLEGRIDY Two-Year Data Confirms Maintenance of Efficacy, Safety in MS Patients

Financial news for BIIB dated on 2014-09-11: Biogen Announces Five-Year Results from ENDORSE Phase 3 Study Show TECFIDERA Provides Strong, Sustained Efficacy for RRMS

Financial news for BIIB dated on 2014-09-09: Have We Seen The Market's Top?

Financial news for BIIB dated on 2014-09-06: Allianz's Analyst Likes Biogen Idec Inc, Celgene Corporation & Gilead

Financial news for BIIB dated on 2014-08-26: Biogen Announces Health Canada Has Okayed Elocetate

Financial news for BIIB dated on 2014-08-21: Isis Pharmaceuticals Says on August 21, 2014, First Infant Received First Dose of Isis-SMNRXx In Phase 3 Study; Isis Earned \$18M Milestone Payment from Biogen

Financial news for BIIB dated on 2014-08-21: 8-K from Isis Pharma Shows Co. Earned \$18M Milestone Payment from Biogen Related to ISIS-SMNRx Phase 3 Study

Financial news for BIIB dated on 2014-08-18: UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Plegridy Approval

Financial news for BIIB dated on 2014-08-16: Biogen Idec's PLEGRIDY Approved by FDA for Treatment of MS

Financial news for BIIB dated on 2014-08-08: #Premarket Primer: Friday, August 8: U.S. To Begin Airstrikes In Iraq

Financial news for BIIB dated on 2014-08-07: Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

Financial news for BIIB dated on 2014-08-06: Why Investors Should Closely Watch Celgene

Financial news for BIIB dated on 2014-08-05: Regulus Enters New Collaboration Agreement with Biogen; Regulus to Receive \$2M Upfront with Potential Future Milestone Payments

Financial news for BIIB dated on 2014-07-23: Vertex Is Poised For An Earnings Breakout

Financial news for BIIB dated on 2014-07-23: Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential Buyout Target

Financial news for BIIB dated on 2014-07-23: Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip

Financial news for BIIB dated on 2014-07-23: Biogen Announces PLEGRIDY Approved in EU for Treatment of MS

Financial news for BIIB dated on 2014-07-23: Markets Mixed; PepsiCo Q2 Earnings Beat Street View

Financial news for BIIB dated on 2014-07-23: Morning Market Movers

Financial news for BIIB dated on 2014-07-23: UPDATE: Biogen Idec Posts Stronger-Than-Expected Q2 Results, Shares Surge

Financial news for BIIB dated on 2014-07-23: Biogen Conference Call Starts

Financial news for BIIB dated on 2014-07-23: Benzinga's Top #PreMarket Gainers

Financial news for BIIB dated on 2014-07-23: Biogen Idec Reports Q2 Adjusted EPS of \$3.49 vs \$2.80 Est; Revenue of \$2.40B vs \$2.14B Est

Financial news for BIIB dated on 2014-07-23: Earnings Scheduled For July 23, 2014

Financial news for BIIB dated on 2014-07-18: Biotech Enters Reporting Season With Large Caps Central To Sector Performance

Financial news for BIIB dated on 2014-07-09: Deutsche Bank Analyst Talks Up Biogen On CNBC; Stock Responds Slightly

Financial news for BIIB dated on 2014-07-03: Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

Financial news for BIIB dated on 2014-06-25: Top 4 Stocks In The Biotechnology Industry With The Highest EPS

Financial news for BIIB dated on 2014-06-23: #Premarket Prep Technical Update - Biogen Trading Lower

Financial news for BIIB dated on 2014-06-19: ISIS Pharma Trades Up Premarket; NYT Says Has Potential Heart Attack Drug

Financial news for BIIB dated on 2014-06-17: Isis Pharmaceuticals Announces \$10M Milestone Payment from Biogen

Financial news for BIIB dated on 2014-06-16: Benzinga's M&A Chatter for Monday June 16, 2014

Financial news for BIIB dated on 2014-06-16: Biogen, AbbVie Report Positive Top-Line Results from Phase 3 Trial of Daclizumaba for MS

Financial news for BIIB dated on 2014-06-10: UPDATE: Morgan Stanley Reiterates On Biogen Idec As Positive RPC1063 Data Poses Threat To Tecfidera

Financial news for BIIB dated on 2014-06-09: UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Good News On Eloctate

Financial news for BIIB dated on 2014-06-09: US Stock Futures Slightly Lower Ahead Of McDonald's Sales Report

Financial news for BIIB dated on 2014-06-09: Isis Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1, Earns \$15M Milestone from Biogen

Financial news for BIIB dated on 2014-06-06: FDA Has Approved Biogen's Eloctate for Use in Adults, Children with Hemophilia A

Financial news for BIIB dated on 2014-06-04: ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy

Financial news for BIIB dated on 2014-05-29: Market Wrap For May 29: Investors Welcome Another Record High For The S&P 500

Financial news for BIIB dated on 2014-05-29: JP Morgan Ratings Imply Pharma Pair Trade

Financial news for BIIB dated on 2014-05-29: #Premarket Technical Update - Biogen

Trading Higher

Financial news for BIIB dated on 2014-05-29: UPDATE: JP Morgan Upgrades Biogen, Seeing Upside To Shares

Financial news for BIIB dated on 2014-05-29: Benzinga's Top Upgrades

Financial news for BIIB dated on 2014-05-29: JP Morgan Upgrades Biogen Idec Inc. to Overweight, Raises PT to \$375.00

Financial news for BIIB dated on 2014-05-28: Array Announces Drug Discovery Deal with Biogen

Financial news for BIIB dated on 2014-05-23: Biogen Reports Adoption of Positive Opinion for Plegridy, Expecting EC Decision on MAA in 2H of This Year

Financial news for BIIB dated on 2014-05-21: Five Star Biotech Stock Watch: Biogen Idec

Financial news for BIIB dated on 2014-05-12: Richard Rudick Named VP Of Development Sciences, Value Based Medicine at Biogen

Financial news for BIIB dated on 2014-05-09: Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS

Financial news for BIIB dated on 2014-05-01: UPDATE: Biogen Reports TYSABRI Improved Walking Speed in Significant Number of MS Patients

Financial news for BIIB dated on 2014-05-01: Biogen Says Tysabri Shows Improved Walking Speed in MS Patients

Financial news for BIIB dated on 2014-04-29: Biogen to Present Plegridy Data from Phase 3 Study at AAN Annual Meeting

Financial news for BIIB dated on 2014-04-28: Market Wrap For April 28: Apple Hits New 52-Week Highs In a Volatile Start To the Trading Week

Financial news for BIIB dated on 2014-04-28: #Premarket Technical Update - Biogen Continues Lower

Financial news for BIIB dated on 2014-04-25: Biotech Stocks Hedge Funds Are Betting On

Financial news for BIIB dated on 2014-04-25: U.S.-Russia Tensions Over Ukraine Could Make This An Interesting Weekend

Financial news for BIIB dated on 2014-04-24: Biogen Raises Full-Year Earnings, But Is That The Entire Picture?

Financial news for BIIB dated on 2014-04-24: Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns

Financial news for BIIB dated on 2014-04-24: Quintiles, Biogen Idec Announce Comprehensive Clinical Development Partnership

Financial news for BIIB dated on 2014-04-24: Nomura Maintains Buy on Biogen Idec Inc., Raises PT to \$415.00

Financial news for BIIB dated on 2014-04-23: Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple Announces 7-for-1 Stock Split

Financial news for BIIB dated on 2014-04-23: #Premarket Technical Update - Biogen Trading Lower After Earnings

Financial news for BIIB dated on 2014-04-23: Biogen in 10Q Reports State, Federal Authorities Investigating Sales and Promotional Practices

Financial news for BIIB dated on 2014-04-23: Biogen Idec Inc. Sees FY2014 EPS \$11.35-11.45 vs \$11.32 Est

Financial news for BIIB dated on 2014-04-23: Biogen Idec Inc. Reports Q1 EPS of \$2.47 vs \$2.57 Est; Revenue of \$2.13B vs \$2.0B Est

Financial news for BIIB dated on 2014-04-23: Earnings Scheduled For April 23, 2014

Financial news for BIIB dated on 2014-04-21: Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII; Amunix Could Recieve up to \$39M

Financial news for BIIB dated on 2014-04-14: Citigroup Saves The Market

Financial news for BIIB dated on 2014-04-14: Biogen to Present Clinical Data from Neurology Portfolio at AAN Annual Meeting

Financial news for BIIB dated on 2014-04-10: Market Wrap For April 10: Wednesday's Rally Completely Forgotten

Financial news for BIIB dated on 2014-04-10: Biogen Announces Naming of Adam Koppel as Senior VP, Chief Strategy Officer

Financial news for BIIB dated on 2014-04-10: Biogen Idec And Sobi Announce Positive Top-Line Efficacy And Safety Results From Phase 3 Pediatric Study Of Investigational Therapy Eloctate For Hemophilia A

Financial news for BIIB dated on 2014-04-08: Biotechs Struggling To Find A Bottom

Financial news for BIIB dated on 2014-03-31: Sobi, Biogen Announce FDA Approves Alprolix)

Financial news for BIIB dated on 2014-03-28: FDA Says Biogen's Alprolix for Hemophilia B Patients Approved

Financial news for BIIB dated on 2014-03-27: Market Wrap For March 27: Markets Lower Following Mixed Economic Data

Financial news for BIIB dated on 2014-03-27: Biotech ETFs Come Back Down To Earth

Financial news for BIIB dated on 2014-03-27: Morgan Stanley's Top Biotech Pick is Biogen

Financial news for BIIB dated on 2014-03-27: Morgan Stanley Initiates Coverage on Biogen Idec Inc. at Overweight, Announces \$395.00 PT

Financial news for BIIB dated on 2014-03-26: Morgan Stanley Starts Biogen Idec With Overweight; \$395 PT

Financial news for BIIB dated on 2014-03-25: Adding Downside Protection To Biogen

Financial news for BIIB dated on 2014-03-24: Have We Seen The Top Of The Market?

Financial news for BIIB dated on 2014-03-21: Health Canada Approves Biogen's Long-Acting ALPROLIX Therapy

Financial news for BIIB dated on 2014-03-20: AVEO Announces Deal with Biogen, Regains Global Rights to AV-203

Financial news for BIIB dated on 2014-03-19: Market Wrap For March 19: Yellen Hints of Higher Rates & Sooner Than Expected End To Taper

Financial news for BIIB dated on 2014-03-19: UPDATE: Stifel Reiterates on Biogen Idec Following Hemophilia Survey

Financial news for BIIB dated on 2014-03-19: Stifel Nicolaus Maintains Buy on Biogen Idec Inc., Raises PT to \$376.00

Financial news for BIIB dated on 2014-03-18: Market Wrap For March 18: Markets Positive Despite Crimea Concerns

Financial news for BIIB dated on 2014-03-18: Biogen Announces Received Notice of PDUFA Date Extension for Plegridy, Extended by Three Months

Financial news for BIIB dated on 2014-03-17: Keurig Green Mountain, Biogen Shares Rally Following Additions to S&P Indices

Financial news for BIIB dated on 2014-03-12: BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)

Financial news for BIIB dated on 2014-03-07: Market Wrap For March 7: Markets Cap Off Positive Week With Small Gains

Financial news for BIIB dated on 2014-03-07: Biogen Shares Down 4%; Seeing Mixed Analyst Sentiment on IMS Tracking on Tecfidera

Financial news for BIIB dated on 2014-03-06: Benzinga's Top Upgrades

Financial news for BIIB dated on 2014-03-06: BMO Capital Upgrades Biogen Idec Inc. to Outperform, Raises PT to \$422.00

Financial news for BIIB dated on 2014-03-05: Market Wrap For March 5: Markets Calm

Following Tuesday's Massive Rally

Financial news for BIIB dated on 2014-03-05: US Stock Futures Flat Ahead Of ADP Jobs Report

Financial news for BIIB dated on 2014-03-05: Eisai, Biogen Enter Collaboration to Develop and Commercialize Alzheimer's Disease Treatments

Financial news for BIIB dated on 2014-03-04: Biotechs vs. Pharmaceuticals: What's the Difference?

Financial news for BIIB dated on 2014-02-27: Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)

Financial news for BIIB dated on 2014-02-26: Moody's Upgrades Biogen Idec To Baal; Outlook Stable

Financial news for BIIB dated on 2014-02-26: Top 4 Large-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio

Financial news for BIIB dated on 2014-02-15: Biogen Idec's Chairman William D. Young to Retire From Board of Directors

Financial news for BIIB dated on 2014-02-14: Credit Suisse Maintains Outperform on Biogen Idec Inc., Raises PT to \$400.00

Financial news for BIIB dated on 2014-02-13: UPDATE: Isis to Receive \$2M Milestone Payment from Biogen Idec

Financial news for BIIB dated on 2014-02-10: Three ETFs To Buy On The Pullback (PJP, SKYY, SPY)

Financial news for BIIB dated on 2014-02-07: Index Investing Is A Raw Deal: Here's A Better Approach

Financial news for BIIB dated on 2014-02-03: First Step to a Winning Investment Strategy

Financial news for BIIB dated on 2014-02-03: Biogen Announces TECFIDERA Approved in EU as First-Line Oral Treatment for MS, Will Introduce TECFIDERA in EU in Coming Weeks

Financial news for BIIB dated on 2014-01-30: Biogen, UCB Announce Agreements to Commercialize MS, Hemophilia Therapies in Asia

Financial news for BIIB dated on 2014-01-29: New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

Financial news for BIIB dated on 2014-01-29: Top Trending Tickers On StockTwits For January 29

Financial news for BIIB dated on 2014-01-29: US Stock Futures Flat; All Eyes On Fed Decision

Financial news for BIIB dated on 2014-01-29: UPDATE: Biogen Idec Posts Higher Q4 Profit

Financial news for BIIB dated on 2014-01-29: Biogen Idec Reports Q4 Adjusted EPS of \$2.34 vs \$2.28 Est; Revenue of \$1.97B vs \$1.93B Est

Financial news for BIIB dated on 2014-01-29: Earnings Scheduled For January 29, 2014

Financial news for BIIB dated on 2014-01-28: Deutsche Bank Boosts Target on Gilead to \$132, on Celgene to \$190, on Biogen to \$415, Says We Would Be Buyers on Weakness

Financial news for BIIB dated on 2014-01-13: CNBC's Brian Sullivan Just Finished Talking with Biogen CEO Scangos at JP Morgan Healthcare Conference: Says Co. In Talks for Acquisitions

Financial news for BIIB dated on 2014-01-09: Market Wrap For January 9: All Eyes on Tomorrow's Job Report

Financial news for BIIB dated on 2014-01-09: Mid-Day Market Update: U.S. Stocks Turn Red; Bed Bath & Beyond Shares Decline On Weak Q3 Earnings

Financial news for BIIB dated on 2014-01-09: Benzinga's Volume Movers

Financial news for BIIB dated on 2014-01-09: Stocks Hitting 52-Week Highs

Financial news for BIIB dated on 2014-01-09: Morning Market Movers

Financial news for BIIB dated on 2014-01-09: Benzinga's Top #PreMarket Gainers

Financial news for BIIB dated on 2014-01-09: Sangamo BioSciences, Biogen Partnership to Develop Novel Therapies for Sickle Cell Disease, Beta-Thalassemia

Financial news for BIIB dated on 2014-01-09: Sunesis Pharmaceuticals Announces Global Licenses for Two Kinase Inhibitor Programs

Financial news for BIIB dated on 2014-01-08: Benzinga's Top Initiations

Financial news for BIIB dated on 2014-01-08: Nomura Initiates Coverage on Biogen Idec Inc. at Buy, Announces \$368.00 PT

Financial news for BIIB dated on 2014-01-07: UPDATE: Biogen Idec's Scangos Sees Tecfidera Offer to a Great Start in the US

Financial news for BIIB dated on 2014-01-07: Biogen Idec CEO Scangos Currently Speaking at Goldman Healthcare Conference: Expecting Tecfidera Uptake in Europe Slower Than US, Will Roll Out One Country at a Time

Financial news for BIIB dated on 2013-12-17: Slideshow: The Top 10 'Highs & Dives' Of S&P 500 Stocks In 2013

Financial news for BIIB dated on 2013-12-17: Biogen Idec, Samsung Bioepis to Market Anti-TNF Biosimilar Product Candidates in Europe

Financial news for BIIB dated on 2013-12-11: Biogen Idec, Pharmacoclics See Surges In Short Interest (BIIB, CELG, PCYC)

Financial news for BIIB dated on 2013-12-09: Biogen, Orphan Biovitrum Announce Positive ALPROLIX, ELOCTATE Phase 3 Data Across Multiple Hemophilia Populations at ASH

Financial news for BIIB dated on 2013-12-05: Biogen, Sobi Announce Publication of Phase 3 ALPROLIXTM Haemophilia B Study Data in NEJM

Financial news for BIIB dated on 2013-12-03: Biogen to Present New Data from Hemophilia Clinical Development, Research Programs

Financial news for BIIB dated on 2013-12-02: Biogen Idec Receives PDUFA Date Extension for ALPROLIX from FDA

Financial news for BIIB dated on 2013-11-29: Deutsche Bank Comments on How Biogen Idec May be Affected by Tecfidera IMS Data

Financial news for BIIB dated on 2013-11-27: UPDATE: Piper Jaffray Resumes Coverage on Biogen Idec as 2014 Biotech Sector Outlook Remains Strong

Financial news for BIIB dated on 2013-11-26: Piper Jaffray Reinstates Overweight on Biogen Idec Inc.

Financial news for BIIB dated on 2013-11-26: ETF Outlook for Tuesday, November 26, 2013

Financial news for BIIB dated on 2013-11-22: Market Wrap For November 22: Markets Finish The Week On a Positive Note

Financial news for BIIB dated on 2013-11-22: Deutsche Bank Maintains Buy on Biogen Idec Inc., Raises PT to \$340.00

Financial news for BIIB dated on 2013-11-22: Citi Lifts Target on Biogen from \$260 to \$320, Maintains Buy

Financial news for BIIB dated on 2013-11-22: Credit Suisse Reiterates on Biogen Idec on Positive RDP Decision

Financial news for BIIB dated on 2013-11-13: Journal Publishes Pivotal Data Demonstrating Efficacy and Safety of ELOCTATE for Hemophilia A

Financial news for BIIB dated on 2013-11-12: Gilead Sciences Leads In Rising Short Interest Among Biotechs

Financial news for BIIB dated on 2013-11-12: UPDATE: Biogen's Kingsley Says Co. Planning Mid-2014 Launch of Eloctate in US

Financial news for BIIB dated on 2013-11-12: Biogen Exec VP Global Commercial Operations Tony Kingsley Speaking at Credit Suisse Conference, Says 35K Patients Are

on Tecfidera After First Six Months

Financial news for BIIB dated on 2013-11-12: Isis Pharmaceuticals Announces \$1.5M Milestone Payment from Biogen Related to Phase 2 study of ISIS-SMNRx

Financial news for BIIB dated on 2013-10-29: #PreMarket Primer: Tuesday, October 29: Fed Meeting Likely Uneventful

Financial news for BIIB dated on 2013-10-28: Benzinga's Volume Movers

Financial news for BIIB dated on 2013-10-28: From Biogen Call: Elocetate Could Be Facing Potential Approval Delay

Financial news for BIIB dated on 2013-10-28: UPDATE: Biogen Idec Posts 22% Rise In Q3 Profit, Lifts Full-Year Outlook

Financial news for BIIB dated on 2013-10-28: Biogen Idec Inc. Raises FY2013 EPS Guidance from \$8.25-8.50 to \$8.65-8.85 vs \$8.59 Est, Sales Growth 23-25%

Financial news for BIIB dated on 2013-10-28: Biogen Idec Inc. Reports Q3 EPS of \$2.35 vs \$2.10 Est; Revenue of \$1.83B vs \$1.78B Est

Financial news for BIIB dated on 2013-10-28: #PreMarket Primer: Monday, October 28: All Eyes On Apple

Financial news for BIIB dated on 2013-10-28: Earnings Scheduled For October 28, 2013

Financial news for BIIB dated on 2013-10-27: Earnings Expectations For The Week Of October 28: Apple, Facebook, GM and More

Financial news for BIIB dated on 2013-10-25: Benzinga Weekly Preview: FOMC Meeting Closely Watched

Financial news for BIIB dated on 2013-10-25: Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)

Financial news for BIIB dated on 2013-10-21: Stocks to Watch for October 21, 2013

Financial news for BIIB dated on 2013-10-11: Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

Financial news for BIIB dated on 2013-10-08: Biotech ETFs Plummeting (XBI, IBB, BBH)

Financial news for BIIB dated on 2013-10-04: Biogen TECFIDERA Data Show Sustained Efficacy and Long-Term Safety in MS Patients

Financial news for BIIB dated on 2013-10-03: US Stock Futures Down Ahead Of Jobless Claims Data

Financial news for BIIB dated on 2013-10-03: Biogen Reports TYSABRI Data Show Significant Reductions in MS Disease Activity

Financial news for BIIB dated on 2013-10-02: 5 Healthcare Stocks With The Highest EPS Estimates For The Next Quarter

Financial news for BIIB dated on 2013-10-02: UPDATE: Credit Suisse Raises PT on Biogen Idec on Higher Tecfidera and Hemophilia Sales Estimates

Financial news for BIIB dated on 2013-10-02: FBR Capital Maintains Outperform on Biogen Idec Inc., Raises PT to \$290.00

Financial news for BIIB dated on 2013-10-01: US Stock Futures Up Ahead of Economic Data

Financial news for BIIB dated on 2013-10-01: Biogen Announces Data from Phase 3 ADVANCE Study of PLEGRIDY Show Significant Clinical and MRI Improvements with

Financial news for BIIB dated on 2013-09-25: BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

Financial news for BIIB dated on 2013-09-18: BofA Merrill Added Biogen to 'US 1' List

Financial news for BIIB dated on 2013-09-14: Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)

Financial news for BIIB dated on 2013-09-10: Amicus, Biogen Announce Deal for Discovery, Development, Commercialization of Parkinson's Treatment

Financial news for BIIB dated on 2013-09-09: Market Wrap for Monday, September 9:

Nasdaq Bounces To 13 Year High

Financial news for BIIB dated on 2013-09-09: Mid-Afternoon Market Update: Markets Lead by the NASDAQ as Various Health Names Drop

Financial news for BIIB dated on 2013-09-09: Mid-Day Market Update: Dow Rises Over 100 Points; Apple Shares Gain

Financial news for BIIB dated on 2013-09-09: Hearing Piper Cautious on Isis Pharmaceuticals

Financial news for BIIB dated on 2013-09-09: Benzinga's Volume Movers

Financial news for BIIB dated on 2013-09-09: Mid-Morning Market Update: Markets Open Higher; Koch Industries To Acquire Molex For \$38.50/Share

Financial news for BIIB dated on 2013-09-09: Benzinga's Top Pre-Market Gainers

Financial news for BIIB dated on 2013-09-09: US Stock Futures Up Ahead Of Consumer Credit Data

Financial news for BIIB dated on 2013-09-09: Biogen, Isis Pharmaceuticals Announce Strategic Collaboration

Financial news for BIIB dated on 2013-09-05: Biotech Breakout Highlights Flawed ETF Thinking

Financial news for BIIB dated on 2013-08-27: Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)

Financial news for BIIB dated on 2013-07-26: Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

Financial news for BIIB dated on 2013-07-26: BMO Capital Maintains Market Perform on Biogen Idec Inc., Raises PT to \$237.00

Financial news for BIIB dated on 2013-07-26: Benzinga Market Primer: Friday, July 26: Futures Flat On Mixed Global Stocks Overnight

Financial news for BIIB dated on 2013-07-25: Biogen Idec Inc. Sees FY2013 EPS \$8.25-8.50

Financial news for BIIB dated on 2013-07-25: Biogen Idec Inc. Reports Q2 EPS of \$2.30 vs \$1.93 Est; Revenue of \$1.70B vs \$1.62B Est

Financial news for BIIB dated on 2013-07-25: Benzinga Market Primer: Thursday, July 25: Futures Lower After Technical Breakdown

Financial news for BIIB dated on 2013-07-22: Bloomberg Reporting Biogen Spokesperson Has Said Female Patient Previously Treated with Tecfidera Died of Bilateral Pneumonia, Not Dehydration

Financial news for BIIB dated on 2013-07-22: Analyst at ISI Said Death from Biogen's Tecfidera Related to Dehydration, Not Linked to Tecfidera

Financial news for BIIB dated on 2013-07-22: Biogen Responds to Reports of Patient Death from Tecfidera

Financial news for BIIB dated on 2013-07-22: Biogen Sells Off; May be Attributed to Report of Tecfidera Death

Financial news for BIIB dated on 2013-07-19: US and EU Regulatory Authorities Accept PLEGRIDY(tm) (peginterferon beta-1a) Marketing Applications for Review

Financial news for BIIB dated on 2013-07-15: Health Care ETFs Looking Healthy Ahead of Earnings

Financial news for BIIB dated on 2013-07-11: Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)

Financial news for BIIB dated on 2013-07-02: Biogen, Sobi Offer New Data from Phase 3 Trial of ALPROLIX

Financial news for BIIB dated on 2013-07-01: UPDATE: Piper Jaffray Raises PT on Biogen Idec on Multiple Positive Factors

Financial news for BIIB dated on 2013-07-01: Benzinga's Top Upgrades

Financial news for BIIB dated on 2013-07-01: Citigroup Upgrades Biogen Idec Inc. to

Buy, Maintains \$236.00 PT

Financial news for BIIB dated on 2013-06-27: UPDATE: Biogen in Pact with Adaptive Biotech for Immune Test

Financial news for BIIB dated on 2013-06-27: Adaptive Biotech., Biogen Idec in Pact for Immunological Services

Financial news for BIIB dated on 2013-06-26: Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)

Financial news for BIIB dated on 2013-06-12: Market Wrap for Wednesday, June 12: Stock and Bond Markets Fall Mid-Week; Liquidity Concerns Remain a Focus

Financial news for BIIB dated on 2013-06-12: Afternoon Market Losers

Financial news for BIIB dated on 2013-06-12: Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)

Financial news for BIIB dated on 2013-06-12: Benzinga's Top Pre-Market Losers

Financial news for BIIB dated on 2013-06-12: Benzinga's Top Downgrades

Financial news for BIIB dated on 2013-06-12: Citigroup Downgrades Biogen Idec Inc. to Neutral, Raises PT to \$236.00

Financial news for BIIB dated on 2013-06-05: Deutsche Bank Reiterates Buy Rating on Biogen, PT \$240.00 On Upside From Quick-Start Program and Inventory

Financial news for BIIB dated on 2013-06-05: Hearing Defense of Biogen Coming Out of Deutsche Bank

Financial news for BIIB dated on 2013-06-04: UPDATE: Biogen Shares Sink as Cowen Warns of 'Double-Counting' on Tecifera Prescriptions

Financial news for BIIB dated on 2013-06-04: Shares of Biogen Lower as Cowen Note Warns of Double Counting for Tecfidera Prescriptions in IMS Health's Weekly NRx Data

Financial news for BIIB dated on 2013-06-04: Benzinga's Top Pre-Market Losers

Financial news for BIIB dated on 2013-05-29: Short Interest in Vertex Rises, in Biogen Idec Falls

Financial news for BIIB dated on 2013-05-21: Biogen Idec Submits BLA to FDA for Approval of PLEGRIDY for Multiple Sclerosis

Financial news for BIIB dated on 2013-05-20: Leerink Swann Highlights Big Gains in Prescriptions for Biogen's MS Treatment

Financial news for BIIB dated on 2013-05-15: Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter

Financial news for BIIB dated on 2013-05-13: FDA Accepts Biogen's Biologics License App for Elocetate

Financial news for BIIB dated on 2013-05-11: Short Interest in Vertex Rises, in Celgene Falls

Financial news for BIIB dated on 2013-05-10: S&P Highlights Biotech ETFs

Financial news for BIIB dated on 2013-05-09: Isis Pharmaceuticals Earns \$3.5M from Biogen Idec

Financial news for BIIB dated on 2013-05-03: Morgan Stanley Reiterates Overweight on Biogen Idec Following AlphaWise Survey

Financial news for BIIB dated on 2013-05-03: Three Sector ETFs Up 20% or More YTD

Financial news for BIIB dated on 2013-05-01: Illumina and Other Bargain Biotech Stocks Worth a Look Now

Financial news for BIIB dated on 2013-04-30: Equal-Weight ETF Trounces Traditional S&P 500 Peers

Financial news for BIIB dated on 2013-04-26: Short Sellers Move into Celgene, Regeneron

Financial news for BIIB dated on 2013-04-26: Benzinga Market Primer: Friday, April 26

Financial news for BIIB dated on 2013-04-25: Benzinga Market Primer: Thursday, April 25

Financial news for BIIB dated on 2013-04-25: Biogen Idec Inc. Reports Q1 EPS of \$1.97 vs \$1.59 Est; Revenue of \$1.40B vs \$1.41B Est

Financial news for BIIB dated on 2013-04-24: Biogen Near Lows, May be Attributed to Cautious JMP Note

Financial news for BIIB dated on 2013-04-23: UPDATE: Deutsche Bank Raises PT on Biogen Idec on Tecfidera Launch Confidence

Financial news for BIIB dated on 2013-04-22: Deutsche Bank Maintains Buy on Biogen Idec Inc., Raises PT to \$240.00

Financial news for BIIB dated on 2013-04-22: Market Wrap for April 22: Stocks Rise Moderately to Begin Week

Financial news for BIIB dated on 2013-04-22: Biotech Mutual Funds Show ETFs Are The Place to Be

Financial news for BIIB dated on 2013-04-22: Stocks Hitting 52-Week Highs

Financial news for BIIB dated on 2013-04-21: A Look Ahead: This Week's ETFs to Watch

Financial news for BIIB dated on 2013-04-19: Citigroup Maintains Buy on Biogen Idec Inc., Raises PT to \$235.00

Financial news for BIIB dated on 2013-04-17: S&P Upgrades Biogen from BBB+ to A-

Financial news for BIIB dated on 2013-04-16: Biogen Loses Appeal in Arzerra Patent Case Against Glaxo

Financial news for BIIB dated on 2013-04-12: UBS Maintains Neutral on Biogen Idec Inc., Raises PT to \$208.00

Financial news for BIIB dated on 2013-04-12: Benzinga's Top Pre-Market Gainers

Financial news for BIIB dated on 2013-04-12: Bank of America Upgrades Biogen Idec Inc. to Buy, Raises PT to \$246.00

Financial news for BIIB dated on 2013-04-11: ETF Showdown: A Pharma Fight

Financial news for BIIB dated on 2013-04-11: Under The Hood: An Unheralded Biotech ETF

Financial news for BIIB dated on 2013-04-11: Biogen Crosses Above \$200

Financial news for BIIB dated on 2013-04-10: Short Sellers Move Out of Amgen, Celgene, Pharmacyclics

Financial news for BIIB dated on 2013-04-09: RBC Capital Boosts Target on Biogen from \$180 to \$215, Maintains Outperform

Financial news for BIIB dated on 2013-04-04: Credit Suisse Maintains Outperform on Biogen Idec Inc., Raises PT to \$225.00

Financial news for BIIB dated on 2013-04-04: Lancet Publishes SELECT Study of Biogen's Daclizumab HYP, Biogen Says 150MG, 300MG DAC HYP Injections Met Endpoint

Financial news for BIIB dated on 2013-04-01: UPDATE: Canaccord Genuity Raises PT on Biogen Idec on Tecfidera Price Announcement

Financial news for BIIB dated on 2013-04-01: Canaccord Genuity maintains Buy on Biogen Idec Inc., Raises PT to \$206.00

Financial news for BIIB dated on 2013-03-28: Biotech Breakout Boosting ETFs

Financial news for BIIB dated on 2013-03-28: UPDATE: Bank of America Raises PT on Biogen Idec Following Tecfidera Approval

Financial news for BIIB dated on 2013-03-28: UPDATE: Goldman Sachs Raises PT on Biogen Idec on Tecfidera Approval

Financial news for BIIB dated on 2013-03-28: UPDATE: Canaccord Genuity Raises PT on Biogen Idec on Tecfidera Approval

Financial news for BIIB dated on 2013-03-28: UPDATE: Jefferies Raises PT on Biogen Idec on FDA Tecfidera Approval

Financial news for BIIB dated on 2013-03-28: Bank of America Maintains Neutral on Biogen Idec Inc., Raises PO to \$187.00

Financial news for BIIB dated on 2013-03-28: Goldman Sachs Maintains Conviction Buy on Biogen Idec Inc., Raises PT to \$211.00

Financial news for BIIB dated on 2013-03-28: Canaccord Genuity Maintains Buy on Biogen Idec Inc., Raises PT to \$200.00

Financial news for BIIB dated on 2013-03-28: Benzinga's Top Pre-Market Gainers

Financial news for BIIB dated on 2013-03-28: Short Sellers Dump Amgen, Focus on Celgene, Gilead Sciences

Financial news for BIIB dated on 2013-03-28: Stifel Nicolaus Maintains Buy on Biogen Idec Inc., Raises PT to \$202.00

Financial news for BIIB dated on 2013-03-28: Jefferies Maintains Buy on Biogen Idec Inc., Raises PT to \$215.00

Financial news for BIIB dated on 2013-03-27: Biogen Confirms US Approval for TECFIDERA

Financial news for BIIB dated on 2013-03-27: Biogen Shares Now Up Nearly 2% Following News of FDA Approval for MS Pill Tecfidera

Financial news for BIIB dated on 2013-03-27: Biogen Wins FDA Approval for MS Pill

Financial news for BIIB dated on 2013-03-26: 13 Drugs Pending FDA Approval in 2013

Financial news for BIIB dated on 2013-03-25: Moving Averages Indicate These Sector ETFs Could be Stretched

Financial news for BIIB dated on 2013-03-25: UPDATE: Morgan Stanley Raises PT on Biogen Idec on Long-Term Potential

Financial news for BIIB dated on 2013-03-25: Morgan Stanley Maintains Overweight on Biogen Idec Inc., Raises PT to \$188.00

Financial news for BIIB dated on 2013-03-22: UPDATE: Bank of America Raises PO On Biogen Idec; Promising New Product Expected

Financial news for BIIB dated on 2013-03-22: Bank of America Maintains Neutral on Biogen Idec Inc., Raises PT to \$182.00

Financial news for BIIB dated on 2013-03-22: Bloomberg Reporting Biogen's Tecfidera Wins Positive Opinion from EMA

Financial news for BIIB dated on 2013-03-20: XenoPort May Be Beneficiary of Biogen Patent Filings

Financial news for BIIB dated on 2013-03-20: Positive Year One Results from Biogen Idec Phase 3 ADVANCE Trial of PLEGRIDY Presented at AAN Meeting

Financial news for BIIB dated on 2013-03-19: US Patent Office Grants Patent Claiming Dosing Regimen for TECFIDERA(tm) (Dimethyl Fumarate)

Financial news for BIIB dated on 2013-03-18: Biogen, Elan Reaffirm Substantial Efficacy from New TYSABRI Data for Treatment of Patients with MS

Financial news for BIIB dated on 2013-03-17: Three Top Performing BRIC Stocks (CBPO, GSH, VIPS)

Financial news for BIIB dated on 2013-03-14: Biogen Enters \$750M Credit Pact

Financial news for BIIB dated on 2013-03-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)

Financial news for BIIB dated on 2013-03-12: Biogen Idec Submits BLA to FDA for Recombinant Factor VIII Therapy for Hemophilia A

Financial news for BIIB dated on 2013-03-04: Biogen Announces FDA Acceptance for Biologics License Application for First Long-Lasting Factor IX Therapy

Financial news for BIIB dated on 2013-03-04: Credit Suisse Maintains Outperform on Biogen Idec Inc., Raises PT to \$200.00

Financial news for BIIB dated on 2013-03-02: Benzinga's M&A Chatter for Friday March

1, 2013

Financial news for BIIB dated on 2013-03-01: Biogen Heads Up To Test \$169 Resistance Level, Breakout In Play

Financial news for BIIB dated on 2013-03-01: Bristol Meyers Squibb Reportedly Considered Large Acquisitions of Biogen and Shire

Financial news for BIIB dated on 2013-03-01: Biogen Spikes Higher

Financial news for BIIB dated on 2013-02-28: Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)

Financial news for BIIB dated on 2013-02-27: Here are the 20 Stocks with the Highest Share Price

Financial news for BIIB dated on 2013-02-27: UPDATE: Canaccord Genuity Upgrades Biogen Idec to Buy on BG-12 Early Launch

Financial news for BIIB dated on 2013-02-27: Canaccord Genuity Upgrades Biogen Idec Inc. to Buy, Raises PT to \$187.00

Financial news for BIIB dated on 2013-02-22: Elan Provides Update on Tysabri Collaboration with Biogen Idec

Financial news for BIIB dated on 2013-02-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

Financial news for BIIB dated on 2013-02-08: UPDATE: Credit Suisse Raises PT to \$185 on Biogen Idec on Tysabri Restructuring

Financial news for BIIB dated on 2013-02-08: Credit Suisse Maintains Outperform on Biogen Idec Inc., Raises PT to \$185.00

Financial news for BIIB dated on 2013-02-08: UPDATE: Citigroup Upgrades Biogen Idec to Buy on Strong Fundamentals

Financial news for BIIB dated on 2013-02-08: Citigroup Upgrades Biogen Idec Inc. to Buy, Raises PT to \$187.00

Financial news for BIIB dated on 2013-02-07: Jefferies Maintains Buy on Biogen Idec Inc., Raises PT to \$201.00

Financial news for BIIB dated on 2013-02-06: Market Wrap for Wednesday, February 6: Major Averages Close Near Unchanged; Euro Falls

Financial news for BIIB dated on 2013-02-06: Deutsche Bank Maintains Buy on Biogen Idec Inc., Raises PT to \$170.00

Financial news for BIIB dated on 2013-02-06: Biogen Expecting to Open \$500-750M Credit Line; Sees Tysabri Deal Adding \$0.50-0.60 to EPS in 2013, \$0.65-0.80 in 2014

Financial news for BIIB dated on 2013-02-06: Elan Agrees to Restructure Tysabri Collaboration with Biogen Idec

Financial news for BIIB dated on 2013-02-04: Acorda Therapeutics Could Be a Stock to Watch in 2013

Financial news for BIIB dated on 2013-01-29: Jefferies Maintains Buy on Biogen Idec Inc., Raises PT to \$187.00

Financial news for BIIB dated on 2013-01-28: UPDATE: Biogen Idec Posts Downbeat Q4 Profit, Issues Weak 2013 Profit Forecast

Financial news for BIIB dated on 2013-01-28: Biogen Idec Inc. Sees FY2013 EPS \$7.15-7.25 vs \$7.25 Est, Sees Sales Growth ~10%

Financial news for BIIB dated on 2013-01-28: Benzinga Market Primer: Monday, January 28

Financial news for BIIB dated on 2013-01-28: Biogen Idec Inc. Reports Q4 EPS of \$1.40 vs \$1.46 Est; Revenue of \$1.42B vs \$1.38B Est

Financial news for BIIB dated on 2013-01-28: US Stock Futures Flat Ahead Of Caterpillar Earnings

Financial news for BIIB dated on 2013-01-28: Earnings Scheduled For January 28, 2013

Financial news for BIIB dated on 2013-01-26: Short Interest Swings in Biotech Stocks

(BIIB, CELG, VVUS)

Financial news for BIIB dated on 2013-01-24: Biogen Idec Announces Positive Top-Line Results from Phase 3 Study of Peginterferon Beta-1a in Multiple Sclerosis

Financial news for BIIB dated on 2013-01-22: Morgan Stanley Sees Possible Near-Term Increase in M&A, Unveils 'Acquisition Likelihood Estimate Ranking Tool'

Financial news for BIIB dated on 2013-01-04: Biogen Submits Biologics License Application to FDA for First Long-Lasting Factor IX Therapy for Hemophilia B

Financial news for BIIB dated on 2013-01-03: Canaccord Genuity Maintains Hold on Biogen Idec Inc., Lowers PT to \$139.00

Financial news for BIIB dated on 2013-01-03: Bank of America Maintains Buy on Biogen Idec Inc., Lowers PO to \$164.00

Financial news for BIIB dated on 2013-01-03: Oppenheimer Maintains Perform on Biogen Idec Inc., Lowers PT to \$141.00

Financial news for BIIB dated on 2013-01-03: UPDATE: Piper Jaffray Downgrades Biogen Idec to Neutral on Valuation

Financial news for BIIB dated on 2013-01-03: Benzinga's Top Pre-Market Losers

Financial news for BIIB dated on 2013-01-03: Biogen Idec Reports Top-Line Results from Phase 3 Trial of Dexpramipexole in People with ALS Did Not Meet Primary Endpoint

Financial news for BIIB dated on 2013-01-03: Piper Jaffray Downgrades Biogen Idec Inc. to Neutral, Lowers PT to \$166.00

Financial news for BIIB dated on 2012-12-28: Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

Financial news for BIIB dated on 2012-12-17: Canaccord Genuity Initiates Coverage on Biogen Idec Inc. at Hold, Announces \$144.00 PT

Financial news for BIIB dated on 2012-12-13: Goldman Sachs Reinstates CL-Buy on Biogen Idec Inc., Announces \$178.00 PT

Financial news for BIIB dated on 2012-12-12: These ETFs Are Awash in 2013 Takeover Targets

Financial news for BIIB dated on 2012-12-12: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for BIIB dated on 2012-12-12: Biogen, Eisai Announce Manufacturing Alliance at Research Triangle Park Plants

Financial news for BIIB dated on 2012-12-10: Biogen, Isis Pharma Announce Collaboration for Antisense Programs

Financial news for BIIB dated on 2012-11-21: Brean Murray Initiates Coverage on Biogen Idec at Buy, Announces PT of \$184

Financial news for BIIB dated on 2012-11-12: Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

Financial news for BIIB dated on 2012-10-31: Biogen Idec and Sobi Announce Positive Top-Line Results from Phase 3 Study

Financial news for BIIB dated on 2012-10-26: BMO Capital Markets Maintains Biogen Idec at Market Perform, Raises PT from \$136 to \$147

Financial news for BIIB dated on 2012-10-25: Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

Financial news for BIIB dated on 2012-10-18: Piper Jaffray Maintains Biogen Idec at Overweight, Raises PT from \$159 to \$179

Financial news for BIIB dated on 2012-10-18: Biogen IDEC Says FDA Extends its Drug Review Date by 3 Months

Financial news for BIIB dated on 2012-10-15: Barclays Maintains Biogen Idec at Overweight, Raises PT from \$140 to \$150

Financial news for BIIB dated on 2012-10-15: Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)

Financial news for BIIB dated on 2012-10-12: Biogen's Sandrock Says Very Confident BG-12 Shows No Cancer Risk; Stacks Up Well vs Other MS Drugs on Safety

Financial news for BIIB dated on 2012-10-12: A Peek Into The Market Before The Trading Starts

Financial news for BIIB dated on 2012-10-12: Biogen Announces New Data from Phase 3 Studies for Oral BG-12 Treatment for Multiple Sclerosis

Financial news for BIIB dated on 2012-10-09: Acorda Therapeutics Names Jane Wasman President, International

Financial news for BIIB dated on 2012-10-08: UPDATE: Credit Suisse Reiterates Outperform Rating, Raises PT on Biogen Idec

Financial news for BIIB dated on 2012-10-08: Credit Suisse Maintains Biogen Idec at Outperform, Raises PT from \$165 to \$175

Financial news for BIIB dated on 2012-10-04: Oppenheimer Downgrades Biogen Idec from Outperform to Perform

Financial news for BIIB dated on 2012-09-27: UPDATE: Stifel Nicolaus Increases PT to \$168 on Biogen Idec on Hemophilia Trial

Financial news for BIIB dated on 2012-09-27: Stifel Nicolaus Maintains Biogen Idec at Buy, Raises PT from \$167 to \$168

Financial news for BIIB dated on 2012-09-27: Jefferies & Company Maintains Biogen Idec at Buy, Raises PT from \$164 to \$176

Financial news for BIIB dated on 2012-09-26: UPDATE: Bank of America Raises PO to \$173 on Biogen Idec on Strong Hemophilia Data

Financial news for BIIB dated on 2012-09-26: Short Interest in Biotech Firms Resumes (BIIB, GILD, ILMN, REGN)

Financial news for BIIB dated on 2012-09-26: Bank of America Maintains Biogen Idec at Buy, Raises PO from \$157 to \$173

Financial news for BIIB dated on 2012-09-26: Benzinga's Top Pre-Market Gainers

Financial news for BIIB dated on 2012-09-26: Biogen and Sobi Announce Positive Top-Line results from Phase 3 Study

Financial news for BIIB dated on 2012-09-19: Biogen Says Data Shows Potential for BG-12 as an MS Treatment

Financial news for BIIB dated on 2012-09-13: Short Sellers Shy Away from Biotech Firms

Financial news for BIIB dated on 2012-09-12: Biogen Idec Foundation Awards \$1M to Museum of Science in MA

Financial news for BIIB dated on 2012-09-10: UBS Downgrades Biogen Idec from Buy to Neutral, Maintains PT at \$156

Financial news for BIIB dated on 2012-09-06: Deutsche Bank Maintains Biogen Idec at Buy, Raises PT from \$150 to \$160

Financial news for BIIB dated on 2012-09-04: Joule Elects Caroline Dorsa to Board of Directors

Financial news for BIIB dated on 2012-08-27: Short Interest in Biotech Firms on the Rise

Financial news for BIIB dated on 2012-08-15: Benzinga's M&A Chatter for Wednesday August 15, 2012

Financial news for BIIB dated on 2012-08-15: Hearing DealReporter Saying Biogen Could Make Bid for Elan

Financial news for BIIB dated on 2012-08-13: Short Sellers Shy Away from Biotech Firms

Financial news for BIIB dated on 2012-07-30: Benzinga's M&A Chatter for Monday July 30, 2012

Financial news for BIIB dated on 2012-07-30: Elan Spokesperson Declines Comment on Bloomberg Report of Possible Takeover by Biogen

Financial news for BIIB dated on 2012-07-25: UBS Maintains Biogen Idec at Buy, Raises PT from \$148 to \$156

Financial news for BIIB dated on 2012-07-25: Morgan Stanley Maintains Biogen Idec at Overweight, Raises PT from \$140 to \$150

Financial news for BIIB dated on 2012-07-25: Jefferies & Company Maintains Biogen Idec at Buy, Raises PT from \$154 to \$164

Financial news for BIIB dated on 2012-07-24: Citigroup Maintains Biogen Idec at Neutral, Raises PT from \$144 to \$147

Financial news for BIIB dated on 2012-07-24: Social Media Outlook for Tuesday July 24 (GWR, BIIB, DV, UPS)

Financial news for BIIB dated on 2012-07-24: Financial Breakfast: Morning News Summary for July 24, 2012

Financial news for BIIB dated on 2012-07-24: Biogen Idec Reports Q2 EPS \$1.82 vs \$1.56 Est; Revenues \$1.4B vs \$1.33B Est

Financial news for BIIB dated on 2012-07-24: Benzinga Market Primer, Tuesday July 24

Financial news for BIIB dated on 2012-07-23: Leerink Swann Resumes Coverage on Biogen Idec at Outperform

Financial news for BIIB dated on 2012-07-17: Biogen, Bayer Ms Drugs Fail To Slow Disability, Study Finds - Bloomberg

Financial news for BIIB dated on 2012-07-16: 3 Unheralded ETFs Up More Than 10% in the Past 90 Days (PBE, TAGS)

Financial news for BIIB dated on 2012-07-09: Stifel Nicolaus Maintains Biogen Idec at Buy, Raises PT from \$144 to \$167

Financial news for BIIB dated on 2012-06-29: BioMarin Pharmaceutical Hits New 52-Week High on Continued Takeover Chatter

Financial news for BIIB dated on 2012-06-29: Biogen Idec, Isis To Develop Antisense Drug For Treatment Of Myotonic Dystrophy Type 1; Biogen Idec Says Isis Will Receive Upfront Payment Of \$12M

Financial news for BIIB dated on 2012-06-28: Benzinga's M&A Chatter for Thursday June 28, 2012

Financial news for BIIB dated on 2012-06-28: Spokesperson for BioMarin Pharmaceutical Won't Comment on Guardian Report on Takeover Bids

Financial news for BIIB dated on 2012-06-28: Editor of Little Bear Blog is Long BioMarin Pharmaceutical on Takeover Chatter

Financial news for BIIB dated on 2012-06-28: UPDATE: BioMarin Spikes Higher on Report GlaxoSmithKline, Sanofi, Biogen Could Bid \$60/Share -Guardian

Financial news for BIIB dated on 2012-06-12: Biogen Idec to Highlight Innovative Pipeline and Commercial Strategy

Financial news for BIIB dated on 2012-06-06: Deutsche Bank Reiterates Buy Rating, \$150 PT for Biogen Idec

Financial news for BIIB dated on 2012-05-18: Disney, Raytheon and Other Avenger Picks for a Heroic Portfolio

Financial news for BIIB dated on 2012-05-09: Biogen Idec Announces US and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for Review

Financial news for BIIB dated on 2012-05-09: UBS Maintains Biogen Idec at Buy, Raises PT from \$135 to \$148

Financial news for BIIB dated on 2012-05-02: UPDATE: Jefferies Raises PT to \$154 on Biogen Idec; Strong MS Dynamics

Financial news for BIIB dated on 2012-05-02: Jefferies & Company Maintains Biogen Idec at Buy, Raises PT from \$137 to \$154

Financial news for BIIB dated on 2012-05-01: Citigroup Maintains Biogen Idec at Neutral, Raises PT from \$130 to \$143

Financial news for BIIB dated on 2012-05-01: Piper Jaffray Maintains Biogen Idec at Overweight, Raises PT from \$140 to \$159

Financial news for BIIB dated on 2012-05-01: Oppenheimer Maintains Biogen Idec at Outperform, Raises PT from \$136 to \$139

Financial news for BIIB dated on 2012-05-01: Financial Breakfast: Morning News Summary for May 1, 2012

Financial news for BIIB dated on 2012-05-01: Biogen Idec Reports Q1 EPS \$1.40 vs \$1.48 Est; Revenues \$1.3B vs \$1.31B Est

Financial news for BIIB dated on 2012-04-25: Oppenheimer Maintains Biogen Idec at Outperform, Raises PT from \$127 to \$136

Financial news for BIIB dated on 2012-04-24: Biogen Idec Announces Positive Results from Phase 3 CONFIRM Clinical Trial Show Efficacy and Safety of Oral BG-12 in Multiple Sclerosis

Financial news for BIIB dated on 2012-04-04: Benzinga's Top Upgrades

Financial news for BIIB dated on 2012-04-04: UPDATE: Goldman Sachs Upgrades Biogen Idec; Raises PT

Financial news for BIIB dated on 2012-04-04: Financial Breakfast: Morning News Summary for April 4, 2012

Financial news for BIIB dated on 2012-04-04: Goldman Sachs Upgrades Biogen Idec from Neutral to Buy, Raises PT from \$120 to \$150

Financial news for BIIB dated on 2012-03-15: UPDATE: Stifel Nicolaus Resumes Buy, \$144 PT on Biogen Idec

Financial news for BIIB dated on 2012-03-14: Biogen Idec Takes Option to MAKScientific MS Program

Financial news for BIIB dated on 2012-03-09: Biogen Idec Spiking Higher on Heavy Volume; Currently at \$121

Financial news for BIIB dated on 2012-03-08: Biogen Idec Trading 2.7% Higher on Heavy Volume; Currently at \$120.16

Financial news for BIIB dated on 2012-03-08: Biogen Idec Spokesperson Refutes Claims of Biopharm Insight Article

Financial news for BIIB dated on 2012-03-08: Update: Biogen Spikes Lower on Negative Biopharm Insight Report

Financial news for BIIB dated on 2012-03-08: Biogen Spikes Lower on Negative Biopharm Insight Report

Financial news for BIIB dated on 2012-02-28: Biogen Idec Submits Application to FDA for Approval of Oral BG-12 to Treat Multiple Sclerosis

Financial news for BIIB dated on 2012-02-28: Biogen Says FDA Approves Avonex Pen & Dose Titration Regimen

Financial news for BIIB dated on 2012-02-28: A Peek Into The Market Before The Trading Starts

Financial news for BIIB dated on 2012-02-28: Biogen Idec Announces FDA Approves AVONEX PEN and Dose Titration Regimen

Financial news for BIIB dated on 2012-02-28: Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis

Financial news for BIIB dated on 2012-02-14: Benzinga's M&A Chatter for Tuesday February 14, 2012

Financial news for BIIB dated on 2012-02-14: Biogen Idec to Acquire Stromedix

Financial news for BIIB dated on 2012-02-10: Morgan Stanley Initiates Coverage on Biogen Idec at Overweight, Announces PT of \$140

Financial news for BIIB dated on 2012-02-02: Biogen Idec Hits 52-Week High of \$122.84

Financial news for BIIB dated on 2012-02-01: Biogen Idec Trading 2.5% Higher on Heavy Volume; Currently at \$120.93

Financial news for BIIB dated on 2012-02-01: Biogen Idec Hits 52-Week High of \$120.69

Financial news for BIIB dated on 2012-01-31: Benzinga's Top Pre-Market Losers

Financial news for BIIB dated on 2012-01-31: Biogen Guides FY2012 EPS \$6.10-6.20 vs \$6.31 Est

Financial news for BIIB dated on 2012-01-31: Biogen Idec Reports Q4 EPS \$1.51 vs \$1.49 Est; Revenues \$1.30B vs \$1.29B Est

Financial news for BIIB dated on 2012-01-26: Biogen Idec Receives Positive Mad Money/Jim Cramer Mention -CNBC

Financial news for BIIB dated on 2012-01-26: From Earlier: Biogen Idec and Elan Corporation Announce ASCEND Study to Evaluate the Effectiveness of TYSABRI as a Treatment for Secondary-Progressive Multiple Sclerosis

Financial news for BIIB dated on 2012-01-23: Biogen Spiking Lower on Heavy volume

Financial news for BIIB dated on 2012-01-23: Oppenheimer Releases Biogen Idec Company Update

Financial news for BIIB dated on 2012-01-20: Quest Diagnostics STRATIFY JCV First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients

Financial news for BIIB dated on 2012-01-20: Elan, Biogen Win FDA Approval to Market Test for Tysabri Risks

Financial news for BIIB dated on 2012-01-20: Deutsche Bank Maintains Buy on Biogen Idec After European Medical Agency Announcement

Financial news for BIIB dated on 2012-01-11: Citigroup Maintains Neutral on Biogen Idec After Analyst Meeting

Financial news for BIIB dated on 2012-01-11: Biogen Idec Block Trade of 398,913 Shares at \$116.1, 34.3% of total volume

Financial news for BIIB dated on 2012-01-09: Just What The Doctor Ordered: 4 ETFs For Biotech M&A

Financial news for BIIB dated on 2012-01-04: Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy

Financial news for BIIB dated on 2011-12-29: Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest Operating Margin

Financial news for BIIB dated on 2011-12-27: Best Biotech Stocks of 2011

Financial news for BIIB dated on 2011-12-20: Deutsche Bank Reiterates Buy, \$129 PT On Biogen Idec

Financial news for BIIB dated on 2011-12-06: J.P. Morgan Reiterates Neutral On Biogen Idec

Financial news for BIIB dated on 2011-12-05: ISI Reiterates Buy, \$120 PT On Biogen

Financial news for BIIB dated on 2011-12-02: Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest EPS

Financial news for BIIB dated on 2011-11-22: Idenix and Spectrum Pharmaceuticals to Open Near 52-Week Highs

Financial news for BIIB dated on 2011-11-14: Deutsche Bank Maintains Buy Rating and \$129 PT on Biogen Idec

Financial news for BIIB dated on 2011-11-14: JP Morgan Maintains Neutral for Biogen Idec on Positive Lemtrada Data

Financial news for BIIB dated on 2011-10-28: Biogen Spiking to New 52-Week Highs, \$120.66

Financial news for BIIB dated on 2011-10-28: Biogen IDEC Inc's Profit Up

Financial news for BIIB dated on 2011-10-28: Financial Breakfast: Morning News Summary for October 28, 2011

Financial news for BIIB dated on 2011-10-28: Biogen Idec Reports Q3 EPS \$1.43 vs \$1.53 Est; Revenues \$1.31B vs \$1.27B Est

Financial news for BIIB dated on 2011-10-27: Biogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases

Financial news for BIIB dated on 2011-10-26: Oppenheimer Raises PT on Biogen Idec to \$127 from \$109, Maintains Outperform

Financial news for BIIB dated on 2011-10-26: Biogen Hits New 52-Week High; \$117.54

Financial news for BIIB dated on 2011-10-26: UPDATE: Piper Jaffray Raises PT on Biogen Idec to \$135

Financial news for BIIB dated on 2011-10-26: Piper Jaffray Raises PT on Biogen Idec to \$135

Financial news for BIIB dated on 2011-10-26: Biogen Idec Announces Positive Top-Line Results from Second Phase 3 Trial Investigating Oral BG-12 in Multiple Sclerosis

Financial news for BIIB dated on 2011-10-25: Biogen Idec Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for BIIB dated on 2011-10-24: Jefferies Maintains Buy on Biogen Idec

Financial news for BIIB dated on 2011-10-24: Jefferies Maintains Buy on Biogen Idec

Financial news for BIIB dated on 2011-10-23: Earnings Expectations for the Week of October 24

Financial news for BIIB dated on 2011-10-21: J.P. Morgan Maintains Neutral on Biogen Idec

Financial news for BIIB dated on 2011-10-20: From Earlier, Biogen Idec and Elan Receive Notification of PDUFA Date Extension

Financial news for BIIB dated on 2011-10-19: Deutsche Bank Maintains Buy Rating and \$129 PT on Biogen Idec

Financial news for BIIB dated on 2011-10-19: Biogen Idec and Elan Announce Data about Early Use and Long-Term Benefit of TYSABRI Presented at 5th Joint Triennial Congress of ECTRIMS and ACTRIMS

Financial news for BIIB dated on 2011-10-17: Earnings Season Kicks Off 10-17-2011

Financial news for BIIB dated on 2011-10-13: Deutsche Bank Comments on Amgen's Restructuring Rumors

Financial news for BIIB dated on 2011-10-13: J.P. Morgan Maintains Neutral on Biogen Idec

Financial news for BIIB dated on 2011-10-05: No New Safety Issues Seen in Biogen Idec's MS Drug BG-12

Financial news for BIIB dated on 2011-10-04: Deutsche Bank Releases Company Update on BIIB

Financial news for BIIB dated on 2011-10-03: Oppenheimer Outperform on Biogen Idec

Financial news for BIIB dated on 2011-09-29: Notable Put Options Activity in Biogen Idec

Financial news for BIIB dated on 2011-09-26: Top 4 Large-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio

Financial news for BIIB dated on 2011-09-16: Notable Put Options Activity in Biogen Idec

Financial news for BIIB dated on 2011-09-09: UBS Upgrades Biogen, Raises PT

Financial news for BIIB dated on 2011-09-06: Biogen Idec Fully Acquires Biogen Dompe Joint Ventures

Financial news for BIIB dated on 2011-08-18: UPDATE: Oppenheimer Upgrades Biogen Idec from Perform to Outperform

Financial news for BIIB dated on 2011-08-18: Oppenheimer Upgrades Biogen Idec To Outperform, \$100 PT

Financial news for BIIB dated on 2011-08-18: Oppenheimer Upgrading Biogen Idec

Financial news for BIIB dated on 2011-08-09: Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis

Financial news for BIIB dated on 2011-08-08: UPDATE: Citadel Securities Initiates Coverage on Biogen Idec

Financial news for BIIB dated on 2011-08-08: Citadel Initiates Biogen Idec With Add Rating, \$130 PT

Financial news for BIIB dated on 2011-07-27: Check Out The Chart: An Unhealthy Biotech ETF?

Financial news for BIIB dated on 2011-07-26: Amgen Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter

Financial news for BIIB dated on 2011-07-26: Biogen IDEC Inc Earnings: Net Income Drops

Financial news for BIIB dated on 2011-07-26: Biogen Idec Guides Year EPS Above \$5.70 vs \$5.86 Est

Financial news for BIIB dated on 2011-07-26: Biogen Idec Reports Q2 EPS of \$1.36 vs. \$1.40 Est; Revenues \$1.21B vs. \$ 1.19B Est

Financial news for BIIB dated on 2011-07-26: Earnings Scheduled For July 26

Financial news for BIIB dated on 2011-07-25: Biogen Idec Receives Conditional Approval in the European Union for FAMPYRA(r) to Improve Walking in Adults with Multiple Sclerosis

Financial news for BIIB dated on 2011-07-21: Fifteen Health Care ETFs Trading Near 52-Week Highs

Financial news for BIIB dated on 2011-07-21: Biogen IDEC Earnings Preview: Analysts Expect Falling Revenue Over Last Quarter

Financial news for BIIB dated on 2011-07-20: Five Health Care ETFs Your Broker Forget To Mention

Financial news for BIIB dated on 2011-07-19: Citi Updates On BIIB

Financial news for BIIB dated on 2011-07-19: ISI Provides Color on Novartis

Financial news for BIIB dated on 2011-07-13: Twelve Health Care ETFs Trading Near 52-Week Highs

Financial news for BIIB dated on 2011-07-13: Morgan Stanley Provides Color on Baxter

Financial news for BIIB dated on 2011-07-13: ISI Provides Color on Biogen Idec

Financial news for BIIB dated on 2011-07-11: J.P. Morgan Maintains Neutral On Biogen Idec Following MS Data

Financial news for BIIB dated on 2011-07-08: Hottest and Coldest Sectors for Friday 7/8/11

Financial news for BIIB dated on 2011-06-29: Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows

Financial news for BIIB dated on 2011-06-22: Carl Icahn Discloses a 3.4% Stake in Biogen Idec

Financial news for BIIB dated on 2011-06-22: Jefferies Maintains Rating, PT On BIIB

Financial news for BIIB dated on 2011-06-21: Biogen Idec Trading Nearly 2% Higher on Deutsche Bank Upgrade

Financial news for BIIB dated on 2011-06-21: Benzinga's Top Pre-Market NASDAQ Gainers

Financial news for BIIB dated on 2011-06-21: Benzinga's Top Upgrades

Financial news for BIIB dated on 2011-06-21: UPDATE: Deutsche Bank Upgrades Biogen Idec to Buy

Financial news for BIIB dated on 2011-06-21: Deutsche Bank Updates 6/21

Financial news for BIIB dated on 2011-06-21: Deutsche Bank Upgrades Biogen To Buy,

Raises PT To \$129